Patent Publication Number: US-2019194750-A1

Title: Biomarkers of response to selective inhibitors of aurora a kinase

Description:
SEQUENCE LISTING 
     This application contains a Sequence Listing which is submitted herewith in electronically readable format. The Sequence Listing file was created on Jun. 23, 2016, is named “sequencelisting.txt,” and its size is 320 kb (328,378 bytes). The entire contents of the Sequence Listing in the sequencelisting.txt file are incorporated herein by this reference. 
     FIELD OF THE DISCLOSURE 
     This disclosure relates to methods for the treatment of various cancers. In particular, the disclosure provides methods for treatment of various cancers by administering to a patient a selective inhibitor of Aurora A kinase if said patient is identified as a likely responder to the treatment by assessing the patient&#39;s genetic profile. 
     BACKGROUND OF THE DISCLOSURE 
     Cells become cancerous when their genotype or phenotype alters in a way that there is uncontrolled growth that is not subject to the confines of the normal tissue environment. One or more genes is/are mutated, amplified, deleted, overexpressed or underexpressed. Chromosome portions can be lost or moved from one location to another. Some cancers have characteristic patterns by which genotypes or phenotypes are altered. 
     Many genes have mutations which are associated with cancer. Some genes have multiple sites where mutations can occur. Many cancers have mutations in and/or mis-expression of more than one gene. Gene mutations can facilitate tumor progression, tumor growth rate or whether a tumor will metastasize. Some mutations can affect whether a tumor cell will respond to therapy. 
     Regulation of the cell cycle checkpoints is a critical determinant of the manner in which tumor cells respond to many chemotherapies and radiation. Many effective cancer therapies work by causing DNA damage; however, resistance to these agents remains a significant limitation in the treatment of cancer. One important mechanism leading to drug resistance is the activation of a checkpoint pathway that arrests the cell cycle to provide time for repair. Through this mechanism cell cycle progression is prevented, and immediate cell death of the damaged cell may be avoided. 
     The cell division cycle also involves various protein kinases that are frequently overexpressed in cancer cells. Aurora A kinase, for example, is a key mitotic regulator that is implicated in the pathogenesis of several tumor types. The Aurora kinases, first identified in yeast (Ipl1),  Xenopus  (Eg2) and  Drosophila  (Aurora), are critical regulators of mitosis. ( Embo J  (1998) 17, 5627-5637 ; Genetics  (1993) 135, 677-691 ; Cell  (1995) 81, 95-105 ; J Cell Sci  (1998) 111(Pt 5), 557-572). In humans, three isoforms of Aurora kinase exist, including Aurora A, Aurora B and Aurora C. Aurora A and Aurora B play critical roles in the normal progression of cells through mitosis, whereas Aurora C activity is largely restricted to meiotic cells. Aurora A and Aurora B are structurally closely related. Their catalytic domains lie in the C-terminus, where they differ in only a few amino acids. Greater diversity exists in their non-catalytic N-terminal domains. It is the sequence diversity in this region of Aurora A and Aurora B that dictates their interactions with distinct protein partners, allowing these kinases to have unique subcellular localizations and functions within mitotic cells. 
     The Aurora A gene (AURKA) localizes to chromosome 20q13.2 which is commonly amplified or overexpressed at a high incidence in a diverse array of tumor types. ( Embo J  (1998) 17, 3052-3065 ; Int J Cancer  (2006) 118, 357-363 ; J Cell Biol  (2003) 161, 267-280 ; Mol Cancer Ther  (2007) 6, 1851-1857 ; J Natl Cancer Inst  (2002) 94, 1320-1329). Increased Aurora A gene expression has been correlated to the etiology of cancer and to a worsened prognosis. ( Int J Oncol  (2004) 25, 1631-1639 ; Cancer Res  (2007) 67, 10436-10444 ; Clin Cancer Res  (2004) 10, 2065-2071 ; Clin Cancer Res  (2007) 13, 4098-4104 ; Int J Cancer  (2001) 92, 370-373 ; Br J Cancer  (2001) 84, 824-831 ; J Natl Cancer Inst  (2002) 94, 1320-1329). This concept has been supported in experimental models, demonstrating that Aurora A overexpression leads to oncogenic transformation. ( Cancer Res  (2002) 62, 4115-4122 ; Mol Cancer Res  (2009) 7, 678-688 ; Oncogene  (2006) 25, 7148-7158 ; Cell Res  (2006) 16, 356-366 ; Oncogene  (2008) 27, 4305-4314 ; Nat Genet  (1998) 20, 189-193). Overexpression of Aurora A kinase is suspected to result in a stoichiometric imbalance between Aurora A and its regulatory partners, leading to chromosomal instability and subsequent transforming events. The potential oncogenic role of Aurora A has led to considerable interest in targeting this kinase for the treatment of cancer. 
     As a key regulator of mitosis, Aurora A plays an essential role in mitotic entry and normal progression of cells through mitosis. ( Nat Rev Mol Cell Biol  (2003) 4, 842-854 ; Curr Top Dev Biol  (2000) 49, 331-42 ; Nat Rev Mol Cell Biol  (2001) 2(1), 21-32). During a normal cell cycle, Aurora A kinase is first expressed in the G2 stage where it localizes to centrosomes and functions in centrosome maturation and separation as well as in the entry of cells into mitosis. In mitotic cells Aurora A kinase predominantly localizes to centrosomes and the proximal portion of incipient mitotic spindles. There it interacts with and phosphorylates a diverse set of proteins that collectively function in the formation of mitotic spindle poles and spindles, the attachment of spindles to sister chromatid at the kinetochores, the subsequent alignment and separation of chromosome, the spindle assembly checkpoint and cytokinesis. ( J Cell Sci  (2007) 120, 2987-2996 ; Trends Cell Biol  (1999) 9, 454-459 ; Nat Rev Mol Cell Biol  (2003) 4, 842-854 ; Trends Cell Biol  (2005) 15, 241-250). 
     Although selective inhibition of Aurora A kinase results in a delayed mitotic entry ( The Journal of biological chemistry  (2003) 278, 51786-51795), cells commonly enter mitosis despite having inactive Aurora A kinase. Cells in which Aurora A kinase has been selectively inhibited demonstrate a variety of mitotic defects including abnormal mitotic spindles (monopolar or multipolar spindles) and defects in the process of chromosome alignment. With time, monopolar and multipolar spindles may resolve to form two opposing spindle poles, although some of these defects may lead immediately to cell death via defective mitoses. While spindle defects resulting from Aurora A kinase inhibition induce mitotic delays, presumably through activation of the spindle assembly checkpoint, cells ultimately divide at a frequency near that of untreated cells. ( Mol Cell Biol  (2007) 27(12), 4513-25 ; Cell Cycle  (2008) 7(17), 2691-704 ; Mol Cancer Ther  (2009) 8(7), 2046-56.). This inappropriate cell division occurs following a slow-acting suppression of the spindle assembly checkpoint due to loss of Aurora A kinase function. (Cell Cycle (2009) 8(6), 876-88). Bipolar spindles that are formed in the absence of Aurora A kinase function frequently show chromosome alignment and segregation defects, including chromosome congression defects at metaphase, lagging chromosomes at anaphase, and telophase bridges. 
     Some patients respond to one therapy better than another, presenting the potential for a patient to follow multiple therapeutic routes to effective therapy. Valuable time early in a patient&#39;s treatment program can be lost pursuing a therapy which eventually is proven ineffective for that patient. Many patients cannot afford the time for trial-and-error choices of therapeutic regimens. Expedient and accurate treatment decisions lead to effective management of the disease. 
     SUMMARY OF THE DISCLOSURE 
     The present disclosure relates to prognosis, planning for treatment and treatment of tumors by measurement of at least one characteristic of a marker provided herein. Markers were identified in tumor biopsies and blood samples from 47 patients enrolled in a phase 1/2 clinical trial of single agent alisertib by associating their characteristics, e.g., size, sequence, composition, activity or amount, with outcome of subsequent treatment of the patient with alisertib therapy. The markers are predictive of whether there will be a favorable outcome (e.g., good response and/or long time-to-progression) after treatment of patients with an Aurora A Kinase inhibitor, such as alisertib. Testing patient samples comprising tumor cells to determine the presence, amounts or changes of genetic markers identifies particular patients who are expected to have a favorable outcome with treatment, e.g., with an Aurora A Kinase inhibitor, e.g., alisertib, and whose disease may be managed by standard or less aggressive treatment, as well as those patients who are expected to have an unfavorable outcome with the treatment and may require an alternative treatment to, a combination of treatments and/or more aggressive treatment with an Aurora A Kinase inhibitor to ensure a favorable outcome and/or successful management of the disease. 
     In one aspect, the disclosure provides kits useful in determination of characteristics, e.g., amounts, presence or changes, of the markers. In another aspect, the disclosure provides methods for determining prognosis and treatment or disease management strategies. In these aspects, the characteristic, e.g., size, sequence, composition, activity or amount of markers in a sample comprising tumor cells is measured. In one embodiment, the tumor is a liquid, e.g., hematological tumor, e.g., a leukemia, a lymphoma or a myeloma. In another embodiment, the tumor is a solid tumor, e.g., non-hematological tumor, e.g., breast cancer, ovarian cancer, prostate cancer, head and neck cancer, small cell lung cancer, non-small cell lung cancer, gastric cancer, renal cancer, pancreatic cancer, bladder cancer or melanoma. 
     In various embodiments, the characteristic, e.g., size, sequence, composition, activity or amount of marker DNA, the size, sequence, composition or amount of marker RNA and/or the size, sequence, composition, activity or amount of marker protein corresponding to a marker gene with one or more mutation, e.g., somatic mutation, described herein is measured. Useful information leading to the prognosis or treatment or disease management strategies is obtained when assays reveal information about a marker gene, e.g., whether the gene is mutated, or not, the identity of the mutation, and/or whether the RNA or protein amount of a mutated gene or genes indicates overexpression or underexpression. In one embodiment, the strategy is determined for therapy with Aurora A Kinase inhibitors, e.g., alisertib, a pharmaceutically acceptable salt or a pharmaceutical composition thereof (MLN8237). 
     A marker gene useful to test for determination of prognosis or treatment or disease management strategy is selected from the group consisting of the marker genes listed below in Table 8. In one embodiment a marker gene useful to test for determination of prognosis or treatment or disease management strategy is selected from the group consisting of genes within the Wnt signaling pathway or the Hippo signaling pathway. In yet a further embodiment, a marker gene useful to test for determination of prognosis or treatment or disease management strategy is selected from the group consisting of LEF1, MAP2K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XPO1, ROR2, CCND1, CTNNB1, AMOT, DVL2, LATS1, LATS2, MOB1B, NPHP4, TJP1, TJP2, WWC1, WWC1, WWTR1 and YAP1. Each marker gene includes mutations or alterations whose presence in DNA or whose effects, e.g., on marker RNA and/or protein characteristics, e.g., amounts, size, sequence or composition, can provide information for determination of prognosis or treatment or disease management. In some embodiments, a gene or a mutant or modified form thereof useful as a marker, has a DNA, an RNA and/or protein characteristic, e.g., size, sequence, composition or amount, e.g., in a sample comprising tumor cells, which is different than a normal DNA, RNA and/or protein. Described herein are examples of modifications of these genes, referred to as “marker genes” whose mutation or amounts can provide such information. 
     The mutation of a marker gene of the present disclosure provides information about outcome after treatment, e.g., with an Aurora A Kinase inhibitor, e.g., alisertib. By examining a characteristic, e.g., size, sequence, composition, activity or amount of one or more of identified markers in a tumor, it is possible to determine which therapeutic agent, combination of agents, dosing and/or administration regimen is expected to provide a favorable outcome upon treatment. By examining the characteristic, e.g., size, sequence, composition, activity or amount of one or more of the identified markers or marker sets in a cancer, it is also possible to determine which therapeutic agent, combination of agents, dosing and/or administration regimen is less likely to provide a favorable outcome upon treatment. By examining the characteristic, e.g., size, sequence, composition, activity or amount of one or more of the identified markers, it is therefore possible to eliminate ineffective or inappropriate therapeutic agents or regimens. Importantly, these determinations can be made on a patient-by-patient basis. Thus, one can determine whether or not a particular therapeutic regimen is likely to benefit a particular patient or type of patient, and/or whether a particular regimen should be started or avoided, continued, discontinued or altered. 
     The present disclosure is directed to methods of identifying and/or selecting a cancer patient for treatment with a therapeutic regimen, e.g., a therapeutic regimen comprising an Aurora A Kinase inhibitor, such as alisertib treatment, if the patient is expected to demonstrate a favorable outcome upon administration of the therapeutic regimen. The method may further comprise treating with the therapeutic regimen a cancer patient who is identified for a favorable outcome. Additionally provided are methods of identifying a patient for alternative therapy or supplemental therapy if the patient is expected to have an unfavorable outcome upon administration of such a therapeutic regimen. These methods typically include measuring, determining, receiving, storing or transmitting information about the characteristic, e.g., size, sequence, composition, activity or amount of one or more markers or mutation of marker genes in a patient&#39;s tumor (e.g., in a patient&#39;s cancer cells, e.g., non-hematological cancer cells, e.g., solid tumor cells), optionally comparing that to the characteristic, e.g., size, sequence, composition, activity or amount of a reference marker, and in a further embodiment, identifying or advising whether the result from the sample corresponds to a favorable outcome of a treatment regimen, e.g., an Aurora A Kinase inhibitor, e.g., alisertib regimen. 
     Additionally provided methods include therapeutic methods which further include the step of beginning, continuing, or commencing a therapy accordingly where the presence of a mutation in a marker gene or the characteristic, e.g., size, sequence, composition, activity or amount of a patient&#39;s marker or markers indicates that the patient is expected to demonstrate a favorable outcome with the therapy, e.g., an Aurora A Kinase inhibitor, such as alisertib therapeutic regimen. In addition, the methods include therapeutic methods which further include the step of stopping, discontinuing, altering or halting a therapy accordingly where the presence of a mutation in a marker gene or the characteristic, e.g., size, sequence, composition, activity or amount of a patient&#39;s marker indicates that the patient is expected to demonstrate an unfavorable outcome with the treatment, e.g., with an Aurora A Kinase inhibitor, such as alisertib treatment regimen, e.g., as compared to a patient identified as having a favorable outcome receiving the same therapeutic regimen. In another aspect, methods are provided for analysis of a patient not yet being treated with a therapy, e.g., an Aurora A Kinase inhibitor, such as alisertib, and identification and prediction of treatment outcome based upon the presence of a mutation in a marker gene or characteristic, e.g., size, sequence, composition, activity or amount of one or more of a patient&#39;s markers described herein. Such methods can include not being treated with the therapy, e.g., an Aurora A Kinase inhibitor, such as alisertib therapy; being treated with therapy, e.g., an Aurora A Kinase inhibitor, such as alisertib therapy in combination with one more additional therapies; being treated with an alternative therapy to an Aurora A Kinase inhibitor, such as alisertib therapy; or being treated with a more aggressive dosing and/or administration regimen of a therapy, e.g., an Aurora A Kinase inhibitor, such as alisertib, e.g., as compared to the dosing and/or administration regimen of a patient identified as having a favorable outcome to a standard Aurora A Kinase inhibitor, such as alisertib therapy. Thus, the provided methods of the disclosure can eliminate ineffective or inappropriate use of therapy, e.g., an Aurora A Kinase inhibitor, such as alisertib therapy regimens. 
     Additional methods include methods to determine the activity of an agent, the efficacy of an agent, or identify new therapeutic agents or combinations. Such methods include methods to identify an agent as useful, e.g., as an Aurora A Kinase inhibitor, such as alisertib, for treating a cancer, e.g., a non-hematological cancer, i.e., a solid tumor cancer (e.g., breast cancer, ovarian cancer, prostate cancer, head and neck cancer, small cell lung cancer, non-small cell lung cancer, gastric cancer, renal cancer, pancreatic cancer, bladder cancer or melanoma), based on its ability to affect the presence of a mutation in a marker gene or characteristic, e.g., size, sequence, composition, activity or amount of a marker or markers of the disclosure. In some embodiments, an inhibitor which decreases or increases the presence of a mutation in a marker gene or characteristic, e.g., size, sequence, composition, activity or amount of a marker or markers provided in a manner that indicates favorable outcome of a patient having cancer would be a candidate agent for the cancer. In another embodiment, an agent which is able to decrease the viability of a tumor cell comprising a marker indicative of an unfavorable outcome would be a candidate agent for the cancer. 
     The present disclosure is also directed to methods of treating a cancer patient with a therapeutic regimen, e.g., an Aurora A Kinase inhibitor, such as alisertib therapeutic regimen (e.g., alone, or in combination with an additional agent such as a chemotherapeutic agent), which includes the step of selecting for treatment a patient whose marker characteristic, e.g., size, sequence, composition, activity or amount indicates that the patient is expected to have a favorable outcome with the therapeutic regimen, and treating the patient with the therapy, e.g., an Aurora A Kinase inhibitor, such as alisertib therapy. In some embodiments, the method can include the step of selecting a patient whose marker characteristic, e.g., size, sequence, composition, activity or amount or amounts indicates that the patient is expected to have a favorable outcome and administering a therapy other than an Aurora A Kinase inhibitor therapy that demonstrates similar expected progression-free survival times as the Aurora A Kinase inhibitor, such as alisertib therapy. 
     Additional methods of treating a cancer patient include selecting patients that are unlikely to experience a favorable outcome upon treatment with a cancer therapy (e.g., an Aurora A Kinase inhibitor, such as alisertib therapy). Such methods can further include one or more of: administering a higher dose or increased dosing schedule of a therapy, e.g., an Aurora A Kinase inhibitor, such as alisertib as compared to the dose or dosing schedule of a patient identified as having a favorable outcome with standard therapy; administering a cancer therapy other than an Aurora A Kinase inhibitor, such as alisertib therapy; administering an Aurora A Kinase inhibitor, such as alisertib in combination with an additional agent. Further provided are methods for selection of a patient having aggressive disease which is expected to demonstrate more rapid time to progression. 
     Additional methods include a method to evaluate whether to treat or pay for the treatment of cancer, e.g., non-hematological cancer, i.e., solid tumor cancer (e.g., breast cancer, ovarian cancer, prostate cancer, head and neck cancer, small cell lung cancer, non-small cell lung cancer, gastric cancer, renal cancer, pancreatic cancer, bladder cancer or melanoma) by reviewing the amount of a patient&#39;s marker or markers for indication of outcome to a cancer therapy, e.g., an Aurora A Kinase inhibitor, such as alisertib therapy regimen, and making a decision or advising on whether payment should be made. 
     The entire contents of all publications, patent applications, patents and other references mentioned herein are incorporated by reference. 
     Other features and advantages of the disclosure will be apparent from the following detailed description, drawings and from the claims. 
     In one aspect, the disclosure provides a method for determining whether to treat a patient having cancer with an Aurora A kinase inhibitor, the method comprising the steps of: (a) obtaining a cancer cell sample from the patient; (b) determining whether any of the WNT pathway genes listed in Table 9 and/or any of the Hippo pathway genes listed in Table 10 contain mutations in comparison to each of the genes&#39; respective wild type sequence; and determining whether to treat the patient with the Aurora A kinase inhibitor based on the mutation analysis in step b), wherein if at least one gene from Table 9 and/or 10 is found to be mutated, the patient may favorably respond to the drug. 
     In one aspect, the disclosure provides a method for identifying a patient having cancer as a candidate for treatment with an Aurora A kinase inhibitor, the method comprising the steps of: (a) obtaining a cancer cell sample from the patient; (b) determining whether any of the WNT pathway genes listed in Table 9 and/or any of the Hippo pathway genes listed in Table 10 contain mutations in comparison to each of the genes&#39; respective wild type sequence; and identifying the patient as a candidate for treatment with the Aurora A kinase inhibitor if the mutation analysis in step b) indicates the presence of a mutation or the presence of several mutations in at least one gene from Table 9 and/or 10. 
     In one aspect, the disclosure provides a method for treating a patient having cancer, the method comprising the steps of: (a) obtaining a cancer cell sample from the patient; (b) determining whether any of the WNT pathway genes listed in Table 9 and/or any of the Hippo pathway genes listed in Table 10 contain mutations in comparison to each of the genes&#39; respective wild type sequence; and treating the subject with an Aurora A Kinase inhibitor if the mutation analysis in b) indicates the presence of a mutation or the presence of several mutations in at least one gene from Table 9 and/or 10. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1 . The left pie chart represents the tumor types of the 47 patients in the clinical trial. A total or five tumor types were treated among the patients, namely breast cancer, head and neck cancer (H&amp;N), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and gastric cancer. The right pie chart indicates the tumour types of responders to treatment with alisertib. 
         FIG. 2 . The mutational landscape of the 47 patients in the clinical trial. The patients (represented by the columns) are sorted by best tumor size change from responders to non-responders. Line segments in the heatmap indicate mutated genes. 
         FIG. 3 . The heatmaps of mutated genes of the WNT and Hippo signaling pathways. In this figure, each column represents a patient, each row represents a mutated gene and each type of tumor is represented by the markings in the cells. The top waterfall plots indicate the distribution of the best tumor size change and each bar corresponds to a column (patient) of the heatmap. Surprisingly, it was determined that both of the pathways were associated with sensitivity to alisertib treatment. The WNT/β-catenin markers and Hippo markers identified herein are listed in Tables 9 and 10, respectively. In this figure we see that breast cancer patients harboring mutations in their LEF1, MAP3K7, FZD2, LATS1 and WWC1 genes, alone or in combination with other markers, are more likely to be responsive to an alisertib therapy regimen. We see that gastric cancer patients harboring mutations in their FZD2 and LATS2 genes, alone or in combination with other markers, are more likely to be responsive to an alisertib therapy regimen. We see that head and neck cancer patients harboring mutations in their LEF1, MAP3K7, JUN, ROR2, CCND1, LATS1, MOB1B and NPHP4 genes, alone or in combination with other markers, are more likely to be responsive to an alisertib therapy regimen. We see that non-small cell lung cancer patients harboring mutations in their XPO1 and TJP1 genes, alone or in combination with other markers, are more likely to be responsive to an alisertib therapy regimen. We see that small cell lung cancer patients harboring mutations in their LEF1, APC, PRKCA, RORA, CAMK2G, CTNNB1, AMOT, DVL2, TJP1, TJP2, WWTR1 and YAP1 genes, alone or in combination with other markers, are more likely to be responsive to an alisertib therapy regimen. 
         FIG. 4 . In each plot, the left box and right box represent wild type (WT) patients and mutant patients, respectively. The y-axis indicates the best tumor size change (%). Faint grey dots represent patients that responded to treatment with alisertib. As can be seen from these plots, patients with mutations in their WNT or Hippo signaling pathways respond more favorably to treatment with alisertib. 
     
    
    
     DETAILED DESCRIPTION OF THE DISCLOSURE 
     One of the continued problems with therapy in cancer patients is individual differences in response to therapies. While advances in development of successful cancer therapies progress, only a subset of patients respond to any particular therapy. With the narrow therapeutic index and the toxic potential of many available cancer therapies, such differential responses potentially contribute to patients undergoing unnecessary, ineffective and even potentially harmful therapy regimens. If a designed therapy could be optimized to treat individual patients, such situations could be reduced or even eliminated. Furthermore, targeted designed therapy may provide more focused, successful patient therapy overall. Accordingly, there is a need to identify particular cancer patients who are expected to have a favorable outcome when administered particular cancer therapies as well as particular cancer patients who may have a favorable outcome using more aggressive and/or alternative cancer therapies, e.g., alternative to previous cancer therapies administered to the patient. It would therefore be beneficial to provide for the diagnosis, staging, prognosis, and monitoring of cancer patients, including, e.g., non-hematological cancer patients, e.g., patients with solid tumors (e.g., breast cancer, ovarian cancer, prostate cancer, head and neck cancer, small cell lung cancer, non-small cell lung cancer, gastric cancer, renal cancer, pancreatic cancer, bladder cancer or melanoma) who would benefit from particular cancer inhibition therapies as well as those who would benefit from a more aggressive and/or alternative cancer inhibition therapy, e.g., alternative to a cancer therapy or therapies the patient has received, thus resulting in appropriate preventative measures. 
     The present disclosure is based, in part, on the recognition that mutation of a marker gene can be associated with sensitivity of a cell comprising the mutated gene to an Aurora A Kinase inhibitor, e.g., alisertib. In some embodiments, the marker gene is involved in the WNT/β-catenin signaling pathway, e.g., a gene whose mutation enables activation of the pathway. The WNT/β-catenin signaling pathway is a well described oncogenic pathway. In another embodiment, the marker gene is involved in the Hippo signaling pathway. Hippo pathway components are largely known as tumor suppressors. Both the WNT/β-catenin and Hippo signaling pathways have functional interactions with Aurora A. Aurora A inhibition with, for example, alisertib, induces cell mitotic defects and results in tetraploidy-induced cell cycle arrest. Interestingly, Hippo pathway genetically and functionally suppresses the WNT/β-catenin signaling pathway. Silencing of the Aurora A gene also results in down-regulation of WNT/β-catenin dependent signaling. 
     A marker gene can exhibit one or more mutations, e.g., somatic mutations, whose presence can affect expression or activity of the encoded gene product. In some embodiments, there can be more than one mutation in a marker gene in a tumor cell or tumor. In additional embodiments, there can be marker gene mutations in cells which have mutations in one or more additional genes, including mutations that can lead to tumorigenesis, but the additional mutated gene(s) may not be a marker gene as considered herein. In some embodiments, the mutation is an activating mutation. In other embodiments, the mutation affects the expression of the marker gene. In other embodiments, a mutation can result in an altered interaction of the encoded gene product with a cellular binding partner. 
     The identification and/or measurement of the mutation in the marker gene can be used to determine whether a favorable outcome can be expected by treatment of a tumor, e.g., with an Aurora Kinase inhibitor, e.g., alisertib therapy or whether an alternative therapy to and/or a more aggressive therapy with, e.g., an Aurora Kinase inhibitor, e.g., alisertib may enhance the response. For example, the compositions and methods provided herein can be used to determine whether a patient is expected to have a favorable outcome to an Aurora Kinase inhibitor, e.g., alisertib therapeutic agent dosing or administration regimen. Based on these identifications, the present disclosure provides, without limitation: 1) methods and compositions for determining whether an Aurora Kinase inhibitor, e.g., alisertib therapy regimen will or will not be effective to achieve a favorable outcome and/or manage the cancer; 2) methods and compositions for monitoring the effectiveness of an Aurora Kinase inhibitor, e.g., alisertib therapy (alone or in a combination of agents) and dosing and administrations used for the treatment of tumors; 3) methods and compositions for treatments of tumors comprising, e.g., an Aurora Kinase inhibitor, e.g., alisertib therapy regimen; 4) methods and compositions for identifying specific therapeutic agents and combinations of therapeutic agents as well as dosing and administration regimens that are effective for the treatment of tumors in specific patients; and 5) methods and compositions for identifying disease management strategies. 
     There has been interest in public cataloging mutations associated with cancers. Examples of public databases which include information about mutations associated with cancers are the Database of Genotypes and Phenotypes (dbGaP) maintained by the National Center for Biotechnology Information (Bethesda, Md.) and Catalogue of Somatic Mutations in Cancer (COSMIC) database maintained by the Wellcome Trust Sanger Institute (Cambridge, UK). 
     Compositions and methods are provided to identify mutations in marker genes in hematological (e.g., multiple myeloma, leukemias, lymphoma, etc.) or solid (e.g., breast cancer, ovarian cancer, prostate cancer, head and neck cancer, small cell lung cancer, non-small cell lung cancer, gastric cancer, renal cancer, pancreatic cancer, bladder cancer or melanoma) tumors to predict response to treatment, time-to-progression and survival upon treatment. 
     Markers were identified based on genetic profiles of tumor cells which exhibit sensitivity to treatment to alisertib. Observed sensitivity generally is consistent among tumor cells tested by more than one method. 
     Unless otherwise defined, all technical and scientific terms used herein have the meanings which are commonly understood by one of ordinary skill in the art to which this disclosure belongs. Generally, nomenclature utilized in connection with, and techniques of cell and tissue culture, molecular biology and protein and oligo- or polynucleotide chemistry and hybridization described herein are those known in the art. GenBank or GenPept accession numbers and useful nucleic acid and peptide sequences can be found at the website maintained by the National Center for Biotechnology Information, Bethesda, Md. The content of all database accession records (e.g., from Affymetrix HG133 annotation files, Entrez, GenBank, RefSeq, COSMIC) cited throughout this application (including the Tables) are hereby incorporated by reference. Standard techniques are used for recombinant DNA, oligonucleotide synthesis, protein purification, tissue culture and transformation and transfection (e.g., electroporation, lipofection, etc). Enzymatic reactions are performed according to manufacturer&#39;s specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures generally are performed according to methods known in the art, e.g., as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al. (2000)  Molecular Cloning: A Laboratory Manual  (3 rd  ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.) or Harlow, E. and Lane, D. (1988)  Antibodies: A Laboratory Manual  (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). The nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are known in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation and delivery, and treatment of patients. Furthermore, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. In the case of conflict, the present specification, including definitions, will control. 
     Definitions 
     Terms used herein shall be accorded the following defined meanings, unless otherwise indicated. 
     As used herein, a “favorable” outcome or prognosis refers to long term survival, long time-to-progression (TTP), and/or good response. Conversely, an “unfavorable” outcome or prognosis refers to short term survival, short time-to-progression (TTP) and/or poor response. 
     A “marker” as used herein, includes a material associated with a marker gene which has been identified as having a mutation in tumor cells of a patient and furthermore that mutation is characteristic of a patient whose outcome is favorable or unfavorable with treatment e.g., by an Aurora A Kinase inhibitor, such as alisertib. Examples of a marker include a material, e.g., a chromosome locus, DNA for a gene, RNA for a gene or protein for a gene. For example, a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein which demonstrates a characteristic, e.g., size, sequence, composition or amount indicative of a short term survival patient; alternatively a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein which demonstrates a mutation or characteristic, e.g., size, sequence, composition or amount indicative of a long term survival patient. In another example, a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein whose mutation or characteristic, e.g., size, sequence, composition or amount is indicative of a patient with a poor response to treatment; alternatively a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein whose mutation or characteristic, e.g., size, sequence, composition or amount is indicative of a patient with a good response to treatment. In a further example, a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein whose mutation or characteristic, e.g., size, sequence, composition or amount is indicative of a patient whose disease has a short time-to-progression (TTP) upon treatment; alternatively a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein whose mutation or characteristic, e.g., size, sequence, composition or amount is indicative of a patient whose disease has a long TTP upon treatment. In a yet a further example, a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein whose mutation or characteristic, e.g., size, sequence, composition or amount is indicative of a patient whose disease has a short term survival upon treatment; alternatively a marker includes a marker gene material, e.g., a chromosome locus, DNA, RNA or protein whose mutation or characteristic, e.g., size, sequence, composition or amount is indicative of a patient whose disease has a long term survival upon treatment. Thus, as used herein, marker is intended to include each and every one of these possibilities, and further can include each single marker individually as a marker; or alternatively can include one or more, or all of the characteristics collectively when reference is made to “markers” or “marker sets.” 
     A “marker nucleic acid” is a nucleic acid (e.g., genomic DNA, mRNA, cDNA) encoded by or corresponding to a marker gene of the disclosure. Such marker nucleic acids include DNA, e.g., sense and anti-sense strands of genomic DNA (e.g., including any introns occurring therein), comprising the entire or a partial sequence, e.g., one or more of the exons of the genomic DNA, up to and including the open reading frame of any of the marker genes or the complement of such a sequence. The marker nucleic acids also include RNA comprising the entire or a partial sequence of any marker or the complement of such a sequence, wherein all thymidine residues are replaced with uridine residues, RNA generated by transcription of genomic DNA (i.e. prior to splicing), RNA generated by splicing of RNA transcribed from genomic DNA, and proteins generated by translation of spliced RNA (i.e. including proteins both before and after cleavage of normally cleaved regions such as transmembrane signal sequences). As used herein, a “marker nucleic acid” may also include a cDNA made by reverse transcription of an RNA generated by transcription of genomic DNA (including spliced RNA). A marker nucleic acid also includes sequences which differ, due to degeneracy of the genetic code, from the nucleotide sequence of nucleic acids encoding a protein which corresponds to a marker, e.g., a mutated marker, of the disclosure, and thus encode the same protein, e.g., mutated protein. As used herein, the phrase “allelic variant” refers to a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence. Such naturally occurring allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals, e.g., in cells, e.g., germline cells, of individuals without cancer. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Detection of any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of naturally occurring allelic variation and that do not alter the functional activity of a wild type marker gene is intended to be within the scope of the wild type version of a marker described herein. A “marker protein” is a protein encoded by or corresponding to a marker, e.g., a mutant nucleic acid, of the disclosure. The terms “protein” and “polypeptide’ are used interchangeably. A protein of a marker specifically can be referred to by its name or amino acid sequence, but it is understood by those skilled in the art, that mutations, deletions and/or post-translational modifications can affect protein structure, appearance, cellular location and/or behavior. Unless indicated otherwise, such differences are not distinguished herein, and a marker described herein is intended to include any or all such varieties. 
     As used herein, a “marker gene” refers to a gene which can have a mutation such that its DNA, RNA and/or protein has a characteristic, e.g., size, sequence, composition or amount(s) which provide information about prognosis (i.e., are “informative”) upon treatment. Marker genes described herein as linked to outcome after treatment with an Aurora A Kinase inhibitor, such as alisertib (e.g., MLN8237) are examples of marker genes and are provided in Tables 8, 9 and 10. A marker gene listed in Tables 8, 9 and 10 can have isoforms which are either ubiquitous or have restricted expression. These sequences are not intended to limit the marker gene identity to that isoform or precursor. The additional isoforms and mature proteins are readily retrievable and understandable to one of skill in the art by reviewing the information provided under the Entrez Gene (database maintained by the National Center for Biotechnology Information, Bethesda, Md.) identified by the ID number listed in Tables 9 and 10. 
     In the WNT pathway, “LEF1” refers to the gene associated with GenBank Accession No. NM_016269.4 (SEQ ID NO:1), encoding GenPept Accession No. NP_057353.1 (SEQ ID NO:2). Other names for LEF1 include TCF1-alpha and T cell-specific transcription factor 1-alpha. The protein encodes a transcription factor belonging to a family of proteins that share homology with the high mobility group protein-1. The protein encoded by this gene can bind to a functionally important site in the T-cell receptor-alpha enhancer, thereby conferring maximal enhancer activity. This transcription factor is involved in the WNT signaling pathway, and it may function in hair cell differentiation and follicle morphogenesis. Mutations in this gene have been found in somatic sebaceous tumors. This gene has also been linked to other cancers, including androgen-independent prostate cancer. Alternative splicing results in multiple transcript variants. Use of LEF1 as marker gene may be organ-specific, i.e., it can be a marker of breast neoplasms, colorectal neoplasms, insulin resistance, and other types of diseases particularly cancers. 
     In the WNT pathway, “MAP3K7” refers to the gene associated with GenBank Accession No. NM_145331.2 (SEQ ID NO:3), encoding GenPept Accession No. NP_663304.1 (SEQ ID NO:4). Other names for MAP3K7 include transforming growth factor-beta-activated kinase 1, TGF-beta activated kinase 1, and TGF-beta-activated kinase 1. The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase mediates the signaling transduction induced by TGF beta and morphogenetic protein (BMP), and controls a variety of cell functions including transcription regulation and apoptosis. In response to IL-1, this protein forms a kinase complex including TRAF6, MAP3K7P1/TAB1 and MAP3K7P2/TAB2; this complex is required for the activation of nuclear factor kappa B. This kinase can also activate MAPK8/JNK, MAP2K4/MKK4, and thus plays a role in the cell response to environmental stresses. Four alternatively spliced transcript variants encoding distinct isoforms have been reported. Use of MAP3K7 as marker gene may be disease-specific, i.e., it can be a marker of arthritis, rheumatoid, endometrial neoplasms, and renal cancers. 
     In the WNT pathway, “APC” refers to the gene associated with GenBank Accession No. NM_000038.5 (SEQ ID NO:5), encoding GenPept Accession No. NP_000029.2 (SEQ ID NO:6). Other names for APC include protein phosphatase 1, regulatory subunit 46, adenomatosis polyposis  coli  tumor suppressor, adenomatous polyposis  coli  protein, deleted in polyposis 2.5, and adenomatosis polyposis  coli . This gene encodes a tumor suppressor protein that acts as an antagonist of the Wnt signaling pathway. It is also involved in other processes including cell migration and adhesion, transcriptional activation, and apoptosis. Defects in this gene cause familial adenomatous polyposis (FAP), an autosomal dominant pre-malignant disease that usually progresses to malignancy. Disease-associated mutations tend to be clustered in a small region designated the mutation cluster region (MCR) and result in a truncated protein product. Use of APC as marker gene may cover many diseases including colorectal neoplasms and other cancer indications. 
     In the WNT pathway, “FZD2” refers to the gene associated with GenBank Accession No. NM_001466.3 (SEQ ID NO:7), encoding GenPept Accession No. NP_001457.1 (SEQ ID NO:8). Other names for FZD2 include frizzled homolog 2 ( Drosophila ), frizzled homolog 2, frizzled-2, frizzled ( Drosophila ) homolog 2, frizzled 2, seven transmembrane spanning receptor, and frizzled family receptor 2. This intronless gene is a member of the frizzled gene family. Members of this family encode seven-transmembrane domain proteins that are receptors for the wingless type MMTV integration site family of signaling proteins. This gene encodes a protein that is coupled to the beta-catenin canonical signaling pathway. Competition between the wingless-type MMTV integration site family, member 3A and wingless-type MMTV integration site family, member 5A gene products for binding of this protein is thought to regulate the beta-catenin-dependent and -independent pathways. Use of FZD2 as marker gene may be similar to MAP3K7, covering arthritis, rheumatoid, colorectal neoplasms, and endometrial neoplasms. 
     In the WNT pathway, “PRKCA” refers to the gene associated with GenBank Accession No. XM_011524990.1 (SEQ ID NO:9), encoding GenPept Accession No. XP_011523292.1 (SEQ ID NO:10). Other names for PRKCA include aging-associated gene 6, and protein kinase C alpha type, PKC-A. Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and the second messenger diacylglycerol. PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. PKC family members also serve as major receptors for phorbol esters, a class of tumor promoters. Each member of the PKC family has a specific expression profile and is believed to play a distinct role in cells. The protein encoded by this gene is one of the PKC family members. This kinase has been reported to play roles in many different cellular processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell volume control. Knockout studies in mice suggest that this kinase may be a fundamental regulator of cardiac contractility and Ca(2+) handling in myocytes. Use of PRKCA as marker gene may be organ-specific; i.e. it can be a marker of Alzheimer disease and amyotrophic lateral. 
     In the WNT pathway, “RORA” refers to the gene associated with GenBank Accession No. NM_002943.3 (SEQ ID NO:11), encoding GenPept Accession No. NP_002934.1 (SEQ ID NO:12). Other names for RORA include retinoic acid receptor-related orphan receptor alpha, ROR-alpha, transcription factor RZR-alpha, thyroid hormone nuclear receptor alpha variant 4, nuclear receptor RZR-alpha, retinoid-related orphan receptor alpha, nuclear receptor ROR-alpha, and nuclear receptor subfamily 1 group F member 1. The protein encoded by this gene is a member of the NR1 subfamily of nuclear hormone receptors. It can bind as a monomer or as a homodimer to hormone response elements upstream of several genes to enhance the expression of those genes. The encoded protein has been shown to interact with NM23-2, a nucleoside diphosphate kinase involved in organogenesis and differentiation, as well as with NM23-1, the product of a tumor metastasis suppressor candidate gene. Also, it has been shown to aid in the transcriptional regulation of some genes involved in circadian rhythm. Four transcript variants encoding different isoforms have been described for this gene. Use of RORA as marker gene may various diseases; i.e. it can be a marker of anoxia, bipolar disorder, cancers, particularly non-small cell lung cancer. 
     In the WNT pathway, “CAMK2G” refers to the gene associated with GenBank Accession No. NM_172171.2 (SEQ ID NO:13), encoding GenPept Accession No. NP_751911.1 (SEQ ID NO:14). Other names for CAMK2G include calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma, calcium/calmodulin-dependent protein kinase type II subunit gamma, and caMK-II subunit gamma. The product of this gene is one of the four subunits of an enzyme which belongs to the serine/threonine protein kinase family, and to the Ca(2+)/calmodulin-dependent protein kinase subfamily. Calcium signaling is crucial for several aspects of plasticity at glutamatergic synapses. In mammalian cells the enzyme is composed of four different chains: alpha, beta, gamma, and delta. The product of this gene is a gamma chain Many alternatively spliced transcripts encoding different isoforms have been described but the full-length nature of all the variants has not been determined. Use of CAMK2G as marker gene may be neuro-degenerative diseases, cardiovascular diseases, and cancer; i.e. it can be a marker of Alzheimer disease, arrhythmias, colorectal neoplasms, and glioblastoma. 
     In the WNT pathway, “JUN” refers to the gene associated with GenBank Accession No. NM_002228.3 (SEQ ID NO:15), encoding GenPept Accession No. NP_002219.1 (SEQ ID NO:16). Other names for JUN include v-jun avian sarcoma virus 17 oncogene homolog, activator protein 1, Jun activation domain binding protein, v-jun sarcoma virus 17 oncogene homolog, enhancer-binding protein AP1, jun oncogene, p39, proto-oncogene c-Jun, transcription factor AP-1, and v-jun sarcoma virus 17 oncogene homolog (avian). This gene is the putative transforming gene of avian sarcoma virus 17. It encodes a protein which is highly similar to the viral protein, and which interacts directly with specific target DNA sequences to regulate gene expression. This gene is intronless and is mapped to 1p32-p31, a chromosomal region involved in both translocations and deletions in human malignancies. Use of JUN as marker gene may be cancer and auto-immune diseases; i.e. it can be a marker of breast neoplasms, colorectal neoplasms, Crohn disease, and asthma. 
     In the WNT pathway, “XPO1” refers to the gene associated with GenBank Accession No. NM_003400.3 (SEQ ID NO:17), encoding GenPept Accession No. NP_003391.1 (SEQ ID NO:18). Other names for XPO1 include exportin 1 (CRM1, yeast, homolog), exportin-1 (required for chromosome region maintenance), exportin 1 (CRM1 homolog, yeast), exportin-1, chromosome region maintenance 1 protein homolog, and chromosome region maintenance 1 homolog. This cell-cycle-regulated gene encodes a protein that mediates leucine-rich nuclear export signal (NES)-dependent protein transport. The protein specifically inhibits the nuclear export of Rev and U snRNAs. It is involved in the control of several cellular processes by controlling the localization of cyclin B, MPAK, and MAPKAP kinase 2. This protein also regulates NFAT and AP-1. Use of XPO1 as marker gene may be related to cancer; i.e. it can be a marker of breast neoplasms, endometrial neoplasms, and ovarian neoplasms. 
     In the WNT pathway, “ROR2” refers to the gene associated with GenBank Accession No. NM_004560.3 (SEQ ID NO:19), encoding GenPept Accession No. NP_004551.2 (SEQ ID NO:20). Other names for ROR2 include neurotrophic tyrosine kinase receptor-related 2, and tyrosine-protein kinase transmembrane receptor ROR2. The protein encoded by this gene is a receptor protein tyrosine kinase and type I transmembrane protein that belongs to the ROR subfamily of cell surface receptors. The protein may be involved in the early formation of the chondrocytes and may be required for cartilage and growth plate development. Mutations in this gene can cause brachydactyly type B, a skeletal disorder characterized by hypoplasia/aplasia of distal phalanges and nails. In addition, mutations in this gene can cause the autosomal recessive form of Robinow syndrome, which is characterized by skeletal dysplasia with generalized limb bone shortening, segmental defects of the spine, brachydactyly, and a dysmorphic facial appearance. Use of ROR2 as marker gene may be related to cancer; i.e. it can be a marker of breast neoplasms, non-small cell lung cancer, and colorectal neoplasms. 
     In the WNT pathway, “CCND1” refers to the gene associated with GenBank Accession No. NM_053056.2 (SEQ ID NO:21), encoding GenPept Accession No. NP_444284.1 (SEQ ID NO:22). Other names for CCND1 include B-cell CLL/lymphoma 1, BCL-1 oncogene, PRAD1 oncogene, B-cell lymphoma 1 protein, and G1/S-specific cyclin-D1, and cyclin D1 (PRAD1: parathyroid adenomatosis 1). The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations, amplification and overexpression of this gene, which alters cell cycle progression, are observed frequently in a variety of tumors and may contribute to tumorigenesis. Use of CCND1 as marker gene may be related to many diseases; i.e. it can be a marker of various types of cancer and neuro-degenerative diseases. 
     In the WNT pathway, “CTNNB1” refers to the gene associated with GenBank Accession No. NM_001098209.1 (SEQ ID NO:23), encoding GenPept Accession No. NP_001091679.1 (SEQ ID NO:24). Other names for CTNNB1 include catenin beta-1, catenin (cadherin-associated protein), and beta 1 (88 kD). The protein encoded by this gene is part of a complex of proteins that constitute adherens junctions (AJs). AJs are necessary for the creation and maintenance of epithelial cell layers by regulating cell growth and adhesion between cells. The encoded protein also anchors the actin cytoskeleton and may be responsible for transmitting the contact inhibition signal that causes cells to stop dividing once the epithelial sheet is complete. Finally, this protein binds to the product of the APC gene, which is mutated in adenomatous polyposis of the colon. Mutations in this gene are a cause of colorectal cancer (CRC), pilomatrixoma (PTR), medulloblastoma (MDB), and ovarian cancer. Three transcript variants encoding the same protein have been found for this gene. Use of CTNNB1 as marker gene may be related to many diseases; i.e. it can be a marker of various types of cancer particularly colorectal neoplasms and immune diseases. 
     In the hippo pathway, “AMOT” refers to the gene associated with GenBank Accession No. NM_001113490.1 (SEQ ID NO:25), encoding GenPept Accession No. NP_001106962.1 (SEQ ID NO:26). Other names for AMOT include angiomotin p130 isoform, and angiomotin p80 isoform. This gene belongs to the motin family of angiostatin binding proteins characterized by conserved coiled-coil domains and C-terminal PDZ binding motifs. The encoded protein is expressed predominantly in endothelial cells of capillaries as well as larger vessels of the placenta where it may mediate the inhibitory effect of angiostatin on tube formation and the migration of endothelial cells toward growth factors during the formation of new blood vessels. Alternative splicing results in multiple transcript variants encoding different isoforms. Use of AMOT as marker gene may be related to cancer; i.e. it can be a marker of breast neoplasms, endometrial neoplasms, and leukemia. 
     In the hippo pathway, “DVL2” refers to the gene associated with GenBank Accession No. NM_004422.2 (SEQ ID NO:27), encoding GenPept Accession No. NP_004413.1 (SEQ ID NO:28). Other names for DVL2 include dishevelled 2 (homologous to  Drosophila  dsh), segment polarity protein dishevelled homolog DVL-2, dishevelled, dsh homolog 2, and dishevelled, dsh homolog 2 ( Drosophila ). This gene belongs to the motin family of angiostatin binding proteins characterized by conserved coiled-coil domains and C-terminal PDZ binding motifs. This gene encodes a member of the dishevelled (dsh) protein family. The vertebrate dsh proteins have approximately 40% amino acid sequence similarity with  Drosophila  dsh. This gene encodes a 90-kD protein that undergoes posttranslational phosphorylation to form a 95-kD cytoplasmic protein, which may play a role in the signal transduction pathway mediated by multiple Wnt proteins. The mechanisms of dishevelled function in Wnt signaling are likely to be conserved among metazoans. Use of DVL2 as marker gene may be related to cancer and psychiatry diseases; i.e. it can be a marker of breast neoplasms, non-small cell cancer, bipolar disorder, and tobacco use disorder. 
     In the hippo pathway, “LATS1” refers to the gene associated with GenBank Accession No. NM_004690.3 (SEQ ID NO:29), encoding GenPept Accession No. NP_004681.1 (SEQ ID NO:30). Other names for LATS1 include WARTS protein kinase, LATS (large tumor suppressor,  Drosophila ) homolog 1, large tumor suppressor homolog 1, serine/threonine-protein kinase LATS1, h-warts, LATS, large tumor suppressor, homolog 1, LATS, and large tumor suppressor, homolog 1 ( Drosophila ). This gene belongs to the motin family of angiostatin binding proteins characterized by conserved coiled-coil domains and C-terminal PDZ binding motifs. This gene encodes a member of the dishevelled (dsh) protein family. The vertebrate dsh proteins have approximately 40% amino acid sequence similarity with  Drosophila  dsh. This gene encodes a 90-kD protein that undergoes posttranslational phosphorylation to form a 95-kD cytoplasmic protein, which may play a role in the signal transduction pathway mediated by multiple Wnt proteins. The mechanisms of dishevelled function in Wnt signaling are likely to be conserved among metazoans. Use of LATS1 as marker gene may be related to cancer and psychiatry diseases; i.e. it can be a marker of breast neoplasms, non-small cell cancer, bipolar disorder, and tobacco use disorder. 
     In the hippo pathway, “LATS2” refers to the gene associated with GenBank Accession No. XM_005266342.1 (SEQ ID NO:31), encoding GenPept Accession No. XP_005266399.1 (SEQ ID NO:32). Other names for LATS2 include serine/threonine kinase KPM, warts-like kinase, LATS (large tumor suppressor,  Drosophila ) homolog 2, kinase phosphorylated during mitosis protein, large tumor suppressor homolog 2, serine/threonine-protein kinase kpm, serine/threonine-protein kinase LATS2, LATS, large tumor suppressor, homolog 2, LATS, and large tumor suppressor, homolog 2 ( Drosophila ). This gene encodes a serine/threonine protein kinase belonging to the LATS tumor suppressor family. The protein localizes to centrosomes during interphase, and early and late metaphase. It interacts with the centrosomal proteins aurora-A and ajuba and is required for accumulation of gamma-tubulin and spindle formation at the onset of mitosis. It also interacts with a negative regulator of p53 and may function in a positive feedback loop with p53 that responds to cytoskeleton damage. Additionally, it can function as a co-repressor of androgen-responsive gene expression. Use of LATS2 as marker gene may be related to cancer and immune diseases; i.e. it can be a marker of breast neoplasms and asthma. 
     In the hippo pathway, “MOB1B” refers to the gene associated with GenBank Accession No. NM_001244766.1 (SEQ ID NO:33), encoding GenPept Accession No. NP_001231695.1 (SEQ ID NO:34). Other names for MOB1B include MOB1 Mps One Binder homolog B, MOB1 Mps One Binder homolog B (yeast), MOB1, Mps One Binder kinase activator-like 1A (yeast), mob1A, mps one binder kinase activator-like 1A, mob1 homolog 1A, MOB1, and Mps One Binder kinase activator-like 1A. The protein encoded by this gene is similar to the yeast Mob1 protein. Yeast Mob1 binds Mps1p, a protein kinase essential for spindle pole body duplication and mitotic checkpoint regulation. Three transcript variants encoding different isoforms have been found for this gene. Use of MOB1B as marker gene may be related to cancer; i.e. it can be a marker of breast neoplasms, endometrial neoplasms, and lung neoplasms. 
     In the hippo pathway, “NPHP4” refers to the gene associated with GenBank Accession No. NM_015102.4 (SEQ ID NO:35), encoding GenPept Accession No. NP_055917.1 (SEQ ID NO:36). Other names for NPHP4 include nephroretinin, nephrocystin-4, and POC10 centriolar protein homolog. This gene encodes a protein involved in renal tubular development and function. This protein interacts with nephrocystin, and belongs to a multifunctional complex that is localized to actin- and microtubule-based structures. Mutations in this gene are associated with nephronophthisis type 4, a renal disease, and with Senior-Loken syndrome type 4, a combination of nephronophthisis and retinitis pigmentosa. Alternative splicing results in multiple transcript variants. Use of NPHP4 as marker gene may be related to cancer and eye diseases; i.e. it can be a marker of breast neoplasms, endometrial neoplasms, and retinitis. 
     In the hippo pathway, “TJP1” refers to the gene associated with GenBank Accession No. NM_003257.4 (SEQ ID NO:37), encoding GenPept Accession No. NP_003248.3 (SEQ ID NO:38). Other names for TJP1 include tight junction protein ZO-1, zona occludens 1, and zonula occludens 1 protein. This gene encodes a protein located on a cytoplasmic membrane surface of intercellular tight junctions. The encoded protein may be involved in signal transduction at cell-cell junctions. Alternative splicing of this gene results in multiple transcript variants. Use of TJP1 as marker gene may be related to cancer and immune diseases; i.e. it can be a marker of breast neoplasms, hepatocellular neoplasms, and asthma. 
     In the hippo pathway, “TJP2” refers to the gene associated with GenBank Accession No. NM_004817.3 (SEQ ID NO:39), encoding GenPept Accession No. NP_004808.2 (SEQ ID NO:40). Other names for TJP2 include Friedreich ataxia region gene X104 (tight junction protein ZO-2), deafness, autosomal dominant 51, zonula occludens protein 2, tight junction protein ZO-2, and zona occludens 2. This gene encodes a zonula occluden that is a member of the membrane-associated guanylate kinase homolog family. The encoded protein functions as a component of the tight junction barrier in epithelial and endothelial cells and is necessary for proper assembly of tight junctions. Mutations in this gene have been identified in patients with hypercholanemia, and genomic duplication of a 270 kb region including this gene causes autosomal dominant deafness-51. Alternatively spliced transcripts encoding multiple isoforms have been observed for this gene. Use of TJP2 as marker gene may be related to cancer; i.e. it can be a marker of breast neoplasms. 
     In the hippo pathway, “WWC1” refers to the gene associated with GenBank Accession No. NM_001161661.1 (SEQ ID NO:41), encoding GenPept Accession No. NP_001155133.1 (SEQ ID NO:42). Other names for WWC1 include kidney and brain protein, WW, C2 and coiled-coil domain containing 1, HBeAg-binding protein 3, protein WWC1, protein KIBRA, protein phosphatase 1, and regulatory subunit 168. The protein encoded by this gene is a cytoplasmic phosphoprotein that interacts with PRKC-zeta and dynein light chain-1. Alleles of this gene have been found that enhance memory in some individuals. Three transcript variants encoding different isoforms have been found for this gene. Use of WWC1 as marker gene may be related to cancer and neurodegenerative diseases; i.e. it can be a marker of breast neoplasms and Alzheimer disease. 
     In the hippo pathway, “WWTR1” refers to the gene associated with GenBank Accession No. NM_001168278.1 (SEQ ID NO:43), encoding GenPept Accession No. NP_001161750.1 (SEQ ID NO:44). Other names for WWTR1 include transcriptional coactivator with PDZ-binding motif, transcriptional co-activator with PDZ-binding motif, and WW domain-containing transcription regulator protein 1. The molecular function of this gene is relatively unknown. Use of WWTR1 as marker gene may be related to cancer; i.e. it can be a marker of breast neoplasms, endometrial neoplasms, lung neoplasms, and ovarian neoplasms. 
     In the hippo pathway, “YAP1” refers to the gene associated with GenBank Accession No. NM_001282101.1 (SEQ ID NO:45), encoding GenPept Accession No. NP_001269030.1 (SEQ ID NO:46). Other names for YAP1 include Yes-associated protein 1, 65 kDa, yes-associated protein 2, yorkie homolog, 65 kDa Yes-associated protein, protein yorkie homolog, transcriptional coactivator YAP1, and yes-associated protein YAP65 homolog. This gene encodes a downstream nuclear effector of the Hippo signaling pathway which is involved in development, growth, repair, and homeostasis. This gene is known to play a role in the development and progression of multiple cancers as a transcriptional regulator of this signaling pathway and may function as a potential target for cancer treatment. Alternative splicing results in multiple transcript variants encoding different isoforms. Use of YAP1 as marker gene may be related to cancer; i.e. it can be a marker of breast neoplasms. 
     As used herein, an “informative” characteristic, e.g., size, sequence, composition or amount of a marker refers to a characteristic, e.g., size, sequence, composition or amount whose difference is correlated to prognosis or outcome. The informative characteristic, e.g., size, sequence, composition or amount of a marker can be obtained by analyzing either nucleic acid, e.g., DNA or RNA, or protein corresponding to the marker gene. The characteristic, e.g., size (e.g., length or molecular weight), sequence (e.g., nucleic acid sequence or protein sequence), composition (e.g., base or amino acid composition or peptide digest or gene fragment pattern) or amount (e.g., copy number and/or expression level) of a marker, e.g., a marker in a sample from a patient is “informative” if it is different than the wild type or allelic variant of the substance being analyzed. In an embodiment where the amount of a marker is being measured, an amount is “informative” if it is greater than or less than a reference amount by a degree greater than the standard error of the assay employed to assess expression. The informative expression level of a marker can be determined upon statistical correlation of the measured expression level and the outcome, e.g., good response, poor response, long time-to-progression, short time-to-progression, short term survival or long term survival. The result of the statistical analysis can establish a threshold for selecting markers to use in the methods described herein. Alternatively, a marker, e.g., a chromosome locus marker, or a marker gene that has differential characteristic, e.g., size, sequence, composition or amounts will have typical ranges of amounts that are predictive of outcome. An informative characteristic, e.g., size, sequence, composition or amount is a characteristic, e.g., size, sequence, composition or amount that falls within the range of characteristic, e.g., size, sequence, composition or amounts determined for the outcome. Still further, a set of markers may together be “informative” if the combination of their characteristics, e.g., sizes, sequences, compositions or amounts either meets or is above or below a pre-determined score for the combination of markers, e.g., chromosome locus markers, or marker genes, in a set as determined by methods provided herein. Measurement of only one characteristic, e.g., marker, of a marker gene (i.e., DNA, RNA or protein) can provide a prognosis, i.e., indicate outcome. Measurement of more than one characteristic, e.g., marker, of a marker gene can provide a prognosis when the informative amounts of the two characteristics are consistent with each other, i.e., the biologies of the results are not contradictory. Examples of consistent results from measurement of multiple characteristics of a marker gene can be identification of a nonsense mutation or deletion in a DNA or RNA and a low amount or low molecular weight of encoded protein, or a mutation in a region which encodes a binding pocket or active site of a protein and low activity of the encoded protein. A different example can occur when a protein is in a pathway with a feedback loop controlling its synthesis based on its activity level. In this example, a low amount or activity of protein can be associated with a high amount of its mutated mRNA as a tissue, due to the marker gene mutation, thus is starved for the protein activity and repeatedly signals the production of the protein. 
     As used herein, “gene deletion” refers to an amount of DNA copy number less than 2 and “amplification” refers to an amount of DNA copy number greater than 2. A “diploid” amount refers to a copy number equal to 2. The term “diploid or amplification” can be interpreted as “not deletion” of a gene copy. In a marker whose alternative informative amount is gene deletion, amplification generally would not be seen. Conversely, the term “diploid or deletion” can be interpreted as “not amplification” of copy number. In a marker whose alternative informative amount is amplification, gene deletion generally would not be seen. For the sake of clarity, sequence deletion can occur within a gene as a result of marker gene mutation and can result in absence of transcribed protein or a shortened mRNA or protein. Such a deletion may not affect copy number. 
     The terms “long term survival” and “short term survival” refer to the length of time after receiving a first dose of treatment that a cancer patient is predicted to live. A “long term survivor” refers to a patient expected have a slower rate of progression or later death from the tumor than those patients identified as short term survivors. “Enhanced survival” or “a slower rate of death” are estimated life span determinations based upon characteristic, e.g., size, sequence, composition or amount of one or more of markers described herein, e.g., as compared to a reference standard such that 70%, 80%, 90% or more of the population will be alive a sufficient time period after receiving a first dose of treatment. A “faster rate of death” or “shorter survival time” refer to estimated life span determinations based upon characteristic, e.g., size, sequence, composition or amount of one or more of markers described herein, e.g., as compared to a reference standard such that 50%, 40%, 30%, 20%, 10% or less of the population will not live a sufficient time period after receiving a first dose of treatment. In some embodiments, the sufficient time period is at least 6, 12, 18, 24 or 30 months measured from the first day of receiving a cancer therapy. 
     A cancer is “responsive” to a therapeutic agent or there is a “good response” to a treatment if its rate of growth is inhibited as a result of contact with the therapeutic agent, compared to its growth in the absence of contact with the therapeutic agent. Growth of a cancer can be measured in a variety of ways, for instance, the characteristic, e.g., size of a tumor or the expression of tumor markers appropriate for that tumor type may be measured. For solid tumors, the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (Eisenhauer et al. (2009)  E. J. Canc.  45:228-247) can be used to support the identification of markers associated with solid tumors and response of solid tumors to an Aurora A Kinase inhibitor. International Working Groups convene periodically to set, update and publish response criteria for various types of cancers. Such published reports can be followed to support the identification of markers of the subject tumors and their response to Aurora A Kinase inhibitors. Examples are criteria for Acute Myelogenous Leukemia (AML, Cheson et al. (2003)  J. Clin. Oncol.  21:4642-4649), lymphomas, e.g., non-Hodgkin&#39;s and Hodgkin&#39;s lymphoma (Cheson et al. (2007)  J. Clin. Oncol.  25:579-596). Criteria take into account analysis methods such as Positron Emission Tomography (PET), e.g., for identifying sites with measurable altered metabolic activity (e.g., at tumor sites) or to trace specific markers into tumors in vivo, immunohistochemistry, e.g., to identify tumor cells by detecting binding of antibodies to specific tumor markers, and flow cytometry, e.g., to characterize cell types by differential markers and fluorescent stains, in addition to traditional methods such as histology to identify cell composition (e.g., blast counts in a blood smear or a bone marrow biopsy, presence and number of mitotic figures) or tissue structure (e.g., disordered tissue architecture or cell infiltration of basement membrane). The quality of being responsive to an Aurora A Kinase inhibitor, such as alisertib therapy can be a variable one, with different cancers exhibiting different levels of “responsiveness” to a given therapeutic agent, under different conditions. In some embodiments, a breast cancer is responsive to Aurora A Kinase inhibition, e.g., alisertib therapy, if the breast cancer patient has mutations in marker genes LEF1, MAP3K7, FZD2, LATS1 and/or WWC1. In some embodiments, a gastric cancer is responsive to Aurora A Kinase inhibition, e.g., alisertib therapy, if the gastric cancer patient has mutations in marker genes FZD2 and/or LATS2. In some embodiments, a head and neck cancer is responsive to Aurora A Kinase inhibition, e.g., alisertib therapy, if the head and neck cancer patient has mutations in marker genes MAP3K7, JUN, ROR2, CCND1, LATS1, MOB1B and/or NPHP4. In some embodiments, a non-small cell lung cancer is responsive to Aurora A Kinase inhibition, e.g., alisertib therapy, if the non-small cell lung cancer patient has mutations in marker genes XPO1 and/or TJP1. In some embodiments, a small cell lung cancer is responsive to Aurora A Kinase inhibition, e.g., alisertib therapy, if the small cell lung cancer patient has mutations in marker genes LEF1, APC, PRKCA, RORA, CAMK2G, CTNNB1, AMOT, DVL2, TJP1, TJP2, WWTR1 and/or YAP1. Still further, measures of responsiveness can be assessed using additional criteria beyond growth size of a tumor, including patient quality of life, degree of metastases, etc. In addition, clinical prognostic markers and variables can be assessed (e.g., M protein in myeloma, PSA levels in prostate cancer) in applicable situations. 
     A cancer is “non-responsive” or has a “poor response” to a therapeutic agent or there is a poor response to a treatment if its rate of growth is not inhibited, or inhibited to a very low degree, as a result of contact with the therapeutic agent when compared to its growth in the absence of contact with the therapeutic agent. As stated above, growth of a cancer can be measured in a variety of ways, for instance, the size of a tumor or the expression of tumor markers appropriate for that tumor type may be measured. For example, the response definitions used to support the identification of markers associated with non-response of tumors to therapeutic agents, guidelines such as those described above can be used. The quality of being non-responsive to a therapeutic agent can be a highly variable one, with different cancers exhibiting different levels of “non-responsiveness” to a given therapeutic agent, under different conditions. Still further, measures of non-responsiveness can be assessed using additional criteria beyond growth size of a tumor, including patient quality of life, degree of metastases, etc. In addition, clinical prognostic markers and variables can be assessed (e.g., M protein in myeloma, PSA levels in prostate cancer) in applicable situations. 
     As used herein, “long time-to-progression, “long TTP” and “short time-to-progression,” “short TTP” refer to the amount of time until when the stable disease brought by treatment converts into an active disease. On occasion, a treatment results in stable disease which is neither a good nor a poor response, e.g., MR, the disease merely does not get worse, e.g., become a progressive disease, for a period of time. This period of time can be at least 4-8 weeks, at least 3-6 months or more than 6 months. 
     “Treatment” shall mean the use of a therapy to prevent or inhibit further tumor growth, as well as to cause shrinkage of a tumor, and to provide longer survival times. Treatment is also intended to include prevention of metastasis of tumor. A tumor is “inhibited” or “treated” if at least one symptom (as determined by responsiveness/non-responsiveness, time to progression, or indicators known in the art and described herein) of the cancer or tumor is alleviated, terminated, slowed, minimized, or prevented. Any amelioration of any symptom, physical or otherwise, of a tumor pursuant to treatment using a therapeutic regimen (e.g., Aurora A Kinase inhibitor, such as alisertib regimen) as further described herein, is within the scope of the disclosure. 
     As used herein, the term “agent” is defined broadly as anything that cancer cells, including tumor cells, may be exposed to in a therapeutic protocol. In the context of the present disclosure, such agents include, but are not limited to, an Aurora A Kinase inhibitor, such as alisertib agents, as well as chemotherapeutic agents as known in the art and described in further detail herein. 
     The term “probe” refers to any molecule which is capable of selectively binding to a specifically intended target molecule, for example a marker of the disclosure. Probes can be either synthesized by one skilled in the art, or derived from appropriate biological preparations. For purposes of detection of the target molecule, probes may be specifically designed to be labeled, as described herein. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, enzymatic reporter reagents and organic monomers. 
     A “normal” characteristic, e.g., size, sequence, composition or amount of a marker may refer to the characteristic, e.g., size, sequence, composition or amount in a “reference sample.” A reference sample can be a matched normal, e.g., germline, sample from the same patient from whom the tumor, e.g., with a somatic mutation, is derived. A reference sample can be a sample from a healthy subject not having the marker-associated disease or a reference characteristic e.g., the average characteristic, e.g., size, sequence, composition or amount of the wild type marker in several healthy subjects. A reference sample characteristic, e.g., size, sequence, composition or amount may be comprised of a characteristic, e.g., size, sequence, composition or amount of one or more markers from a reference database. Alternatively, a “normal” characteristic, e.g., size, sequence, composition or level of expression of a marker is the characteristic, e.g., size, sequence, composition or amount of the marker, e.g., marker gene in non-tumor cells in a similar environment or response situation from the same patient from whom the tumor is derived. The normal amount of DNA copy number is 2 or diploid, with the exception of X-linked genes in males, where the normal DNA copy number is 1. 
     “Over-expression” and “under-expression” of a marker gene, refer to expression of the marker gene of a patient at a greater or lesser level (e.g. more than three-halves-fold, at least two-fold, at least three-fold, greater or lesser level etc.), respectively, than normal level of expression of the marker gene, e.g., as measured by mRNA or protein, in a test sample that is greater than the standard error of the assay employed to assess expression. A “significant” expression level may refer to a level which either meets or is above or below a pre-determined score for a marker gene set as determined by methods provided herein. 
     “Complementary” refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue of a first nucleic acid region is capable of forming specific hydrogen bonds (“base pairing”) with a residue of a second nucleic acid region which is antiparallel to the first region if the residue is thymine or uracil. Similarly, it is known that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is antiparallel to the first strand if the residue is guanine. A first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if, when the two regions are arranged in an antiparallel fashion, at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region. In an embodiment, the first region comprises a first portion and the second region comprises a second portion, whereby, when the first and second portions are arranged in an antiparallel fashion, at least about 50%, at least about 75%, at least about 90%, or at least about 95% or all of the nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion. 
     “Homologous” as used herein, refers to nucleotide sequence similarity between two regions of the same nucleic acid strand or between regions of two different nucleic acid strands. When a nucleotide residue position in both regions is occupied by the same nucleotide residue, then the regions are homologous at that position. A first region is homologous to a second region if at least one nucleotide residue position of each region is occupied by the same residue. Homology between two regions is expressed in terms of the proportion of nucleotide residue positions of the two regions that are occupied by the same nucleotide residue (i.e., by percent identity). By way of example, a region having the nucleotide sequence 5′-ATTGCC-3′ and a region having the nucleotide sequence 5′-TATGGC-3′ share homology with 50% identity. In one embodiment, the first region comprises a first portion and the second region comprises a second portion, whereby, at least about 50%, at least about 75%, at least about 90%, or at least about 95% of the nucleotide residue positions of each of the portions are occupied by the same nucleotide residue. In an embodiment of 100% identity, all nucleotide residue positions of each of the portions are occupied by the same nucleotide residue. 
     Unless otherwise specified herewithin, the terms “antibody” and “antibodies” broadly encompass naturally-occurring forms of antibodies, e.g., polyclonal antibodies (e.g., IgG, IgA, IgM, IgE) and monoclonal and recombinant antibodies such as single-chain antibodies, two-chain and multi-chain proteins, chimeric, CDR-grafted, human and humanized antibodies and multi-specific antibodies, as well as fragments and derivatives of all of the foregoing, which fragments (e.g., dAbs, scFv, Fab, F(ab)′ 2 , Fab′) and derivatives have at least an antigenic binding site. Antibody derivatives may comprise a protein or chemical moiety conjugated to an antibody. The term “antibody” also includes synthetic and genetically engineered variants. 
     A “kit” is any article of manufacture (e.g., a package or container) comprising at least one reagent, e.g. a probe, for specifically detecting a marker or marker set of the disclosure. The article of manufacture may be promoted, distributed, sold or offered for sale as a unit for performing, e.g., in vitro, the methods of the present disclosure, e.g., on a sample having been obtained from a patient. The reagents included in such a kit can comprise probes/primers and/or antibodies for use in detecting short term and long term survival marker expression. In addition, a kit of the present disclosure can contain instructions which describe a suitable detection assay. Such a kit can be conveniently used, e.g., in a clinical or a contract testing setting, to generate information, e.g., on expression levels, characteristic, e.g., size, sequence or composition of one or more marker, to be recorded, stored, transmitted or received to allow for diagnosis, evaluation or treatment of patients exhibiting symptoms of cancer, in particular patients exhibiting the possible presence of a cancer capable of treatment with Aurora A Kinase inhibition therapy, including, e.g., hematological cancers e.g., myelomas (e.g., multiple myeloma), lymphomas (e.g., non-hodgkins lymphoma), leukemias (e.g., acute myelogenous leukemia), and solid tumors (e.g., breast cancer, ovarian cancer, prostate cancer, head and neck cancer, small cell lung cancer, non-small cell lung cancer, gastric cancer, renal cancer, pancreatic cancer, bladder cancer or melanoma, etc.). 
     The present methods and compositions are designed for use in diagnostics and therapeutics for a patient suffering from cancer. A cancer or tumor is treated or diagnosed according to the present methods. “Cancer” or “tumor” is intended to include any neoplastic growth in a patient, including an initial tumor and any metastases. The cancer can be of the hematological or solid tumor type. Hematological tumors include tumors of hematological origin, including, e.g., myelomas (e.g., multiple myeloma), leukemias (e.g., Waldenstrom&#39;s syndrome, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, other leukemias), lymphomas (e.g., B-cell lymphomas, non-Hodgkin&#39;s lymphoma) and myelodysplastic syndrome. Solid tumors can originate in organs, and include cancers such as in skin, lung, brain, breast, prostate, ovary, colon, kidney, pancreas, liver, esophagus, stomach, intestine, bladder, uterus, cervix, testis, adrenal gland, etc. The cancer can comprise a cell in which a marker gene has a mutation. As used herein, cancer cells, including tumor cells, refer to cells that divide at an abnormal (increased) rate or whose control of growth or survival is different than for cells in the same tissue where the cancer cell arises or lives. Cancer cells include, but are not limited to, cells in carcinomas, such as squamous cell carcinoma, basal cell carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, adenocarcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, undifferentiated carcinoma, bronchogenic carcinoma, melanoma, renal cell carcinoma, hepatoma-liver cell carcinoma, bile duct carcinoma, cholangiocarcinoma, papillary carcinoma, transitional cell carcinoma, choriocarcinoma, semonoma, embryonal carcinoma, mammary carcinomas, gastrointestinal carcinoma, colonic carcinomas, bladder carcinoma, prostate carcinoma, and squamous cell carcinoma of the neck and head region; sarcomas, such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordosarcoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, synoviosarcoma and mesotheliosarcoma; hematologic cancers, such as myelomas, leukemias (e.g., acute myelogenous leukemia, chronic lymphocytic leukemia, granulocytic leukemia, monocytic leukemia, lymphocytic leukemia), and lymphomas (e.g., follicular lymphoma, mantle cell lymphoma, diffuse large Bcell lymphoma, malignant lymphoma, plasmocytoma, reticulum cell sarcoma, or Hodgkins disease); and tumors of the nervous system including glioma, meningoma, medulloblastoma, schwannoma or epidymoma. 
     As used herein, the terms “proliferative disorders” or “proliferative diseases” includes, but is not limited to, cancerous hyperproliferative disorders (e.g., brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head and neck, renal, liver, kidney, ovarian, prostate, colorectal, colon, epidermoid, esophageal, testicular, gynecological or thyroid cancer, acute myeloid leukemia, multiple myeloma, mesothelioma, Non-small cell lung carcinoma (NSCLC), Small cell lung carcinoma (SCLC), neuroblastoma, and acute lymphoblastic leukemia (ALL)); non-cancerous hyperproliferative disorders (e.g., benign hyperplasia of the skin (e.g., psoriasis), restenosis, and benign prostatic hypertrophy (BPH)); and diseases related to vasculogenesis or angiogenesis (e.g., tumor angiogenesis, hemangioma, glioma, melanoma, Kaposi&#39;s sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer). 
     As used herein, the term “noninvasive” refers to a procedure which inflicts minimal harm to a subject. In the case of clinical applications, a noninvasive sampling procedure can be performed quickly, e.g., in a walk-in setting, typically without anaesthesia and/or without surgical implements or suturing. Examples of noninvasive samples include blood, serum, saliva, urine, buccal swabs, throat cultures, stool samples and cervical smears. Noninvasive diagnostic analyses include x-rays, magnetic resonance imaging, positron emission tomography, etc. 
     As used herein, the term “Aurora A kinase” refers to a serine/threonine kinases involved in mitotic progression. Aurora A kinase is also known as AIK, ARK1, AURA, BTAK, STK6, STK7, STK15, AURORA2, MGC34538, and AURKA. A variety of cellular proteins that play a role in cell division are substrates for phosphorylation by the Aurora A kinase enzyme, including, without limitation, p53, TPX-2, XIEg5 (in  Xenopus ), and D-TACC (in  Drosophila ). The Aurora A kinase enzyme is also itself a substrate for autophosphorylation, e.g., at Thr288. Preferably, the Aurora A kinase is a human Aurora A kinase. 
     The term “inhibitor of Aurora A kinase” or “Aurora A kinase inhibitor” is used to signify a compound that is capable of interacting with Aurora A kinase and inhibiting its enzymatic activity. Inhibiting Aurora A kinase enzymatic activity means reducing the ability of Aurora A kinase to phosphorylate a substrate peptide or protein. In various embodiments, such reduction of Aurora A kinase activity is at least about 75%, at least about 90%, at least about 95%, or at least about 99%. In various embodiments, the concentration, e.g., the IC 50 , of Aurora A kinase inhibitor required to reduce an Aurora A kinase enzymatic activity is less than about 1 μM, less than about 500 nM, less than about 100 nM, or less than about 50 nM. In one embodiment, the concentration that is required to inhbit the enzymatic activity of Aurora A kinase is lower than the concentration of the inhibitor that is required to inhibit the enzymatic activity of Aurora B kinase. In an embodiment, the concentration of Aurora A kinase inhibitor required to reduce an Aurora A kinase enzymatic activity is 50 nM to 100 nM. In an embodiment, the concentration of Aurora A kinase inhibitor required to reduce an Aurora A kinase enzymatic activity is 100 nM to 500 nM. In an embodiment, the concentration of Aurora A kinase inhibitor required to reduce an Aurora A kinase enzymatic activity is 50 nM to 500 nM. In an embodiment, the concentration of Aurora A kinase inhibitor required to reduce an Aurora A kinase enzymatic activity is 50 nM to 1 μM. In an embodiment, the concentration of Aurora A kinase inhibitor required to reduce an Aurora A kinase enzymatic activity is 100 nM to 1 μM. In an embodiment, the concentration of Aurora A kinase inhibitor required to reduce an Aurora A kinase enzymatic activity is 500 nM to 1 μM. In various embodiments, the concentration of an Aurora A kinase inhibitor that is required to reduce Aurora A kinase enzymatic activity is at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 50-fold, at least about 100-fold, at least about 500-fold, or at least about 1000-fold lower than the concentration of the inhibitor that is required to reduce Aurora B kinase enzymatic activity. In other embodiments, the concentration of an Aurora A kinase inhibitor that is required to reduce Aurora A kinase enzymatic activity is 2-fold to 10-fold 5-fold to 50-fold, 10-fold to 100-fold, 20-fold to 200-fold or 50-fold to 500-fold lower than the concentration of the inhibitor that is required to reduce Aurora B kinase enzymatic activity. 
     Inhibition of Aurora A and inhibition of Aurora B result in markedly different cellular phenotypes. ( Proc. Natl. Acad. Sci . (2007) 104: 4106 ; Mol Cancer Ther  (2009) 8(7), 2046-56 ; Chem Biol . (2008) 15(6) 552-62). For example, inhibition of Aurora A in the absence of Aurora B inhibition results in increased mitotic index as measured by quantifying phosphorylated histone H3 on serine 10 (pHisH3). pHisH3 is a unique substrate of Aurora B in physiological systems (e.g. intact cells). By contrast, inhibition of Aurora B or dual inhibition of Aurora A and Aurora B results in a decrease in pHisH3. Accordingly, as used herein, the term “selective inhibitor of Aurora A kinase” or “selective Aurora A kinase inhibitor” refers to an inhibitor that exhibits an Aurora A kinase inhibitor phenotype at effective antitumor concentrations. In some embodiments, the selective Aurora A kinase inhibitor causes a transient mitotic delay, as measured by quantification of pHisH3, when administered to mice at a dose where the free fraction adjusted concentration (C ave ) in plasma is equivalent to the free fraction adjusted concentration achieved in plasma in humans at the maximum tolerated dose (MTD). As used herein, “free fraction adjusted concentration” refers to the plasma concentration of free drug (not protein bound). 
     The term “about” is used herein to mean approximately, in the region of, roughly, or around. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 10%. 
     As used herein, the term “comprises” means “includes, but is not limited to.” 
     The term “patient”, as used herein, means an animal, preferably a mammal, more preferably a human. In some embodiments, the patient has been treated with an agent, e.g., an Aurora A kinase selective inhibitor, prior to initiation of treatment according to the method of the disclosure. In some embodiments, the patient is a patient at risk of developing or experiencing a recurrence of a proliferative disorder. 
     The term “aliphatic” or “aliphatic group”, as used herein, means a substituted or unsubstituted straight-chain, branched or cyclic C 1-12  hydrocarbon, which is completely saturated or which contains one or more units of unsaturation, but which is not aromatic. For example, suitable aliphatic groups include substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl groups and hybrids thereof, such as (cylcoalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl. 
     The terms “alkyl”, “alkenyl”, and “alkynyl”, used alone or as part of a larger moiety, refer to a straight and branched chain aliphatic group having from 1 to 12 carbon atoms. For purposes of the present disclosure, the term “alkyl” will be used when the carbon atom attaching the aliphatic group to the rest of the molecule is a saturated carbon atom. However, an alkyl group may include unsaturation at other carbon atoms. Thus, alkyl groups include, without limitation, methyl, ethyl, propyl, allyl, propargyl, butyl, pentyl, and hexyl. 
     For purposes of the present disclosure, the term “alkenyl” will be used when the carbon atom attaching the aliphatic group to the rest of the molecule forms part of a carbon-carbon double bond. Alkenyl groups include, without limitation, vinyl, 1-propenyl, 1-butenyl, 1-pentenyl, and 1-hexenyl. 
     For purposes of the present disclosure, the term “alkynyl” will be used when the carbon atom attaching the aliphatic group to the rest of the molecule forms part of a carbon-carbon triple bond. Alkynyl groups include, without limitation, ethynyl, 1-propynyl, 1-butynyl, 1-pentynyl, and 1-hexynyl. 
     The term “cycloaliphatic”, used alone or as part of a larger moiety, refers to a saturated or partially unsaturated cyclic aliphatic ring system having from 3 to about 14 members, wherein the aliphatic ring system is optionally substituted. In some embodiments, the cycloaliphatic is a monocyclic hydrocarbon having 3-8 or 3-6 ring carbon atoms. Nonlimiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, and cyclooctadienyl. In some embodiments, the cycloaliphatic is a bridged or fused bicyclic hydrocarbon having 6-12, 6-10, or 6-8 ring carbon atoms, wherein any individual ring in the bicyclic ring system has 3-8 members. 
     In some embodiments, two adjacent substituents on the cycloaliphatic ring, taken together with the intervening ring atoms, form an optionally substituted fused 5- to 6-membered aromatic or 3-to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S. Thus, the term “cycloaliphatic” includes aliphatic rings that are fused to one or more aryl, heteroaryl, or heterocyclyl rings. Nonlimiting examples include indanyl, 5,6,7,8-tetrahydro-quinoxalinyl, decahydronaphthyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aliphatic ring. The term “cycloaliphatic” may be used interchangeably with the terms “carbocycle”, “carbocyclyl”, “carbocyclo”, or “carbocyclic”. 
     The terms “aryl” and “ar-”, used alone or as part of a larger moiety, e.g., “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refer to a C 6  to C 14  aromatic hydrocarbon, comprising one to three rings, each of which is optionally substituted. Preferably, the aryl group is a C 6-10  aryl group. Aryl groups include, without limitation, phenyl, naphthyl, and anthracenyl. In some embodiments, two adjacent substituents on the aryl ring, taken together with the intervening ring atoms, form an optionally substituted fused 5- to 6-membered aromatic or 4- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S. Thus, the term “aryl”, as used herein, includes groups in which an aromatic ring is fused to one or more heteroaryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the aromatic ring. Nonlimiting examples of such fused ring systems include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, fluorenyl, indanyl, phenanthridinyl, tetrahydronaphthyl, indolinyl, phenoxazinyl, benzodioxanyl, and benzodioxolyl. An aryl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic. The term “aryl” may be used interchangeably with the terms “aryl group”, “aryl moiety”, and “aryl ring”. 
     An “aralkyl” or “arylalkyl” group comprises an aryl group covalently attached to an alkyl group, either of which independently is optionally substituted. Preferably, the aralkyl group is C 6-10  aryl(C 1-6 )alkyl, C 6-10  aryl(C 1-4 )alkyl, or C 6-10  aryl(C 1-3 )alkyl, including, without limitation, benzyl, phenethyl, and naphthylmethyl. 
     The terms “heteroaryl” and “heteroar-”, used alone or as part of a larger moiety, e.g., heteroaralkyl, or “heteroaralkoxy”, refer to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 □ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to four heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. In some embodiments, two adjacent substituents on the heteroaryl, taken together with the intervening ring atoms, form an optionally substituted fused 5- to 6-membered aromatic or 4- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of 0, N, and S. Thus, the terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. A heteroaryl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group”, or “heteroaromatic”, any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted. 
     As used herein, the terms “heterocycle”, “heterocyclyl”, “heterocyclic radical”, and “heterocyclic ring” are used interchangeably and refer to a stable 3- to 7-membered monocyclic, or to a fused 7- to 10-membered or bridged 6- to 10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term “nitrogen” includes a substituted nitrogen. As an example, in a heterocyclyl ring having 1-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or  + NR (as in N-substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. 
     In some embodiments, two adjacent substituents on a heterocyclic ring, taken together with the intervening ring atoms, for an optionally substituted fused 5- to 6-membered aromatic or 3- to 8-membered non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of 0, N, and S. Thus, the terms “heterocycle”, “heterocyclyl”, “heterocyclyl ring”, “heterocyclic group”, “heterocyclic moiety”, and “heterocyclic radical”, are used interchangeably herein, and include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocyclyl ring. A heterocyclyl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted. 
     As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond between ring atoms. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined. 
     The terms “haloaliphatic”, “haloalkyl”, “haloalkenyl” and “haloalkoxy” refer to an aliphatic, alkyl, alkenyl or alkoxy group, as the case may be, which is substituted with one or more halogen atoms. As used herein, the term “halogen” or “halo” means F, Cl, Br, or I. The term “fluoroaliphatic” refers to a haloaliphatic wherein the halogen is fluoro. 
     The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., —(CH 2 ) n —, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms is replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group. An alkylene chain also may be substituted at one or more positions with an aliphatic group or a substituted aliphatic group. 
     The term “substituted”, as used herein, means that a hydrogen radical of the designated moiety is replaced with the radical of a specified substituent, provided that the substitution results in a stable or chemically feasible compound. The phrase “one or more substituents”, as used herein, refers to a number of substituents that equals from one to the maximum number of substituents possible based on the number of available bonding sites, provided that the above conditions of stability and chemical feasibility are met. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and the substituents may be either the same or different. 
     An aryl (including the aryl moiety in aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including the heteroaryl moiety in heteroaralkyl and heteroaralkoxy and the like) group may contain one or more substituents. Examples of suitable substituents on the unsaturated carbon atom of an aryl or heteroaryl group 
     include -halo, —NO 2 , —CN, —R*, —C(R*)═C(R*) 2 , —C═C—R*, —OR*, —SRº, —S(O)Rº, —SO 2 Rº, SO 3 Rº, —SO 2 N(R + ) 2 , —N(R + ) 2 , —NR + C(O)R*, —NR + C(O)N(R + ) 2 , —NR + CO 2 Rº, —O—CO 2 R*, —OC(O)N(R + ) 2 , —O—C(O)R*, —CO 2 R*, —C(O)—C(O)R*, —C(O)R*, —C(O)N(R + ) 2 , —C(O)N(R + )C(═NR + )—N(R + ) 2 , —N(R + )C(═NR + )—N(R + )—C(O)R*, —C(═NR + )—N(R + ) 2 , —C(═NR + )—OR*, —N(R + )—N(R + ) 2 , —N(R + )C(═NR + )—N(R + ) 2 , —NR + SO 2 Rº, —NR + SO 2 N(R + ) 2 , —P(O)(R*) 2 , —P(O)(OR*) 2 , —O—P(O)—OR*, and —P(O)(NR + )—N(R + ) 2 ; or two adjacent substituents, taken together with their intervening atoms, form a 5-6 membered unsaturated or partially unsaturated ring having 0-3 ring atoms selected from the group consisting of N, O, and S. 
     An aryl (including the aryl moiety in aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including the heteroaryl moiety in heteroaralkyl and heteroaralkoxy and the like) group may contain one or more substituents. Examples of suitable substituents on the unsaturated carbon atom of an aryl or heteroaryl group 
     include -halo, —NO 2 , —CN, —R*, —C(R*)═C(R*) 2 , —C═C—R*, —OR*, —SRº, —S(O)Rº, —SO 2 Rº, —SO 3 Rº, —SO 2 N(R + ) 2 , —N(R + ) 2 , —NR + C(O)R*, —NR + C(O)N(R + ) 2 , —NR + CO 2 Rº, —O—CO 2 R*, —OC(O)N(R + ) 2 , —O—C(O)R*, —CO 2 R*, —C(O)—C(O)R*, —C(O)R*, —C(O)N(R + ) 2 , —C(O)N(R + )C(═NR + )—N(R + ) 2 , —N(R + )C(═NR + )—N(R + )—C(O)R*, —C(═NR)—N(R + ) 2 , —C(═NR + )—OR*, —N(R + )—N(R) 2 , —N(R + )C(═NR + )—N(R) 2 , —NR + SO 2 Rº, —NR + SO 2 N(R + ) 2 , —P(O)(R*) 2 , —P(O)(OR*) 2 , —O—P(O)—OR*, and —P(O)(NR)—N(R + ) 2 ; or two adjacent substituents, taken together with their intervening atoms, form a 5-6 membered unsaturated or partially unsaturated ring having 0-3 ring atoms selected from the group consisting of N, O, and S. 
     Each R + , independently, is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group, or two R +  on the same nitrogen atom, taken together with the nitrogen atom, form a 5-8 membered aromatic or non-aromatic ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S. Each R* independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group. Each Rº is an optionally substituted aliphatic or aryl group. 
     An aliphatic group or a non-aromatic heterocyclic ring may be substituted with one or more substituents. Examples of suitable substituents on the saturated carbon of an aliphatic group or of a non-aromatic heterocyclic ring include, without limitation, those listed above for the unsaturated carbon of an aryl or heteroaryl group and the following: ═O, ═S, ═C(R*) 2 , ═N—N(R*) 2 , ═N—OR*, ═N—NHC(O)R*, ═N—NHCO 2 Rº, ═N—NHSO 2 Rº, or ═N—R*, where each R* and Rº is as defined above. 
     Suitable substituents on the nitrogen atom of a non-aromatic heterocyclic ring include —R*, —N(R*) 2 , —C(O)R*, —CO 2 R*, —C(O)—C(O)R* —C(O)CH 2 C(O)R*, —SO 2 R*, —SO 2 N(R*) 2 , —C(═S)N(R*) 2 , —C(═NH)—N(R*) 2 , and —NR*SO 2 R*; wherein each R* is as defined above. 
     Unless otherwise stated, structures depicted herein are meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structure except for the replacement of a hydrogen atom by a deuterium or tritium, or the replacement of a carbon atom by a  13 C- or  14 C-enriched carbon are within the scope of the disclosure. 
     It will be apparent to one skilled in the art that certain compounds described herein may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the disclosure. Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the disclosure. 
     Any molecule capable of selectively inhibiting the enzymatic activity of Aurora A kinase may be used in the methods, pharmaceutical compositions, and kits of the present disclosure. In some embodiments the selective Aurora A kinase inhibitor is a small molecular weight compound. In particular, selective inhibitors of Aurora A kinase include the compounds described herein, as well as compounds disclosed in, for example, US Publication No. 2008/0045501, U.S. Pat. No. 7,572,784, WO 05/111039, WO 08/021038, U.S. Pat. No. 7,718,648, WO 08/063525, US Publication No. 2008/0167292, U.S. Pat. No. 8,026,246, WO 10/134965, US Publication No. 2010/0310651, WO 11/014248, US Publication No. 2011/0039826, and US Publication No. 2011/0245234, each of which is hereby incorporated by reference in its entirety, as well as the compounds sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate, KW-2449 (Kyowa), ENMD-2076 (EntreMed), and MK-5108 (Vertex/Merck). Also suitable for use in the methods, pharmaceutical compositions, and kits of the disclosure are solvated and hydrated forms of any of these compounds. Also suitable for use in the methods, pharmaceutical compositions, and kits of the disclosure are pharmaceutically acceptable salts of any of the compounds, and solvated and hydrated forms of such salts. These selective Aurora A kinase inhibitors can be prepared in a number of ways well known to one skilled in the art of organic synthesis, including, but not limited to, the methods of synthesis described in detail in the references referred to herein. 
     Aurora A kinase inhibitors can be assayed in vitro or in vivo for their ability to selectively bind to and/or inhibit an Aurora A kinase. In vitro assays include assays to determine selective inhibition of the ability of an Aurora A kinase to phosphorylate a substrate protein or peptide. Alternate in vitro assays quantitate the ability of the compound to selectively bind to an Aurora A kinase. Selective inhibitor binding may be measured by radiolabelling the inhibitor prior to binding, isolating the inhibitor/Aurora A kinase complex and determining the amount of radiolabel bound. Alternatively, selective inhibitor binding may be determined by running a competition experiment in which new inhibitors are incubated with Aurora A kinase bound to a known radioligand. The compounds also can be assayed for their ability to affect cellular or physiological functions mediated by Aurora A kinase activity. In order to assess selectivity for Aurora A kinase over Aurora B kinase, inhibitors can also be assayed in vitro and in vivo for their ability to selectively bind to and/or inhibit an Aurora B kinase, using assays analogous to those described above for Aurora A kinase. Inhibitors can be assayed in vitro and in vivo for their ability to inhibit Aurora A kinase in the absence of Aurora B kinase inhibition, by immunofluorescent detection of pHisH3. ( Proc. Natl. Acad. Sci . (2007) 104, 4106). Assays for each of these activities are known in the art. 
     In some embodiments, the selective Aurora A kinase inhibitor is a compound represented by formula (I): 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt thereof;
 
wherein:
         Ring A is a substituted or unsubstituted 5- or 6-membered aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring;   Ring B is a substituted or unsubstituted aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring;   Ring C is a substituted or unsubstituted aryl, heteroaryl, heterocyclyl, or cycloaliphatic ring;   R e  is hydrogen, —OR 5 , —N(R 4 ) 2 , —SR 5 , or a C 1-3  aliphatic optionally substituted with R 3  or R 7 ;   each of R x  and R y  independently is hydrogen, fluoro, or an optionally substituted C 1-6  aliphatic; or
           R x  and R y , taken together with the carbon atom to which they are attached, form an optionally substituted 3- to 6-membered cycloaliphatic ring;   
           each R 3  independently is selected from the group consisting
           of -halo, —OH, —O(C 1-3  alkyl), —CN, —N(R 4 ) 2 , —C(O)(C 1-3  alkyl), —CO 2 H, —CO 2 (C 1-3  alkyl), —C(O) NH 2 , and —C(O)NH(C 1-3  alkyl);   
           each R 4  independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R 4  on the same nitrogen atom, taken together with the nitrogen atom, form an optionally substituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S;   each R 5  independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; and each R 7  independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group.       

     Ring A is a substituted or unsubstituted 5- or 6-membered aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring. Examples of Ring A include furano, dihydrofurano, thieno, dihydrothieno, cyclopenteno, cyclohexeno, 2H-pyrrolo, pyrrolo, pyrrolino, pyrrolidino, oxazolo, thiazolo, imidazolo, imidazolino, imidazolidino, pyrazolo, pyrazolino, pyrazolidino, isoxazolo, isothiazolo, oxadiazolo, triazolo, thiadiazolo, 2H-pyrano, 4H-pyrano, benzo, pyridino, piperidino, dioxano, morpholino, dithiano, thiomorpholino, pyridazino, pyrimidino, pyrazino, piperazino, and triazino, any of which groups may be substituted or unsubstituted. Preferred values for Ring A include, without limitation, substituted or unsubstituted rings selected from the group consisting of furano, thieno, pyrrolo, oxazolo, thiazolo, imidazolo, pyrazolo, isoxazolo, isothiazolo, triazolo, benzo, pyridino, pyridazino, pyrimidino, and pyrazino. 
     Ring A may be substituted or unsubstituted. In some embodiments, each substitutable saturated ring carbon atom in Ring A is unsubstituted or is substituted with ═O, ═S, ═C(R 5 ) 2 , ═N—N(R 4 ) 2 , ═N—OR 5 , ═N—NHC(O)R 5 , ═N—NHCO 2 R 6 , ═N—NHSO 2 R 6 , ═N—R 5  or —R b , where R b , R 4 , R 5 , and R 6  are as defined below. Each substitutable unsaturated ring carbon atom in Ring A is unsubstituted or substituted with —R b . Each substitutable ring nitrogen atom in Ring A is unsubstituted or is substituted with —R 9b , and one ring nitrogen atom in Ring A optionally is oxidized. Each R 9b  independently is —C(O)R 5 , —C(O)N(R 4 ) 2 , —CO 2 R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , or a C 1-4  aliphatic optionally substituted with R 3  or R 7 . 
     Each R b  independently is R 2b , an optionally substituted aliphatic, or an optionally substituted aryl, heterocyclyl, or heteroaryl group; or two adjacent R b , taken together with the intervening ring atoms, form an optionally substituted fused 4- to 8-membered aromatic or non-aromatic ring having 0-3 ring heteroatoms selected from the group consisting of O, N, and S. 
     Each R 2b  independently 
     is -halo, —NO 2 , —CN, —C(R 5 )═C(R 5 ) 2 , —C(R 5 )═C(R 5 )(R 10 ), —C≡C—R 5 , —C≡C—R 10 , —OR 5 , —SR 6 , —S(O)R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , —N(R 4 ) 2 , —NR 4 C(O)R 5 , —NR 4 C(O)N(R 4 ) 2 , —NR 4 CO 2 R 6 , —O—CO 2 R 5 , —OC(O)N(R 4 ) 2 , —O—C(O)R 5 , —CO 2 R 5 , —C(O)—C(O)R 5 , —C(O)R 5 , —C(O)N(R 4 ) 2 , —C(═NR 4 )—N(R 4 ) 2 , —C(═NR 4) —OR 5 , —N(R 4 )—N(R 4 ) 2 , N(R 4 )C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )SO 2 R 6 , —N(R 4 )SO 2 N(R 4 ) 2 , —P(O)(R 5 ) 2 , or —P(O)(OR 5 ) 2 , where the variables R 4 , R 5 , and R 7  have the values described above; each R 6  independently is an optionally substituted aliphatic or aryl group; and each R 10  independently is —CO 2 R 5  or —C(O)N(R 4 ) 2 . 
     In some embodiments, Ring A is substituted by 0-2 substituents R b . In some such embodiments, each R b  independently is C 1-3  aliphatic or R 2b , and each R 2b  independently is selected from the group consisting of -halo, —NO 2 , —C(R 5 )═C(R 5 ) 2 , —C≡C—R 5 , —OR 5 , and —N(R 4 ) 2 . In some embodiments, each R b  independently is selected from the group consisting of -halo, C 1-3  aliphatic, C 1-3  fluoroaliphatic, and —OR 5 , where R 5  is hydrogen or C 1-3  aliphatic. In certain preferred embodiments, Ring A is substituted with 0, 1, or 2 substituents, preferably 0 or 1 substituents, independently selected from the group consisting of chloro, fluoro, bromo, methyl, trifluoromethyl, and methoxy. 
     In some embodiments, Ring B is a substituted or unsubstituted mono- or bicyclic aryl or heteroaryl ring selected from the group consisting of furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indolyl, isoindolyl, indazolyl, benzo[b]furanyl, benzo[b]thienyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, purinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and pteridinyl. 
     Each substitutable saturated ring carbon atom in Ring B is unsubstituted or is substituted with ═O, ═S, ═C(R 5 ) 2 , ═N—N(R 4 ) 2 , ═N—OR 5 , ═N—NHC(O)R 5 , ═N—NHCO 2 R 6 , ═N—NHSO 2 R 6 , ═N—R 5  or —R c . Each substitutable unsaturated ring carbon atom in Ring B is unsubstituted or substituted with —R c . Each substitutable ring nitrogen atom in Ring B is unsubstituted or is substituted with —R 9c , and one ring nitrogen atom in Ring B optionally is oxidized. Each R 9c  independently is —C(O)R 5 , —C(O)N(R 4 ) 2 , —CO 2 R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , or a C 1-4  aliphatic optionally substituted with R 3  or R 7 . Ring B may be unsubstituted or may be substituted on any one or more of its component rings, wherein the substituents may be the same or different. In some embodiments, Ring B is substituted with 0-2 independently selected R c  and 0-3 independently selected R 2c  or C 1-6  aliphatic groups. The variables R 3 , R 4 , R 5 , R 6 , and R 7  are as defined above for Ring A, and R c  and R 2c  are defined below. 
     Each R c  independently is R 2c , an optionally substituted C 1-6  aliphatic, or an optionally substituted aryl, heteroaryl, or heterocyclyl group. 
     Each R 2c  independently is -halo, —NO 2 , —CN, — 
     C(R 5 )═C(R 5 ) 2 , —C(R 5 )═C(R 5 )(R 10 ), —C≡C—R 5 , —C≡C—R 10 , —OR 5 , —SR 6 , —S(O)R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , —N(R 4 ) 2 , —NR 4 C(O)R 5 , —NR 4 C(O)N(R 4 ) 2 , —NR 4 CO 2 R 6 , —O—CO 2 R 5 , —OC(O)N(R 4 ) 2 , —O—C(O)R 5 , —CO 2 R 5 , —C (O)—C(O)R 5 , —C(O)R 5 , —C(O)N(R 4 ) 2 , —C(═NR 4 )—N(R 4 ) 2 , —C(═NR 4 )—OR 5 , —N(R 4 )—N(R 4 ) 2 , —N(R 4 )C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )SO 2 R 6 , —N(R 4 )SO 2 N(R 4 ) 2 , —P(O)(R 5 ) 2 , or —P(O)(OR 5 ) 2 . 
     In some embodiments, Ring B is a monocyclic 5- or 6-membered aryl or heteroaryl ring, substituted with 0-2 independently selected R c  and 0-2 independently selected R 2c  or C 1-6  aliphatic groups. In certain such embodiments, Ring B is a substituted or unsubstituted phenyl or pyridyl ring. 
     In some embodiments, Ring B is substituted with 0-2 substituents R c . In some such embodiments, each R c  independently is C 1-3  aliphatic or R 2c , and each R 2c  independently is selected from the group consisting of -halo, —NO 2 , —C(R 5 )═C(R 5 ) 2 , —C≡C—R 5 , —OR 5 , and —N(R 4 ) 2 . In some embodiments, each R c  independently is selected from the group consisting of -halo, C 1-3  aliphatic, C 1-3  haloaliphatic, and —OR 5 , where R 5  is hydrogen or C 1-3  aliphatic. In certain preferred embodiments, Ring B is substituted with 0, 1, or 2 substituents, independently selected from the group consisting of chloro, fluoro, bromo, methyl, trifluoromethyl, and methoxy. 
     Each substitutable saturated ring carbon atom in Ring C is unsubstituted or is substituted with ═O, ═S, ═C(R 5 ) 2 , ═N—N(R 4 ) 2 , ═N—OR 5 , ═N—NHC(O)R 5 , ═N—NHCO 2 R 6 , ═N—NHSO 2 R 6 , ═N—R 5  or —R d . Each substitutable unsaturated ring carbon atom in Ring C is unsubstituted or substituted with —R d . Each substitutable ring nitrogen atom in Ring C is unsubstituted or is substituted with —R 9d , and one ring nitrogen atom in Ring C optionally is oxidized. Each R 9d  independently is —C(O)R 5 , —C(O)N(R 4 ) 2 , —CO 2 R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , or a C 1-4  aliphatic optionally substituted with R 3  or R 7 . Ring C may be unsubstituted or may be substituted on any one or more of its component rings, wherein the substituents may be the same or different. In some embodiments, Ring C is substituted with 0-2 independently selected R d  and 0-3 independently selected R 2d  or C 1-6  aliphatic groups. The variables R 3 , R 4 , R 5 , R 6 , and R 7  are as described above for Rings A and B. The variables R d  and R 2d  are described below. 
     Each R d  independently is R 2d , an optionally substituted aliphatic, or an optionally substituted aryl, heteroaryl, or heterocyclyl group. 
     Each R 2d  independently is -halo, —NO 2 , —CN, —C(R 5 )═C(R 5 ) 2 , — 
     C(R 5 )═C(R 5 ) 2 (R 10 ), —C≡C—R 5 , —C≡C—R, —OR 5 , —SR 6 , —S(O)R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , —N(R 4 ) 2 , —NR 4 C(O)R 5 , —NR 4 C(O)N(R 4 ) 2 , —NR 4 CO 2 R 6 , —O—CO 2 R 5 , —OC(O)N(R 4 ) 2 , —O—C(O)R 5 , —CO 2 R 5 , —C(O)—C(O)R 5 , —C(O)R 5 , —C(O)N(R 4 ) 2 , —C(═NR 4 )—N(R 4 ) 2 , —C(═NR 4 )—OR 5 , —N(R 4 )—N(R 4 ) 2 , —N(R 4 )C(═NR 4 )—N(R 4 ) 2 , —N( R 4 )SO 2 R 6 , —N(R 4 )SO 2 N(R 4 ) 2 , —P(O)(R 5 ) 2 , or —P(O)(OR 5 ) 2 . Additionally, R 2d  can be —SO 3 R 5 , —C(O)N(R 4 )C(═NR 4 )—N(R 4 ) 2  or —N(R 4 )C(═NR 4 )—N(R 4 )—C(O)R 5 . 
     In some embodiments, Ring C is a monocyclic 5- or 6-membered aryl or heteroaryl ring, which is substituted with 0-2 independently selected substituents R d  and 0-2 independently selected R 2d  or C 1 6 aliphatic groups. In some such embodiments, Ring C is an optionally substituted heteroaryl ring selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, and oxazolyl. In some other embodiments, Ring C is a substituted or unsubstituted phenyl ring. In some embodiments, Ring C is a monocyclic 5- or 6-membered aryl or heteroaryl ring, which is substituted with 0, 1, or 2 substituents R d , as defined above. 
     In some other embodiments, Ring C is a monocyclic 5- or 6-membered heterocyclyl or cycloaliphatic ring, which is substituted with 0-2 independently selected substituents R d  and 0-2 independently selected R 2d  or C 1-6  aliphatic groups. 
     In some embodiments, the selective Aurora A kinase inhibitor is a compound represented by formula (II): 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt thereof;
 
wherein:
         R e  is hydrogen or a C 1-3  aliphatic optionally substituted with R 3  or R 7 ;   Ring A is substituted with 0-3 R b ;
           each R b  independently is selected from the group consisting of C 1-6  aliphatic, R 2b , R 7b , -T 1 -R 2b , and -T 1 -R 7b ;   each R 2b  independently
               is -halo, —NO 2 , —CN, —C(R 5 )═C(R 5 ) 2 , —C≡C—R 5 , —OR 5 , —SR 6 , —S(O)R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , —N(R 4 ) 2 , —NR 4 C(O)R 5 , —NR 4 C(O)N(R 4 ) 2 , —NR 4 CO 2 R 6 , —O—CO 2 R 5 , —OC(O)N(R 4 ) 2 , —O—C(O)R 5 , —CO 2 R 5 , —C(O)—C(O)R 5 , —C(O)R 5 , —C(O)N(R 4 ) 2 , —C(═NR 4 )—N(R 4 ) 2 , —C(═NR 4 )—OR 5 , —N(R 4 )—N(R 4 ) 2 , —N(R 4 )C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )SO 2 R 6 , —N(R 4 )SO 2 N(R 4 ) 2 , —P(O)(R 5 ) 2 , or —P(O)(OR 5 ) 2 ;   
               each R 7b  independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group;   
           Ring B is substituted with 0-2 independently selected R c  and 0-2 independently selected R 2c  or C 1-6  aliphatic groups;
           each R c  independently is selected from the group consisting of C 1-6  aliphatic, R 2c , R 7c , -T 1 -R 2c , and -T 1 -R 7c ;   each R 2c  independently
               is -halo, —NO 2 , —CN, —C(R 5 )═C(R 5 ) 2 , —C≡C—R 5 , —OR 5 , —SR 6 , —S(O)R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , —N(R 4 ) 2 , —NR 4 C(O)R 5 , —NR 4 C(O)N(R 4 ) 2 , —NR 4 CO 2 R 6 , —O—CO 2 R 5 , —OC(O)N(R 4 ) 2 , —O—C(O)R 5 , —CO 2 R 5 , —C(O)—C(O)R 5 , —C(O)R 5 , —C(O)N(R 4 ) 2 , —C(═NR 4 )—N(R 4 ) 2 , —C(═NR 4 )—OR 5 , —N(R 4 )—N(R 4 ) 2 , —N(R 4 )C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )SO 2 R 6 , —N(R 4 )SO 2 N(R 4 ) 2 , —P(O)(R 5 ) 2 , or —P(O)(OR 5 ) 2 ;   
               each R 7c  independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group;   
           T 1  is a C 1-6  alkylene chain optionally substituted with R 3  or R 3b , wherein T 1  or a portion thereof optionally forms part of a 3- to 7-membered ring;   Ring C is substituted with 0-2 independently selected R d  and 0-3 independently selected R 2d  or C 1-6  aliphatic groups;
           each R d  independently is selected from the group consisting of C 1-6  aliphatic, R 2d , R 7d , -T 2 -R 2d , -T 2 -R 7d , —V-T 3 -R 2d , and —V-T 3 -R 7d ;   T 2  is a C 1-6  alkylene chain optionally substituted with R 3  or R 3b , wherein the alkylene chain optionally is interrupted
               by —C(R 5 )═C(R 5 )—, —C≡C—, —O—, —S—, —S(O)—, —S(O) 2 —, —SO 2 N(R 4 )—, —N(R 4 )—, —N(R 4 )C(O)—, —NR 4 C(O)N(R 4 )—, —N(R 4 )CO 2 —, —C(O)N(R 4 )—, —C(O)—, —C(O)—C(O)—, —CO 2 —, —OC(O)—, —OC(O)O—, —OC(O)N(R 4 )—, —N(R 4 )—N(R 4 )—, —N(R 4 )SO 2 —, or —SO 2 N(R 4 )—, and wherein T 2  or a portion thereof optionally forms part of a 3-7 membered ring;   
               T 3  is a C 1-6  alkylene chain optionally substituted with R 3  or R 3b , wherein the alkylene chain optionally is interrupted
               by —C(R 5 )═C(R 5 )—, —C≡C—, —O—, —S—, —S(O)—, —S(O) 2 —, —SO 2 N(R 4 )—, —N(R 4 )—, —N(R 4 )C(O)—, —NR 4 C(O)N(R 4 )—, —N(R 4 )CO 2 —, —C(O)N(R 4 )—, —C(O)—, —C(O)—C(O)—, —CO 2 —, —OC(O)—, —OC(O)O—, —OC(O)N(R 4 )—, —N(R 4 )—N(R 4 )—, —N(R 4 )SO 2 —, or —SO 2 N(R 4 )—, and wherein T 3  or a portion thereof optionally forms part of a 3-7 membered ring;   
               V
               is —C(R 5 )═C(R 5 )—, —C≡C—, —O—, —S—, —S(O)—, —S(O) 2 —, —SO 2 N(R 4 )—, —N(R 4 )—, —N(R 4 )C(O)—, —NR 4 C(O)N(R 4 )—, —N(R 4 )CO 2 —, —C(O)N(R 4 )—, —C(O)—, —C(O)—C(O)—, —CO 2 —, —OC(O)—, —OC(O)O—, —OC(O)N(R 4 )—, —C(NR 4 )═N—, —C(OR 5 )═N—, —N(R 4 )—N(R 4 )—, —N(R 4 )SO 2 —, —N (R 4 )SO 2 N(R 4 )—, —P(O)(R 5 )—, —P(O)(OR 5 )—O—, —P(O)—O—, or —P(O)(NR 5 )—N(R 5 )—;   
               R 2d  
               is -halo, —NO 2 , —CN, —C(R 5 )═C(R 5 ) 2 , —C≡C—R 5 , —OR 5 , —SR 6 , —S(O)R 6 , —SO 2 R 6 , —SO 2 N(R 4 ) 2 , —N(R 4 ) 2 , —NR 4 C(O)R 5 , —NR 4 C(O)N(R 4 ) 2 , —NR 4 CO 2 R 6 , —O—CO 2 R 5 , —OC(O)N(R 4 ) 2 , —O—C(O)R 5 , —CO 2 R 5 , —C(O)—C(O)R 5 , —C(O)R 5 , —C(O)N(R 4 ) 2 , —C(═NR 4 )—N(R 4 ) 2 , —C(═N R 4 )—OR 5 , —N(R 4 )—N(R 4 ) 2 , —N(R 4 )C(═NR 4 )—N(R 4 ) 2 , —N(R 4 )SO 2 R 6 , —N(R 4 )SO 2 N(R 4 ) 2 , —P(O)(R 5 ) 2 , or —P(O)(OR 5 ) 2 ; and   
               each R 7d  independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group.   
           each R 3  independently is selected from the group consisting of -halo, —OH, —O(C 1-3  alkyl), —CN, —N(R 4 ) 2 , —C(O)(C 1-3  alkyl), —CO 2 H, —CO 2 (C 1-3  alkyl), —C(O) NH 2 , and —C(O)NH(C 1-3  alkyl);   each R 3b  independently is a C 1-3  aliphatic optionally substituted with R 3  or R 7 , or two substituents R 3b  on the same carbon atom, taken together with the carbon atom to which they are attached, form a 3- to 6-membered carbocyclic ring;   each R 4  independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R 4  on the same nitrogen atom, taken together with the nitrogen atom, form an optionally substituted 5- to 8-membered heteroaryl or heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S;   each R 5  independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group;   each R 6  independently is an optionally substituted aliphatic or aryl group; and   each R 7  independently is an optionally substituted aryl, heterocyclyl, or heteroaryl group.       

     Table 1 provides the chemical names for specific examples of compounds of formula (II). 
     
       
         
           
               
             
               
                 TABLE 1 
               
               
                   
               
               
                 Examples of Compounds of Formula (II) 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 II-1 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(2-methylamino-ethyl)-benzamide 
               
               
                 II-2 
                 N-(2-Amino-ethyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-ylamino]-N-methyl-benzamide 
               
               
                 II-3 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-methyl-N-(2-methylamino-ethyl)-benzamide 
               
               
                 II-4 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(2-dimethylamino-ethyl)-benzamide 
               
               
                 II-5 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(2-dimethylamino-ethyl)-N-methyl-benzamide 
               
               
                 II-6 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(3-dimethylamino-propyl)-benzamide 
               
               
                 II-7 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(3-dimethylamino-propyl)-N-methyl-benzamide 
               
               
                 II-8 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-piperazin-1-yl-methanone 
               
               
                 II-9 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone 
               
               
                 II-10 
                 {4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone 
               
               
                 II-11 
                 [4-(9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-phenyl]- 
               
               
                   
                 (4-methyl-piperazin-1-yl)-methanone 
               
               
                 II-12 
                 {4-[9-Chloro-7-(2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone 
               
               
                 II-13 
                 {4-[9-Chloro-7-(4-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone 
               
               
                 II-14 
                 {4-[7-(2-Fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone 
               
               
                 II-15 
                 2-{3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-1-(4-methyl-piperazin-1-yl)-ethanone 
               
               
                 II-16 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-piperidin-4-yl-benzamide 
               
               
                 II-17 
                 (4-Amino-piperidin-1-yl)-{4-[9-chloro-7-(2-fluoro-phenyl)-5H- 
               
               
                   
                 benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone 
               
               
                 II-18 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(4-dimethylamino-piperidin-1-yl)-methanone 
               
               
                 II-19 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide 
               
               
                 II-20 
                 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide 
               
               
                 II-21 
                 4-(9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-N-[3-(4- 
               
               
                   
                 methyl-piperazin-1-yl)-propyl]-benzamide 
               
               
                 II-22 
                 4-[9-Chloro-7-(2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide 
               
               
                 II-23 
                 4-[9-Chloro-7-(4-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide 
               
               
                 II-24 
                 4-[7-(2-Fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide 
               
               
                 II-25 
                 2-{3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-N-[3-(4-methyl-piperazin-1-yl)-propyl]-acetamide 
               
               
                 II-26 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-morpholin-4-yl-methanone 
               
               
                 II-27 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N,N-bis-(2-hydroxy-ethyl)-benzamide 
               
               
                 II-28 
                 {4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-morpholin-4-yl-methanone 
               
               
                 II-29 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(2-morpholin-4-yl-ethyl)-benzamide 
               
               
                 II-30 
                 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(2-morpholin-4-yl-ethyl)-benzamide 
               
               
                 II-31 
                 4-(9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-N-(2- 
               
               
                   
                 morpholin-4-yl-ethyl)-benzamide 
               
               
                 II-32 
                 4-[9-Chloro-7-(2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-N-(3-morpholin-4-yl-propyl)-benzamide 
               
               
                 II-33 
                 4-[9-Chloro-7-(4-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(2-morpholin-4-yl-ethyl)-benzamide 
               
               
                 II-34 
                 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 2-hydroxy-N-(2-morpholin-4-yl-ethyl)-benzamide 
               
               
                 II-35 
                 [9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-pyridin- 
               
               
                   
                 2-yl-amine 
               
               
                 II-36 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,5- 
               
               
                   
                 dichloro-phenyl)-amine 
               
               
                 II-37 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- 
               
               
                   
                 methoxy-phenyl)-amine 
               
               
                 II-38 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- 
               
               
                   
                 ethoxy-phenyl)-amine 
               
               
                 II-39 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3- 
               
               
                   
                 methoxy-phenyl)-amine 
               
               
                 II-40 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(2- 
               
               
                   
                 methoxy-phenyl)-amine 
               
               
                 II-41 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- 
               
               
                   
                 chloro-phenyl)-amine 
               
               
                 II-42 
                 [9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- 
               
               
                   
                 chloro-phenyl)-amine 
               
               
                 II-43 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3- 
               
               
                   
                 chloro-phenyl)-amine 
               
               
                 II-44 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(2- 
               
               
                   
                 chloro-phenyl)-amine 
               
               
                 II-45 
                 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 phenol 
               
               
                 II-46 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- 
               
               
                   
                 morpholin-4-yl-phenyl)-amine 
               
               
                 II-47 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-[4-(4- 
               
               
                   
                 methyl-piperazin-1-yl)-phenyl]-amine 
               
               
                 II-48 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- 
               
               
                   
                 pyridin-4-ylmethyl-phenyl)-amine 
               
               
                 II-49 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzonitrile 
               
               
                 II-50 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4-nitro- 
               
               
                   
                 phenyl)-amine 
               
               
                 II-51 
                 4-[7-(2-Fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic 
               
               
                   
                 acid 
               
               
                 II-52 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzoic acid 
               
               
                 II-53 
                 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzoic acid 
               
               
                 II-54 
                 4-(9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-benzoic 
               
               
                   
                 acid 
               
               
                 II-55 
                 4-[9-Chloro-7-(2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-56 
                 4-[9-Chloro-7-(4-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzoic acid 
               
               
                 II-57 
                 4-[9-Fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzoic acid 
               
               
                 II-58 
                 4-[7-(2-Fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-59 
                 4-[10-Fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-60 
                 4-[10-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-61 
                 4-[10-Bromo-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-62 
                 4-[7-(2-Fluoro-phenyl)-10-methoxy-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-63 
                 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzamide 
               
               
                 II-64 
                 3-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzamide 
               
               
                 II-65 
                 {3-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-acetic acid 
               
               
                 II-66 
                 2-{3-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-acetamide 
               
               
                 II-67 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzenesulfonic acid 
               
               
                 II-68 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzenesulfonamide 
               
               
                 II-69 
                 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide 
               
               
                 II-70 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- 
               
               
                   
                 trifluoromethanesulfonyl-phenyl)-amine 
               
               
                 II-71 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4- 
               
               
                   
                 dimethoxy-phenyl)-amine 
               
               
                 II-72 
                 [9-Chloro-7-(2-fluoro-phenyl)-6,7-dihydro-5H-benzo[c]pyrimido[4,5-e]azepin- 
               
               
                   
                 2-yl]-(3,4-dimethoxy-phenyl)-amine 
               
               
                 II-73 
                 [9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4- 
               
               
                   
                 dimethoxy-phenyl)-amine 
               
               
                 II-74 
                 (9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)-(3,4-dimethoxy- 
               
               
                   
                 phenyl)-amine 
               
               
                 II-75 
                 (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-yl]-amine 
               
               
                 II-76 
                 (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-9-isopropyl-5H- 
               
               
                   
                 benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine 
               
               
                 II-77 
                 (3,4-Dimethoxy-phenyl)-[10-fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-yl]-amine 
               
               
                 II-78 
                 [10-Bromo-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4- 
               
               
                   
                 dimethoxy-phenyl)-amine 
               
               
                 II-79 
                 (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-10-trifluoromethyl-5H- 
               
               
                   
                 benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine 
               
               
                 II-80 
                 (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-10-methyl-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-yl]-amine 
               
               
                 II-81 
                 (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-10-methoxy-5H- 
               
               
                   
                 benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine 
               
               
                 II-82 
                 (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-11-methyl-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-yl]-amine 
               
               
                 II-83 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(2,3- 
               
               
                   
                 dihydro-benzo[1,4]dioxin-6-yl)-amine 
               
               
                 II-84 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4- 
               
               
                   
                 fluoro-3-methoxy-phenyl)-amine 
               
               
                 II-85 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 2-hydroxy-benzoic acid 
               
               
                 II-86 
                 4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 2-hydroxy-benzoic acid 
               
               
                 II-87 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4- 
               
               
                   
                 dichloro-phenyl)-amine 
               
               
                 II-88 
                 [9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,5- 
               
               
                   
                 dimethoxy-phenyl)-amine 
               
               
                 II-89 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,5- 
               
               
                   
                 dimethyl-phenyl)-amine 
               
               
                 II-90 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-phenyl- 
               
               
                   
                 amine 
               
               
                 II-91 
                 4-[9-Chloro-7-(2,5-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-92 
                 4-[9-Chloro-7-(2,3-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-93 
                 (3-Dimethylamino-pyrrolidin-1-yl)-{4-[7-(2-fluoro-phenyl)-9-methoxy-5H- 
               
               
                   
                 benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone 
               
               
                 II-94 
                 4-[9-Chloro-7-(2,5-dimethoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-95 
                 4-[7-(2-Fluoro-phenyl)-9-methoxy-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-N,N-bis-(2-hydroxy-ethyl)-benzamide 
               
               
                 II-96 
                 4-[9-Chloro-7-(2,4-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-97 
                 4-[9-Chloro-7-(2,4-difluoro-phenyl)-7H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-98 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(3-dimethylamino-azetidin-1-yl)-methanone 
               
               
                 II-99 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-methyl-N-(1-methyl-pyrrolidin-3-yl)-benzamide 
               
               
                 II-100 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(3-dimethylamino-pyrrolidin-1-yl)-methanone 
               
               
                 II-101 
                 4-[9-Chloro-7-(2,4-dimethoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-102 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(3-methylamino-pyrrolidin-1-yl)-methanone 
               
               
                 II-103 
                 (3-Amino-pyrrolidin-1-yl)-{4-[9-chloro-7-(2-fluoro-phenyl)-5H- 
               
               
                   
                 benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone 
               
               
                 II-104 
                 4-[9-Chloro-7-(2,3-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid methyl ester 
               
               
                 II-105 
                 4-[9-Chloro-7-(2,5-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid methyl ester 
               
               
                 II-106 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-phosphonic acid 
               
               
                 II-107 
                 N-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-methanesulfonamide 
               
               
                 II-108 
                 N-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-N-methyl-acetamide 
               
               
                 II-109 
                 2-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoylamino}-succinic acid 
               
               
                 II-110 
                 [9-Chloro-7-(2-fluoro-phenyl)-4-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 yl]-(3,4-dimethoxy-phenyl)-amine 
               
               
                 II-111 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(3,5-dimethyl-piperazin-1-yl)-methanone 
               
               
                 II-112 
                 1-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoyl}-pyrrolidine-2-carboxylic acid 
               
               
                 II-113 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(3-methyl-piperazin-1-yl)-methanone 
               
               
                 II-114 
                 [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-[4-(2H- 
               
               
                   
                 tetrazol-5-yl)-phenyl]-amine 
               
               
                 II-115 
                 N-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-acetamide 
               
               
                 II-116 
                 5-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 2-fluoro-benzoic acid 
               
               
                 II-117 
                 N-(3-Amino-propyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-ylamino]-N-methyl-benzamide 
               
               
                 II-118 
                 2-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoylamino}-propionic acid 
               
               
                 II-119 
                 5-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 pyridine-2-carboxylic acid 
               
               
                 II-120 
                 2-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-N-(2-morpholin-4-yl-ethyl)-acetamide 
               
               
                 II-121 
                 5-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 2-methoxy-benzoic acid 
               
               
                 II-122 
                 5-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 2-methyl-benzoic acid 
               
               
                 II-123 
                 6-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 nicotinic acid 
               
               
                 II-124 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(2-morpholin-4-yl-ethyl)-benzenesulfonamide 
               
               
                 II-125 
                 2-Chloro-5-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-126 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-acetic acid 
               
               
                 II-127 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 2-trifluoromethyl-benzoic acid 
               
               
                 II-128 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide 
               
               
                 II-129 
                 N-(3-Amino-propyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-ylamino]-benzamide 
               
               
                 II-130 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(3-methylamino-propyl)-benzamide 
               
               
                 II-131 
                 N-(2-Amino-2-methyl-propyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H- 
               
               
                   
                 benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzamide 
               
               
                 II-132 
                 2-(3,4-Dimethoxy-phenylamino)-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepine-10-carboxylic acid 
               
               
                 II-133 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 2-methyl-benzoic acid 
               
               
                 II-134 
                 2-Chloro-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-135 
                 4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-136 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 2-fluoro-benzoic acid 
               
               
                 II-137 
                 4-[7-(2-Fluoro-phenyl)-9-methoxy-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-138 
                 (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-9-methoxy-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-yl]-amine 
               
               
                 II-139 
                 [9,10-Dichloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]- 
               
               
                   
                 (3,4-dimethoxy-phenyl)-amine 
               
               
                 II-140 
                 4-[9,10-Dichloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-141 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 2-methoxy-benzoic acid 
               
               
                 II-142 
                 N-(2-Amino-ethyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-ylamino]-benzamide 
               
               
                 II-143 
                 4-(9-Chloro-7-phenyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-benzoic 
               
               
                   
                 acid 
               
               
                 II-144 
                 [7-(2-Bromo-phenyl)-9-chloro-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4- 
               
               
                   
                 dimethoxy-phenyl)-amine 
               
               
                 II-145 
                 2-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-1-(4-methyl-piperazin-1-yl)-ethanone 
               
               
                 II-146 
                 3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzoic acid 
               
               
                 II-147 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-[2-(1H-imidazol-4-yl)-ethyl]-benzamide 
               
               
                 II-148 
                 4-[7-(2-Fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-N-(2-morpholin-4-yl-ethyl)-benzamide 
               
               
                 II-149 
                 {3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-acetic acid 
               
               
                 II-150 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(2-pyridin-4-yl-ethyl)-benzamide 
               
               
                 II-151 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(2-pyridin-3-yl-ethyl)-benzamide 
               
               
                 II-152 
                 (9-Chloro-7-phenyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)-(3,4-dimethoxy- 
               
               
                   
                 phenyl)-amine 
               
               
                 II-153 
                 4-[7-(2-Fluoro-phenyl)-10-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-154 
                 (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-yl]-amine 
               
               
                 II-155 
                 4-[9-Chloro-7-(4-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-156 
                 4-[9-Chloro-7-(3-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-157 
                 4-[9-Chloro-7-(3-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide 
               
               
                 II-158 
                 4-[9-Chloro-7-(3-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(2-morpholin-4-yl-ethyl)-benzamide 
               
               
                 II-159 
                 {4-[9-Chloro-7-(3-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone 
               
               
                 II-160 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-methyl-N-(2-pyridin-2-yl-ethyl)-benzamide 
               
               
                 II-161 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 N-(2-pyridin-2-yl-ethyl)-benzamide 
               
               
                 II-162 
                 4-[9-Chloro-7-(3-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzoic acid 
               
               
                 II-163 
                 {3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone 
               
               
                 II-164 
                 9-Chloro-7-(2-fluorophenyl)-N-{4-[(4-pyridin-2-ylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-165 
                 9-Chloro-7-(2-fluorophenyl)-N-(4-{[4-(2-morpholin-4-yl-2-oxoethyl)piperazin- 
               
               
                   
                 1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-166 
                 9-Chloro-7-(2-fluorophenyl-N-(4-{[4-(2-furoyl)piperazin-1-yl]carbonyl}phenyl)- 
               
               
                   
                 5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-167 
                 Benzyl-4-(4-{[9-chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)piperazine-1-carboxylate 
               
               
                 II-168 
                 Ethyl-4-(4-{[9-chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)piperazine-1-carboxylate 
               
               
                 II-169 
                 2-[4-(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)piperazin-1-yl]benzoic acid 
               
               
                 II-170 
                 2-[4-(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)piperazin-1-yl]-N-isopropylacetamide 
               
               
                 II-171 
                 9-Chloro-7-(2-fluorophenyl)-N-(4-{[4-(2-pyrrolidin-1-ylethyl)piperazin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-172 
                 N-[2-(aminocarbonyl)phenyl]-4-{[9-chloro-7-(2-fluorophenyl)-5H-pyrimido- 
               
               
                   
                 [5,4-d][2]benzazepin-2-yl]amino}benzamide 
               
               
                 II-173 
                 9-Chloro-7-(2-fluorophenyl)-N-{4-[(4-pyrimidin-2-ylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-174 
                 4-{[9-Chloro-7-(2-chloro-6-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoic acid 
               
               
                 II-175 
                 9-Chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-176 
                 9-Chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)pyrrolidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-177 
                 9-Chloro-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-7-(2-fluoro-6- 
               
               
                   
                 methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-178 
                 9-Chloro-N-(4-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-(2- 
               
               
                   
                 fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-179 
                 9-Chloro-N-(4-{[3-(dimethylamino)azetidin-1-yl]carbonyl}phenyl)-7-(2-fluoro- 
               
               
                   
                 6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-180 
                 9-Chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)azetidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-181 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-[4-(3-piperidin-1-yl-propyl)-piperazin-1-yl]-methanone 
               
               
                 II-182 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-[4-(2-piperidin-1-yl-ethyl)-piperazin-1-yl]-methanone 
               
               
                 II-183 
                 {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(4-dimethylamino-piperidin-1-yl)-methanone 
               
               
                 II-184 
                 {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone 
               
               
                 II-185 
                 4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-N-(3-dimethylamino-propyl)-N-methyl-benzamide 
               
               
                 II-186 
                 {4-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-ylamino]-phenyl}-(4-dimethylamino-piperidin-1-yl)-methanone 
               
               
                 II-187 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-[4-(2-dipropylamino-ethyl)-piperazin-1-yl]-methanone 
               
               
                 II-188 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-[4-(3-pyrrolidin-1-yl-propyl)-piperazin-1-yl]-methanone 
               
               
                 II-189 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-[4-(2-morpholin-4-yl-ethyl)-piperazin-1-yl]-methanone 
               
               
                 II-190 
                 4-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin- 
               
               
                   
                 2-ylamino]-benzoic acid 
               
               
                 II-191 
                 {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(3(S)-methyl-piperazin-1-yl)-methanone 
               
               
                 II-192 
                 (3-Amino-azetidin-1-yl)-{4-[9-chloro-7-(2-fluoro-phenyl)-5H- 
               
               
                   
                 benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone 
               
               
                 II-193 
                 {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(3-dimethylaminomethyl-azetidin-1-yl)-methanone 
               
               
                 II-194 
                 {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(3(R)-methyl-piperazin-1-yl)-methanone 
               
               
                 II-195 
                 {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-piperazin-1-yl-methanone 
               
               
                 II-196 
                 (3-Amino-pyrrolidin-1-yl)-{4-[9-chloro-7-(2,6-difluoro-phenyl)-5H- 
               
               
                   
                 benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone 
               
               
                 II-197 
                 {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(3-methylamino-pyrrolidin-1-yl)-methanone 
               
               
                 II-198 
                 4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-N-methyl-N-(3-methylamino-propyl)-benzamide 
               
               
                 II-199 
                 {4-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5- 
               
               
                   
                 e]azepin-2-ylamino]-phenyl}-(3-methylamino-pyrrolidin-1-yl)-methanone 
               
               
                 II-200 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 cyclohexanecarboxylic acid 
               
               
                 II-201 
                 9-chloro-N-(4-{[4-(2-ethoxyphenyl)piperazin-1-yl]carbonyl}phenyl)-7-(2- 
               
               
                   
                 fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-202 
                 N-[amino(imino)methyl]-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzamide 
               
               
                 II-203 
                 3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoic acid 
               
               
                 II-204 
                 9-chloro-7-(2,6-difluorophenyl)-N-(3-{[3-(dimethylamino)azetidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-205 
                 9-chloro-7-(2,6-difluorophenyl)-N-(3-{[4-(dimethylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-206 
                 9-chloro-7-(2,6-difluorophenyl)-N-(3-{[3-(dimethylamino)pyrrolidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-207 
                 N-[2-(aminomethyl)-1,3-benzoxazol-5-yl]-9-chloro-7-(2,6-difluorophenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-208 
                 9-chloro-N-[4-({4-[3-(diethylamino)propyl]piperazin-1-yl}carbonyl)phenyl]-7- 
               
               
                   
                 (2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-209 
                 9-chloro-N-[4-({4-[2-(diethylamino)ethyl]piperazin-1-yl}carbonyl)phenyl]-7-(2- 
               
               
                   
                 fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-210 
                 9-chloro-N-[4-({4-[3-(dimethylamino)propyl]piperazin-1-yl}carbonyl)phenyl]-7- 
               
               
                   
                 (2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-211 
                 9-chloro-7-(2-fluorophenyl)-N-[4-({4-[(1-methylpiperidin-3- 
               
               
                   
                 yl)methyl]piperazin-1-yl}carbonyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 amine 
               
               
                 II-212 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-nitrophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-amine 
               
               
                 II-213 
                 9-chloro-N-(3-chloro-4-{[4-(2-pyrrolidin-1-ylethyl)piperazin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 amine 
               
               
                 II-214 
                 9-chloro-N-{3-chloro-4-[(3-methylpiperazin-1-yl)carbonyl]phenyl}-7-(2- 
               
               
                   
                 fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-215 
                 9-chloro-N-(3-chloro-4-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7- 
               
               
                   
                 (2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-216 
                 9-chloro-N-{3-chloro-4-[(3-methylpiperazin-1-yl)carbonyl]phenyl}-7-(2,6- 
               
               
                   
                 difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-217 
                 N-[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]benzene-1,4-diamine 
               
               
                 II-218 
                 methyl 2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoate 
               
               
                 II-219 
                 1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)piperazine-2-carboxylic acid 
               
               
                 II-220 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[4-(methylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-221 
                 N-{4-[(3-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6- 
               
               
                   
                 difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-222 
                 9-chloro-7-(2,6-difluorophenyl)-N-{3-[(3,5-dimethylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-223 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[[4-(dimethylamino)piperidin-1-yl](imino)methyl]benzamide 
               
               
                 II-224 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[imino(piperazin-1-yl)methyl]benzamide 
               
               
                 II-225 
                 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-yl]amino}-N-[3-(dimethylamino)propyl]-N-methylbenzamide 
               
               
                 II-226 
                 3-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-yl]amino}-N-[3-(dimethylamino)propyl]-N-methylbenzamide 
               
               
                 II-227 
                 9-chloro-N-(3-{[3-(dimethylamino)azetidin-1-yl]carbonyl}phenyl)-7-(2-fluoro- 
               
               
                   
                 6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-228 
                 9-chloro-N-{3-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-7-(2-fluoro-6- 
               
               
                   
                 methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-229 
                 9-chloro-N-(3-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-7-(2-fluoro- 
               
               
                   
                 6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-230 
                 N-(4-{[3-(aminomethyl)azetidin-1-yl]carbonyl}phenyl)-9-chloro-7-(2- 
               
               
                   
                 fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-231 
                 9-chloro-N-(3-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-(2- 
               
               
                   
                 fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-232 
                 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-{4-[(3-methylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-233 
                 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-{4-[(4-methylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-234 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)azetidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-235 
                 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-(methylamino)azetidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-236 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzonitrile 
               
               
                 II-237 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[[3-(dimethylamino)pyrrolidin-1-yl](imino)methyl]benzamide 
               
               
                 II-238 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]benzamide 
               
               
                 II-239 
                 N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6- 
               
               
                   
                 difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-240 
                 N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6- 
               
               
                   
                 methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-241 
                 N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6- 
               
               
                   
                 methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-242 
                 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[4-(methylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-243 
                 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-[4-(piperazin-1-ylcarbonyl)phenyl]- 
               
               
                   
                 5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-244 
                 9-chloro-7-(2,6-difluorophenyl)-N-{4-[[4-(dimethylamino)piperidin-1- 
               
               
                   
                 yl](imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-245 
                 N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)guanidine 
               
               
                 II-246 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-methyl-N-[2-(methylamino)ethyl]benzamide 
               
               
                 II-247 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[2-(dimethylamino)ethyl]-N-methylbenzamide 
               
               
                 II-248 
                 methyl 4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoyl)piperazine-2-carboxylate 
               
               
                 II-249 
                 2-[(4-carboxyphenyl)amino]-7-(2-fluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepine-9-carboxylic acid 
               
               
                 II-250 
                 9-chloro-7-(2,6-difluorophenyl)-N-{4-[[3-(dimethylamino)pyrrolidin-1- 
               
               
                   
                 yl](imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-251 
                 9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- 
               
               
                   
                 yl)(imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-252 
                 N-(2-aminoethyl)-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}-N-methylbenzamide 
               
               
                 II-253 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-254 
                 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-yl]amino}-N-methyl-N-[2-(methylamino)ethyl]benzamide 
               
               
                 II-255 
                 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-yl]amino}-N-[2-(dimethylamino)ethyl]-N-methylbenzamide 
               
               
                 II-256 
                 7-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepine-9-carboxylic acid 
               
               
                 II-257 
                 N-(3-aminopropyl)-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}-N-methylbenzamide 
               
               
                 II-258 
                 2-chloro-5-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-yl]amino}benzoic acid 
               
               
                 II-259 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[[3-(dimethylamino)azetidin-1-yl](imino)methyl]benzamide 
               
               
                 II-260 
                 N-(2-amino-2-methylpropyl)-4-{[9-chloro-7-(2,6-difluorophenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzamide 
               
               
                 II-261 
                 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-yl]amino}-N-methyl-N-[3-(methylamino)propyl]benzamide 
               
               
                 II-262 
                 N-{4-[(3-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6- 
               
               
                   
                 methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-263 
                 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-(methylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-264 
                 N-(3-aminopropyl)-4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide 
               
               
                 II-265 
                 N-(2-aminoethyl)-4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}-N-methylbenzamide 
               
               
                 II-266 
                 4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)piperazine-2-carboxylic acid 
               
               
                 II-267 
                 9-chloro-7-(2,6-difluorophenyl)-N-{4-[[3-(dimethylamino)azetidin-1- 
               
               
                   
                 yl](imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-268 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{imino[3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl]methyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-269 
                 9-chloro-N-(4-chloro-3-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-7- 
               
               
                   
                 (2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-270 
                 9-chloro-7-(2,6-difluorophenyl)-N-[4-(5,5-dimethyl-4,5-dihydro-1H-imidazol-2- 
               
               
                   
                 yl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-271 
                 N-[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]-N′- 
               
               
                   
                 pyrimidin-2-ylbenzene-1,4-diamine 
               
               
                 II-272 
                 4-{[9-(3-aminoprop-1-yn-1-yl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoic acid 
               
               
                 II-273 
                 9-bromo-7-(2,6-difluorophenyl)-N-(3-methoxyphenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-amine 
               
               
                 II-274 
                 4-{[9-bromo-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoic acid 
               
               
                 II-275 
                 7-(2,6-difluorophenyl)-N-(3-methoxyphenyl)-9-(3-pyrrolidin-1-ylprop-1-yn-1- 
               
               
                   
                 yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-276 
                 9-(3-aminoprop-1-yn-1-yl)-7-(2,6-difluorophenyl)-N-(3-methoxyphenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-277 
                 4-({9-chloro-7-[2-(trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl}amino)benzoic acid 
               
               
                 II-278 
                 N-{4-[(3-aminoazetidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6-difluorophenyl)- 
               
               
                   
                 5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-279 
                 4-[(9-chloro-7-pyridin-2-yl-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl)amino]benzoic acid 
               
               
                 II-280 
                 N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)-4-methylpiperazine-1-carboxamide 
               
               
                 II-281 
                 9-chloro-N-(4-chloro-3-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7- 
               
               
                   
                 (2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-282 
                 9-chloro-N-(4-chloro-3-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7- 
               
               
                   
                 (2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-283 
                 2-chloro-5-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-yl]amino}-N-methyl-N-[2-(methylamino)ethyl]benzamide 
               
               
                 II-284 
                 N-{4-[(3-aminopyrrolidin-1-yl)(imino)methyl]phenyl}-9-chloro-7-(2,6- 
               
               
                   
                 difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-285 
                 2-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)-1,4,5,6-tetrahydropyrimidin-5-ol 
               
               
                 II-286 
                 N-{4-[(3-aminoazetidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6- 
               
               
                   
                 methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-287 
                 N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-[2- 
               
               
                   
                 (trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-288 
                 9-chloro-N-(4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7-[2- 
               
               
                   
                 (trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-289 
                 N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-[2- 
               
               
                   
                 (trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-290 
                 9-chloro-N-(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-[2- 
               
               
                   
                 (trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-291 
                 9-chloro-N-(4-chloro-3-{[3-(methylamino)azetidin-1-yl]carbonyl}phenyl)-7- 
               
               
                   
                 (2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-292 
                 N-{3-[(4-aminopiperidin-1-yl)carbonyl]-4-chlorophenyl}-9-chloro-7-(2,6- 
               
               
                   
                 difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-293 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-294 
                 methyl 4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoyl)piperidine-4-carboxylate 
               
               
                 II-295 
                 4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoyl)piperidine-4-carboxylic acid 
               
               
                 II-296 
                 N-{4-[(3-aminoazetidin-1-yl)carbonyl]phenyl}-9-chloro-7-[2- 
               
               
                   
                 (trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-297 
                 9-chloro-N-(4-{[3-(methylamino)azetidin-1-yl]carbonyl}phenyl)-7-[2- 
               
               
                   
                 (trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-298 
                 N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-pyridin-2-yl-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-299 
                 N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-pyridin-2-yl-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-300 
                 ethyl 2-amino-4-[(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoyl)amino]butanoate 
               
               
                 II-301 
                 4-{[9-chloro-7-(3-fluoropyridin-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoic acid 
               
               
                 II-302 
                 9-{[3-(dimethylamino)azetidin-1-yl]carbonyl}-7-(2-fluorophenyl)-N-(3- 
               
               
                   
                 methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-303 
                 7-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-N-methyl-N-[3- 
               
               
                   
                 (methylamino)propyl]-5H-pyrimido[5,4-d][2]benzazepine-9-carboxamide 
               
               
                 II-304 
                 N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(3-fluoropyridin-2- 
               
               
                   
                 yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-305 
                 N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-(3-fluoropyridin-2- 
               
               
                   
                 yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-306 
                 2-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)-4,5-dihydro-1H-imidazole-5-carboxylic acid 
               
               
                 II-307 
                 N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)-2-(dimethylamino)acetamide 
               
               
                 II-308 
                 2-amino-N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}phenyl)-2-methylpropanamide 
               
               
                 II-309 
                 ethyl (2R)-4-amino-2-[(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoyl)amino]butanoate 
               
               
                 II-310 
                 4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)-N-methylpiperazine-2-carboxamide 
               
               
                 II-311 
                 7-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-N-(3-morpholin-4-ylpropyl)- 
               
               
                   
                 5H-pyrimido[5,4-d][2]benzazepine-9-carboxamide 
               
               
                 II-312 
                 9-[(3,5-dimethylpiperazin-1-yl)carbonyl]-7-(2-fluorophenyl)-N-(3- 
               
               
                   
                 methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-313 
                 9-chloro-N-(3-chloro-4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-7- 
               
               
                   
                 (2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-314 
                 ethyl 2-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-yl]amino}phenyl)-4,5-dihydro-1H-imidazole-5-carboxylate 
               
               
                 II-315 
                 9-chloro-N-(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-pyridin-2- 
               
               
                   
                 yl-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-316 
                 9-chloro-N-(4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7-pyridin-2- 
               
               
                   
                 yl-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-317 
                 4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)piperazine-2-carboxamide 
               
               
                 II-318 
                 N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]-3-chlorophenyl}-9-chloro-7-(2,6- 
               
               
                   
                 difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-319 
                 N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)piperidine-4-carboxamide 
               
               
                 II-320 
                 4-{[9-chloro-7-(2-fluoro-6-{methyl[2-(methylamino)ethyl]amino}phenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic acid 
               
               
                 II-321 
                 9-chloro-7-(2,4-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-322 
                 9-chloro-7-(2,4-dimethoxyphenyl)-N-{4-[(3,5-dimethylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-323 
                 9-chloro-7-(2-chloro-6-fluorophenyl)-N-{4-[(3-methylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-324 
                 9-chloro-7-(2-chloro-6-fluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-325 
                 9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[4-(methylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-326 
                 9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[3-(methylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-327 
                 9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-328 
                 9-chloro-N-(3,4-dimethoxyphenyl)-7-{2-[(dimethylamino)methyl]phenyl}-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-329 
                 9-chloro-7-(2-methoxyphenyl)-N-{4-[(3-methylpiperazin-1-yl)carbonyl]phenyl}- 
               
               
                   
                 5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-330 
                 9-chloro-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-7-(2- 
               
               
                   
                 methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-331 
                 9-chloro-7-(2-methoxyphenyl)-N-(4-{[4-(methylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-332 
                 9-chloro-7-(2-methoxyphenyl)-N-(4-{[3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-333 
                 9-chloro-7-(2-methoxyphenyl)-N-(4-{[3-(methylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-334 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-methylbenzamide 
               
               
                 II-335 
                 4-{[9-chloro-7-(2-fluoro-6-{methyl[3-(methylamino)propyl]amino}phenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic acid 
               
               
                 II-336 
                 4-{[9-chloro-7-(2-fluoro-6-{methyl[3-(methylamino)propyl]amino}phenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide 
               
               
                 II-337 
                 1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)ethanone 
               
               
                 II-338 
                 N-[3-(3-aminoprop-1-yn-1-yl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-339 
                 4-[(9-chloro-7-{2-fluoro-6-[(2-hydroxyethyl)amino]phenyl}-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl)amino]-N-methylbenzamide 
               
               
                 II-340 
                 4-[(7-{2-[(2-aminoethyl)amino]-6-fluorophenyl}-9-chloro-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl)amino]-N-methylbenzamide 
               
               
                 II-341 
                 4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpiperidine-4-carboxamide 
               
               
                 II-342 
                 4-[(9-chloro-7-{2-[4-(dimethylamino)piperidin-1-yl]-6-fluorophenyl}-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl)amino]-N-methylbenzamide 
               
               
                 II-343 
                 9-chloro-7-(2,6-difluorophenyl)-N-{3-[3-(dimethylamino)prop-1-yn-1- 
               
               
                   
                 yl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-344 
                 9-chloro-7-(2,6-difluorophenyl)-N-(3-iodophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-amine 
               
               
                 II-345 
                 4-{[9-chloro-7-(2-{[2-(dimethylamino)ethyl]amino}-6-fluorophenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide 
               
               
                 II-346 
                 4-[(9-chloro-7-{2-[[2-(dimethylamino)ethyl](methyl)amino]-6-fluorophenyl}- 
               
               
                   
                 5H-pyrimido[5,4-d][2]benzazepin-2-yl)amino]-N-methylbenzamide 
               
               
                 II-347 
                 4-{[9-chloro-7-(2-fluoro-6-{methyl[2-(methylamino)ethyl]amino}phenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide 
               
               
                 II-348 
                 4-({7-[2-(4-aminopiperidin-1-yl)-6-fluorophenyl]-9-chloro-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino)-N-methylbenzamide 
               
               
                 II-349 
                 7-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-N-methyl-N-[2- 
               
               
                   
                 (methylamino)ethyl]-5H-pyrimido[5,4-d][2]benzazepine-9-carboxamide 
               
               
                 II-350 
                 4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoyl)piperidine-4-carboxamide 
               
               
                 II-351 
                 9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[3-(methylamino)azetidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-352 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-methyl-1,3-thiazol-2-yl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-amine 
               
               
                 II-353 
                 7-(2,6-difluorophenyl)-2-[(3-methoxyphenyl)amino]-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepine-9-carboxylic acid 
               
               
                 II-354 
                 4-({9-chloro-7-[2-fluoro-6-(methylamino)phenyl]-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino)-N-methylbenzamide 
               
               
                 II-355 
                 2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-methyl-1,3-thiazole-4-carboxamide 
               
               
                 II-356 
                 N-1H-benzimidazol-2-yl-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-amine 
               
               
                 II-357 
                 7-(2,6-difluorophenyl)-2-[(4-methyl-1,3-thiazol-2-yl)amino]-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepine-9-carboxylic acid 
               
               
                 II-358 
                 3-amino-1-(3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}phenyl)propan-1-one 
               
               
                 II-359 
                 1-(3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)-3-(dimethylamino)propan-1-one 
               
               
                 II-360 
                 2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-1,3-thiazole-4-carboxylic acid 
               
               
                 II-361 
                 ethyl 2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-1,3-thiazole-4-carboxylate 
               
               
                 II-362 
                 9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]- 
               
               
                   
                 1,3-thiazol-2-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-363 
                 ethyl 2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-1,3-oxazole-5-carboxylate 
               
               
                 II-364 
                 2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-1,3-oxazole-5-carboxylic acid 
               
               
                 II-365 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[(3R)-3-methylpiperazin-1-yl]carbonyl}- 
               
               
                   
                 1,3-thiazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-366 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[(2R)-2-methylpiperazin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-367 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl]carbonyl}-1,3-thiazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-368 
                 2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-1,3-oxazole-4-carboxylic acid 
               
               
                 II-369 
                 9-chloro-7-(2,6-difluorophenyl)-N-{5-[(3,5-dimethylpiperazin-1-yl)carbonyl]- 
               
               
                   
                 1,3-oxazol-2-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-370 
                 9-chloro-7-(2,6-difluorophenyl)-N-(5-{[3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl]carbonyl}-1,3-oxazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-371 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5-methyl-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoic acid 
               
               
                 II-372 
                 9-chloro-7-(2,6-difluorophenyl)-N-{3-[3-(dimethylamino)propyl]phenyl}-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-373 
                 N-[3-(3-aminopropyl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-amine 
               
               
                 II-374 
                 9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]- 
               
               
                   
                 1,3-oxazol-2-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-375 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl]carbonyl}-1,3-oxazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-376 
                 7-(2,6-difluorophenyl)-2-({4-[(3,5-dimethylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}amino)-N-methyl-5H-pyrimido[5,4-d][2]benzazepine-9- 
               
               
                   
                 carboxamide 
               
               
                 II-377 
                 2-{[4-(aminocarbonyl)phenyl]amino}-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepine-9-carboxylic acid 
               
               
                 II-378 
                 1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)-N-methyl-4-(methylamino)piperidine-4-carboxamide 
               
               
                 II-379 
                 N-{4-[(3-amino-3-methylpyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6- 
               
               
                   
                 difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-380 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-methyl-3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-381 
                 1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)-4-(methylamino)piperidine-4-carboxamide 
               
               
                 II-382 
                 9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,3,5-trimethylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-383 
                 N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide 
               
               
                 II-384 
                 N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzamide 
               
               
                 II-385 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-hydroxybenzamide 
               
               
                 II-386 
                 N-{4-[(aminooxy)carbonyl]phenyl}-9-chloro-7-(2,6-difluorophenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-387 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-7H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoic acid 
               
               
                 II-388 
                 4-{[9-chloro-7-(2,3-difluorophenyl)-7H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoic acid 
               
               
                 II-389 
                 3-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpyrrolidine-3-Icarboxamide 
               
               
                 II-390 
                 3-amino-1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoyl)pyrrolidine-3-carboxamide 
               
               
                 II-391 
                 9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,3-dimethylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-392 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)benzamide 
               
               
                 II-393 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)-3-methylpyrrolidin- 
               
               
                   
                 1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-394 
                 9-chloro-7-(2,6-difluorophenyl)-N-(3-methyl-1H-pyrazol-5-yl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-395 
                 2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-yl]amino}benzoic acid 
               
               
                 II-396 
                 4-amino-1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpiperidine-4-carboxamide 
               
               
                 II-397 
                 4-amino-1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoyl)-N,N-dimethylpiperidine-4-carboxamide 
               
               
                 II-398 
                 4-[(9-methoxy-7-oxo-6,7-dihydro-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl)amino]benzoic acid 
               
               
                 II-399 
                 2-({4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}amino)-9-methoxy-5,6- 
               
               
                   
                 dihydro-7H-pyrimido[5,4-d][2]benzazepin-7-one 
               
               
                 II-400 
                 9-methoxy-2-[(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)amino]- 
               
               
                   
                 5,6-dihydro-7H-pyrimido[5,4-d][2]benzazepin-7-one 
               
               
                 II-401 
                 4-[(8-methyl-7-oxo-5,6,7,8-tetrahydropyrimido[5,4-c]pyrrolo[3,2-e]azepin-2- 
               
               
                   
                 yl)amino]benzoic acid 
               
               
                 II-402 
                 2-({4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}amino)-8-methyl-5,8- 
               
               
                   
                 dihydropyrimido[5,4-c]pyrrolo[3,2-e]azepin-7(6H)-one 
               
               
                 II-403 
                 2-[(3-methoxyphenyl)amino]-8-methyl-5,8-dihydropyrimido[5,4-c]pyrrolo[3,2- 
               
               
                   
                 e]azepin-7(6H)-one 
               
               
                 II-404 
                 9-chloro-2-[(3,4-dimethoxyphenyl)amino]-5,6-dihydro-7H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-7-one 
               
               
                 II-405 
                 4-{[4-amino-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-yl]amino}benzoic acid 
               
               
                 II-406 
                 9-chloro-N-(3-chloro-4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7- 
               
               
                   
                 (2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-407 
                 9-chloro-N-(3-chloro-4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7-(2- 
               
               
                   
                 fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-408 
                 4-{[9-chloro-7-(2-fluoro-6-hydroxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoic acid 
               
               
                 II-409 
                 9-chloro-N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-7-(2,6- 
               
               
                   
                 difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-410 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[2-(methylamino)-7- 
               
               
                   
                 azabicyclo[2.2.1]hept-7-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-amine 
               
               
                 II-411 
                 1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)-N-methyl-3-(methylamino)pyrrolidine-3-carboxamide 
               
               
                 II-412 
                 1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)-3-(methylamino)pyrrolidine-3-carboxamide 
               
               
                 II-413 
                 1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}benzoyl)-N-methyl-3-(methylamino)piperidine-3- 
               
               
                   
                 carboxamide 
               
               
                 II-414 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-methyl-3-(methylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-415 
                 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-methyl-3- 
               
               
                   
                 (methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-amine 
               
               
                 II-416 
                 {2-Chloro-4-[9-chloro-7-(2-fluoro-6-methoxy-phenyl)-5H- 
               
               
                   
                 benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3-methyl-3-methylamino- 
               
               
                   
                 piperidin-1-yl)-methanone 
               
               
                 II-417 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[4-methyl-4-(methylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-418 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[4-(dimethylamino)-4-methylpiperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-419 
                 N-{4-[(4-amino-4-methylpiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6- 
               
               
                   
                 difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-420 
                 9-chloro-N-(3-chloro-4-{[4-methyl-4-(methylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-amine 
               
               
                 II-421 
                 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[4-methyl-4- 
               
               
                   
                 (methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-amine 
               
               
                 II-422 
                 2-Chloro-4-[9-chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5- 
               
               
                   
                 e]azepin-2-ylamino]-phenyl}-(4-methyl-4-methylamino-piperidin-1-yl)- 
               
               
                   
                 methanone 
               
               
                 II-423 
                 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(3-fluoro-4-{[4-methyl-4- 
               
               
                   
                 (methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-amine 
               
               
                 II-424 
                 9-chloro-N-{3-chloro-4-[(3,3,5,5-tetramethylpiperazin-1-yl)carbonyl]phenyl}-7- 
               
               
                   
                 (2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-425 
                 N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-fluoro-N-methylbenzamide 
               
               
                 II-426 
                 N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide 
               
               
                 II-427 
                 N-8-azabicyclo[3.2.1]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide 
               
               
                 II-428 
                 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)-8-azabicyclo[3.2.1]oct- 
               
               
                   
                 8-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-429 
                 9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-(methylamino)-8- 
               
               
                   
                 azabicyclo[3.2.1]oct-8-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin- 
               
               
                   
                 2-amine 
               
               
                 II-430 
                 4-{[7-(2,6-difluorophenyl)-9-methyl-5H-pyrimido[5,4-c]thieno[2,3-e]azepin-2- 
               
               
                   
                 yl]amino}benzoic acid 
               
               
                 II-431 
                 7-(2,6-difluorophenyl)-N-{4-[(3,3,5,5-tetramethylpiperazin-1- 
               
               
                   
                 yl)carbonyl]phenyl}-5H-pyrimido[5,4-c]thieno[2,3-e]azepin-2-amine 
               
               
                 II-432 
                 N-{4-[(3-amino-3-methylpyrrolidin-1-yl)carbonyl]phenyl}-7-(2,6- 
               
               
                   
                 difluorophenyl)-10-methyl-5,10-dihydropyrimido[5,4-c]pyrrolo[2,3-e]azepin-2- 
               
               
                   
                 amine 
               
               
                 II-433 
                 7-(2,6-difluorophenyl)-9-methyl-N-(4-{[3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5H-furo[2,3-c]pyrimido[4,5-e]azepin-2-amine 
               
               
                 II-434 
                 4-(2,6-difluorophenyl)-2-methyl-N-(4-{[3-methyl-3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-6H-pyrimido[5,4-c][1,3]thiazolo[4,5-e]azepin-9-amine 
               
               
                 II-435 
                 N-{4-[(3-amino-3-methylpyrrolidin-1-yl)carbonyl]phenyl}-7-(2-fluoro-6- 
               
               
                   
                 methoxyphenyl)-5,9-dihydropyrimido[5,4-c]pyrrolo[3,4-e]azepin-2-amine 
               
               
                 II-436 
                 4-{[4-(2,6-difluorophenyl)-1-methyl-1,6-dihydropyrazolo[4,3-c]pyrimido[4,5- 
               
               
                   
                 e]azepin-9-yl]amino}benzoic acid 
               
               
                 II-437 
                 1-{4-[4-(2,6-Difluoro-phenyl)-2-methyl-6H-3-thia-5,8,10-triaza-benzo[e]azulen- 
               
               
                   
                 9-ylamino]-benzoyl}-4-dimethylamino-piperidine-4-carboxylic acid 
               
               
                   
                 methylamide 
               
               
                 II-438 
                 4-(4-{[7-(2,6-difluorophenyl)-5H-furo[3,2-c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 yl]amino}benzoyl)-N-methylpiperazine-2-carboxamide 
               
               
                 II-439 
                 4-(4-{[4-(2,6-difluorophenyl)-6H-isoxazolo[4,5-c]pyrimido[4,5-e]azepin-9- 
               
               
                   
                 yl]amino}benzoyl)-N-methylpiperazine-2-carboxamide 
               
               
                 II-440 
                 4-(2,6-difluorophenyl)-9-[(4-{[3-methyl-3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)amino]-3,6-dihydroimidazo[4,5-c]pyrimido[4,5-e]azepin- 
               
               
                   
                 2(1H)-one 
               
               
                 II-441 
                 2-amino-N-(3-{[7-(2,6-difluorophenyl)-8,10-dimethyl-5H-pyrimido[5,4- 
               
               
                   
                 c]thieno[3,4-e]azepin-2-yl]amino}phenyl)-N,2-dimethylpropanamide 
               
               
                 II-442 
                 9-chloro-7-(2,6-difluorophenyl)-N-{3-[(2,2,6,6-tetramethylpiperidin-4- 
               
               
                   
                 yl)oxy]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-443 
                 4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)-N-methyl-1-(methylamino)cyclohexanecarboxamide 
               
               
                 II-444 
                 7-(3-{[7-(2-fluoro-6-methoxyphenyl)-9-methoxy-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl]amino}phenyl)-1,7-diazaspiro[4.4]nonan-6-one 
               
               
                 II-445 
                 9-chloro-N-[4-(3,8-diazabicyclo[3.2.1]oct-3-ylcarbonyl)phenyl]-7-(2,6- 
               
               
                   
                 difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-446 
                 1-(3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)-3,5,5-trimethylpiperazin-2-one 
               
               
                 II-447 
                 9-chloro-N-[4-(2,6-dimethylpiperidin-4-yl)phenyl]-7-(2-fluoro-6- 
               
               
                   
                 methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-448 
                 N-[4-(1-amino-1-methylethyl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-449 
                 N-[4-(2,5-diazaspiro[3.4]oct-2-ylcarbonyl)phenyl]-7-(2,6-difluorophenyl)-10- 
               
               
                   
                 methyl-5H-isothiazolo[5,4-c]pyrimido[4,5-e]azepin-2-amine 
               
               
                 II-450 
                 4-(2,6-difluorophenyl)-1-methyl-9-[(4-{[4-methyl-4-(methylamino)piperidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)amino]-1,6-dihydro-2H-pyrimido[5,4-c][1,3]thiazolo[4,5- 
               
               
                   
                 e]azepin-2-one 
               
               
                 II-451 
                 4-(2,6-difluorophenyl)-N-[4-(1H-imidazol-2-yl)phenyl]-1-methyl-1,6- 
               
               
                   
                 dihydroimidazo[4,5-c]pyrimido[4,5-e]azepin-9-amine 
               
               
                 II-452 
                 4-{[7-(2,6-difluorophenyl)-5H-[1]benzofuro[2,3-c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 yl]amino}benzoic acid 
               
               
                 II-453 
                 7-(2-fluorophenyl)-N-{4-[(3,3,5,5-tetramethylpiperazin-1-yl)carbonyl]phenyl}- 
               
               
                   
                 8,9,10,11-tetrahydro-5H-pyrido[4′,3′:4,5]thieno[3,2-c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 amine 
               
               
                 II-454 
                 9-bromo-7-(2-fluorophenyl)-N-(4-{[3-(methylamino)pyrrolidin-1- 
               
               
                   
                 yl]carbonyl}phenyl)-5,8-dihydropyrimido[5,4-c]pyrrolo[3,2-e]azepin-2-amine 
               
               
                 II-455 
                 7-(2-fluorophenyl)-N-(3-methyl-1H-indazol-6-yl)-5,12- 
               
               
                   
                 dihydropyrimido[4′,5′:5,6]azepino[4,3-b]indol-2-amine 
               
               
                 II-456 
                 1-(4-{[7-(2,6-difluorophenyl)-9,10-dimethyl-5,8-dihydropyrimido[5,4- 
               
               
                   
                 c]pyrrolo[3,2-e]azepin-2-yl]amino}benzoyl)-3-(methylamino)pyrrolidine-3- 
               
               
                   
                 carboxamide 
               
               
                 II-457 
                 {3-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone 
               
               
                 II-458 
                 [9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(2- 
               
               
                   
                 methylaminomethyl-benzothiazol-6-yl)-amine 
               
               
                 II-459 
                 4-[9-Chloro-7-(2-isopropoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-460 
                 4-[9-Chloro-7-(2-fluoro-6-isopropoxy-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-ylamino]-benzoic acid 
               
               
                 II-461 
                 4-[9-Chloro-7-(2-ethoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-462 
                 4-[9-Chloro-7-(2-ethoxy-6-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-463 
                 4-[9-Chloro-7-(2-fluoro-6-methyl-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-464 
                 4-[9-Chloro-7-(2-trifluoromethoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin- 
               
               
                   
                 2-ylamino]-benzoic acid 
               
               
                 II-465 
                 4-[9-Chloro-7-(2-fluoro-6-trifluoromethoxy-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-ylamino]-benzoic acid 
               
               
                 II-466 
                 4-[9-Chloro-7-(3-fluoro-2-trifluoromethoxy-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-ylamino]-benzoic acid 
               
               
                 II-467 
                 4-[9-Chloro-7-(2,3-dimethoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-468 
                 4-[9-Chloro-7-(2-isobutyl-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-469 
                 4-(7-Benzofuran-2-yl-9-chloro-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)- 
               
               
                   
                 benzoic acid 
               
               
                 II-470 
                 4-[9-Chloro-7-(1-methyl-1H-pyrrol-2-yl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-471 
                 4-[9-Chloro-7-(1-methyl-1H-imidazol-2-yl)-5H-benzo[c]pyrimido[4,5-e]azepin- 
               
               
                   
                 2-ylamino]-benzoic acid 
               
               
                 II-472 
                 4-(9-Chloro-7-thiophen-2-yl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)- 
               
               
                   
                 benzoic acid 
               
               
                 II-473 
                 4-[9-Chloro-7-(2H-pyrazol-3-yl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-474 
                 4-[9-Chloro-7-(2-ethynyl-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-475 
                 4-[7-(2-Aminomethyl-phenyl)-9-chloro-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-476 
                 4-[9-Chloro-7-(5-fluoro-2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin- 
               
               
                   
                 2-ylamino]-benzoic acid 
               
               
                 II-477 
                 4-[9-Chloro-7-(3-methoxy-pyridin-2-yl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-478 
                 4-[8-Fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzoic acid 
               
               
                 II-479 
                 4-[8-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 benzoic acid 
               
               
                 II-480 
                 4-[11-Fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-481 
                 4-[11-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-482 
                 6-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 pyridazine-3-carboxylic acid 
               
               
                 II-483 
                 2-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]- 
               
               
                   
                 1H-imidazole-4-carboxylic acid 
               
               
                 II-484 
                 4-[9-Chloro-7-(2-fluoro-phenyl)-4-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-benzoic acid 
               
               
                 II-485 
                 4-[4-Aminomethyl-9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido- 
               
               
                   
                 [4,5-e]azepin-2-ylamino]-benzoic acid 
               
               
                 II-486 
                 4-(9-Aminomethyl-7-phenyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)- 
               
               
                   
                 benzoic acid 
               
               
                 II-487 
                 9-Chloro-7-(2-fluorophenyl)-N-{4-[(2-methylpiperazin-1-yl)carbonyl]phenyl}- 
               
               
                   
                 5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-488 
                 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[{3-[(dimethylamino)methyl]azetidin-1- 
               
               
                   
                 yl}(imino)methyl]benzamide 
               
               
                 II-489 
                 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[imino(piperazin-1-yl)methyl]benzamide 
               
               
                 II-490 
                 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[imino(3-methylpiperazin-1-yl)methyl]benzamide 
               
               
                 II-491 
                 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[[3-(dimethylamino)pyrrolidin-1-yl](imino)methyl]benzamide 
               
               
                 II-492 
                 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[imino(4-methylpiperazin-1-yl)methyl]benzamide 
               
               
                 II-493 
                 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]benzamide 
               
               
                 II-494 
                 1-[[(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)amino](imino)methyl]pyrrolidine-3-carboxamide 
               
               
                 II-495 
                 1-[[(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoyl)amino](imino)methyl]piperidine-3-carboxamide 
               
               
                 II-496 
                 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[{4-[(cyclopropylcarbonyl)amino]piperidin-1- 
               
               
                   
                 yl}(imino)methyl]benzamide 
               
               
                 II-497 
                 4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[(dimethylamino)(imino)methyl]benzamide 
               
               
                 II-498 
                 N-[[(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)amino](imino)methyl]cyclopropanecarboxamide 
               
               
                 II-499 
                 N-[[(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)amino](imino)methyl]-3- 
               
               
                   
                 (dimethylamino)cyclopentanecarboxamide 
               
               
                 II-500 
                 4-({9-Chloro-7-[2-fluoro-6-(trifluoromethyl)phenyl]-5H-pyrimido- 
               
               
                   
                 [5,4-d][2]benzazepin-2-yl}amino)benzoic acid 
               
               
                 II-501 
                 4-{[9-Chloro-7-(2,6-dichlorophenyl)-5H&gt;-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoic acid 
               
               
                 II-502 
                 4-{[9-Chloro-7-(2-fluoro-6-methylphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoic acid 
               
               
                 II-503 
                 4-{[7-(2-Bromo-6-chlorophenyl)-9-chloro-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}benzoic acid 
               
               
                 II-504 
                 9-Chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]-3- 
               
               
                   
                 fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-505 
                 4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]-N-methylbenzamide 
               
               
                 II-506 
                 4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[[3-(dimethylamino)azetidin-1-yl](imino)methyl]-N- 
               
               
                   
                 methylbenzamide 
               
               
                 II-507 
                 3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]benzamide 
               
               
                 II-508 
                 3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[[3-(dimethylamino)pyrrolidin-1-yl](imino)methyl]benzamide 
               
               
                 II-509 
                 9-Chloro-7-(2,6-difluorophenyl)-N-{3-[(3,5-dimethylpiperazin-1-yl)carbonyl]-4- 
               
               
                   
                 fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-510 
                 N-[[(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)amino](imino)methyl]-3- 
               
               
                   
                 (dimethylamino)cyclopentanecarboxamide 
               
               
                 II-511 
                 N-[[(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-2-fluorophenyl)amino](imino)methyl]-3- 
               
               
                   
                 (dimethylamino)cyclopentanecarboxamide 
               
               
                 II-512 
                 N-[[(5-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-2-fluorophenyl)amino](imino)methyl]-3- 
               
               
                   
                 (dimethylamino)cyclopentanecarboxamide 
               
               
                 II-513 
                 N-(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)-3,5-dimethylpiperazine-1-carboximidamide 
               
               
                 II-514 
                 4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[[3-(dimethylamino)pyrrolidin-1-yl](imino)methyl]-N- 
               
               
                   
                 methylbenzamide 
               
               
                 II-515 
                 N-(3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)-3,5-dimethylpiperazine-1-carboximidamide 
               
               
                 II-516 
                 N-(3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)-N,3,5-trimethylpiperazine-1-carboximidamide 
               
               
                 II-517 
                 3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-N-[[3-(dimethylamino)azetidin-1-yl](imino)methyl]benzamide 
               
               
                 II-518 
                 N-(5-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-2-fluorophenyl)-N,3,5-trimethylpiperazine-1-carboximidamide 
               
               
                 II-519 
                 N-[[(3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)amino](imino)methyl]-3- 
               
               
                   
                 (dimethylamino)cyclopentanecarboxamide 
               
               
                 II-520 
                 9-Chloro-7-(2,6-difluorophenyl)-N-{3-[(3,5-dimethylpiperazin-1- 
               
               
                   
                 yl)(imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-521 
                 N-(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}phenyl)-N,3,5-trimethylpiperazine-1-carboximidamide 
               
               
                 II-522 
                 N-(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-2-fluorophenyl)-3,5-dimethylpiperazine-1-carboximidamide 
               
               
                 II-523 
                 9-Chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1- 
               
               
                   
                 yl)(imino)methyl]-3-fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-524 
                 5-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-2-(2,6-dimethylpiperidin-4-yl)-1H-isoindole-1,3(2H)-dione 
               
               
                 II-525 
                 N-[2-(Aminomethyl)-1H-benzimidazol-6-yl]-9-chloro-7-(2-fluorophenyl)-5H- 
               
               
                   
                 pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-526 
                 9-Chloro-7-(2-fluorophenyl)-N-{2-[(methylamino)methyl]-1H-benzimidazol-6- 
               
               
                   
                 yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-527 
                 9-Chloro-N-{2-[(dimethylamino)methyl]-1H-benzimidazol-6-yl}-7-(2- 
               
               
                   
                 fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-528 
                 9-Chloro-7-(2-fluorophenyl)-N-{2-[(methylamino)methyl]-1,3-benzothiazol-6- 
               
               
                   
                 yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-529 
                 9-Chloro-7-(2,6-difluorophenyl)-N-{2-[(methylamino)methyl]-1H- 
               
               
                   
                 benzimidazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-530 
                 9-Chloro-7-(2,6-difluorophenyl)-N-{2-[(methylamino)methyl]-1,3-benzoxazol- 
               
               
                   
                 6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-531 
                 9-Chloro-7-(2-fluorophenyl)-N-{2-[(methylamino)methyl]-1,3-benzoxazol-6- 
               
               
                   
                 yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-532 
                 9-Chloro-7-(2,6-difluorophenyl)-N-{3-[(3,5-dimethylpiperazin-1- 
               
               
                   
                 yl)(imino)methyl]-4-fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-533 
                 9-Chloro-7-(2,6-difluorophenyl)-N-{2-[(methylamino)methyl]-1,3-benzothiazol- 
               
               
                   
                 6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine 
               
               
                 II-534 
                 {3-[9-Chloro-7-(2,6-difluorophenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone 
               
               
                 II-535 
                 3-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2- 
               
               
                   
                 ylamino]-N-methyl-N-(4-methyl-pentyl)-benzamide 
               
               
                   
               
            
           
         
       
     
     In some embodiments, the selective Aurora A kinase inhibitor is represented by formula (III): 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt thereof;
 
wherein:
         R a  is selected from the group consisting of C 1-3  aliphatic, C 1-3  fluoroaliphatic, —R 1 , -T-R 1 , —R 2 , and -T-R 2 ;
           T is a C 1-3  alkylene chain optionally substituted with fluoro;   R 1  is an optionally substituted aryl, heteroaryl, or heterocyclyl group;   R 2  is selected from the group consisting of halo, —C≡C—R 3 , —CH═CH—R 3 , —N(R 4 ) 2 , and —OR 5 ;   R 3  is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group;   each R 4  independently is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R 4  on the same nitrogen atom, taken together with the nitrogen atom form an optionally substituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclyl ring having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S;   R 5  is hydrogen or an optionally substituted aliphatic, aryl, heteroaryl, or heterocyclyl group; and   
           R b  is selected from the group consisting of fluoro,
           chloro, —CH 3 , —CF 3 , —OH, —OCH 3 , —OCF 3 , —OCH 2 CH 3 , and —OCH 2 CF 3 .   
               

     In some embodiments, R 1  is a 5- or 6-membered aryl, heteroaryl, or heterocyclyl ring optionally substituted with one or two substituents independently selected from the group consisting of halo, C 1-3  aliphatic, and C 1-3  fluoroaliphatic. In certain embodiments, R 1  is a phenyl, furyl, pyrrolidinyl, or thienyl ring optionally substituted with one or two substituents independently selected from the group consisting of halo, C 1-3  aliphatic, and C 1-3  fluoroaliphatic. 
     In some embodiments, R 3  is hydrogen, C 1-3  aliphatic, C 1-3  fluoroaliphatic, or —CH 2 —OCH 3 . 
     In some embodiments, R 5  is hydrogen, C 1-3  aliphatic, or C 1-3  fluoroaliphatic. 
     In certain embodiments, R a  is halo, C 1-3  aliphatic, 
     C 1-3  fluoroaliphatic, —OH, —O(C 1-3  aliphatic), —O(C 1-3  fluoroaliphatic), —C≡C—R 3 , —CH═CH—R 3 , or an optionally substituted pyrrolidinyl, thienyl, furyl, or phenyl ring, wherein R 3  is hydrogen,
 
C 1-3  aliphatic, C 1-3  fluoroaliphatic, or —CH 2 —OCH 3 . In certain particular embodiments, R a  is selected from the group consisting of chloro, fluoro, C 1-3  aliphatic,
 
C 1-3  fluoroaliphatic, —OCH 3 , —OCF 3 , —C≡C—H, —C≡C—CH 3 , —C≡C—CH 2 OCH 3 , —CH═CH 2 , —CH═CHCH 3 , N-methylpyrrolidinyl, thienyl, methylthienyl, furyl, methylfuryl, phenyl, fluorophenyl, and tolyl.
 
     Table 2 provides the chemical names for specific examples of compounds of formula (II). 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 Examples of Compounds of Formula (III) 
               
            
           
           
               
               
            
               
                   
                 Chemical Name 
               
               
                   
                   
               
            
           
           
               
               
            
               
                 III-1 
                 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-2-methoxybenzoic acid 
               
               
                 III-2 
                 4-{[9-ethynyl-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-2-methoxybenzoic acid 
               
               
                 III-3 
                 4-({9-chloro-7-[2-fluoro-6-(trifluoromethoxy)phenyl]-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino)-2-methoxybenzoic acid 
               
               
                 III-4 
                 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(1-methyl-1H-pyrrol-2-yl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino}-2-methoxybenzoic acid 
               
               
                 III-5 
                 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(4-methyl-3-thienyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino}-2-methoxybenzoic acid 
               
               
                 III-6 
                 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(3-methyl-2-furyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino}-2-methoxybenzoic acid 
               
               
                 III-7 
                 4-({9-ethynyl-7-[2-fluoro-6-(2,2,2-trifluoroethoxy)phenyl]-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino)-2-methoxybenzoic acid 
               
               
                 III-8 
                 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2- 
               
               
                   
                 methoxybenzoic acid 
               
               
                 III-9 
                 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(2-methylphenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino}-2-methoxybenzoic acid 
               
               
                 III-10 
                 4-{[7-(2-fluoro-6-methoxyphenyl)-9-prop-1-yn-1-yl-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino}-2-methoxybenzoic acid 
               
               
                 III-11 
                 4-{[7-(2-fluoro-6-methoxyphenyl)-9-vinyl-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-2-methoxybenzoic acid 
               
               
                 III-12 
                 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(2-fluorophenyl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino}-2-methoxybenzoic acid 
               
               
                 III-13 
                 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(3-methoxyprop-1-yn-1-yl)-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino}-2-methoxybenzoic acid 
               
               
                 III-14 
                 4-({7-(2-fluoro-6-methoxyphenyl)-9-[(1E)-prop-1-en-1-yl]-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino)-2-methoxybenzoic acid 
               
               
                 III-15 
                 4-({9-chloro-7-[2-fluoro-6-(2,2,2-trifluoroethoxy)phenyl]-5H-pyrimido[5,4- 
               
               
                   
                 d][2]benzazepin-2-yl}amino)-2-methoxybenzoic acid 
               
               
                 III-16 
                 4-{[7-(2-fluoro-6-methoxyphenyl)-9-(2-furyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-2-methoxybenzoic acid 
               
               
                 III-17 
                 4-{[9-chloro-7-(2-fluoro-6-hydroxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-2-methoxybenzoic acid 
               
               
                 III-18 
                 4-{[7-(2-fluoro-6-methoxyphenyl)-9-phenyl-5H-pyrimido[5,4-d][2]benzazepin-2- 
               
               
                   
                 yl]amino}-2-methoxybenzoic acid 
               
               
                   
               
            
           
         
       
     
     In one embodiment, the compound of formula (III) is 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid (alisertib (MLN8237)), or a pharmaceutically acceptable salt thereof. In a particular embodiment, the compound of formula (I) is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate. In another embodiment, the compound of formula (III) is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate monohydrate. In another embodiment, the compound of formula (III) is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate or a crystakline form thereof, as described in US Publication No. 2008/0167292, U.S. Pat. No. 8,026,246, and US Publication No. 2011/0245234, hereby incorporated by reference in their entirety. 
     The present disclosure provides a method of treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of anyone of the compounds of formulas (I), (II) or (III), or a pharmaceutically acceptable salt thereof. 
     In some embodiments, the disclosure provides anyone of the compounds of formulas (I), (II) or (III), or a pharmaceutically acceptable salt thereof for use in treating cancer. In some embodiments, the disclosure provides the use of anyone of the compounds of formulas (I), (II) or (III), or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition (as described herein) for the treatment of cancer. In some embodiments, the disclosure provides the use of a therapeutically effective amount of anyone of the compounds of formulas (I), (II) or (III), or a pharmaceutically acceptable salt thereof, for the treatment of cancer. 
     In some embodiments, the disclosure provides a method of determining whether to treat a patient with cancer with a therapeutically effective amount of anyone of the compounds of formulas (I), (II) or (III), or a pharmaceutically acceptable salt thereof, based on identifying the patient with cancer as being likely to respond to the treatment based upon the presence of mutations in the patient&#39;s cell sample(s). In some embodiments, the disclosure provides a method of determining whether to treat a patient with cancer with a therapeutically effective amount of an Aurora A Kinase inhibitor, e.g., alisertib, or a pharmaceutically acceptable salt thereof based on identifying the patient with cancer as being likely to respond to the treatment based upon the presence of mutations in the patient&#39;s cell sample(s). In some embodiments, the mutations in the patient&#39;s cell samples are mutations of genes in the Wnt/β-catenin signaling pathway or the Hippo signaling pathway. 
     In some embodiments, the present disclosure provides a method of treating cancer, comprising administering a therapeutically effective amount of an Aurora A Kinase inhibitor, e.g., alisertib, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, to a cancer patient whose tumor sample is characterized by having a mutation in a gene selected from the group consisting of LEF1, MAP3K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XPO1, ROR2, CCND1, CTNNB1, AMOT, DVL2, LATS1, LATS2, MOB1B, NPHP4, TJP1, TJP2, WWC1, WWTR1 and YAP1. 
     In some embodiments, the disclosure provides a compound of anyone of formulas (I), (II) or (III), or a pharmaceutically acceptable salt or a pharmaceutical composition thereof, for use in treating cancer in a patient with a mutation in a gene selected from the group consisting of LEF1, MAP3K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XPO1, ROR2, CCND1, CTNNB1, AMOT, DVL2, LATS1, LATS2, MOB1B, NPHP4, TJP1, TJP2, WWC1, WWTR1 and YAP1. 
     Described herein is the assessment of outcome for treatment of a tumor through measurement of the amount of pharmacogenomic markers. Also described herein is the assessment of the treatment outcome by noninvasive, convenient or low-cost means, for example, from blood samples. The disclosure provides methods for determining, assessing, advising or providing an appropriate therapy regimen for treating a tumor or managing disease in a patient. Monitoring a treatment using the kits and methods disclosed herein can identify the potential for unfavorable outcome and allow their prevention, and thus a savings in morbidity, mortality and treatment costs through adjustment in the therapeutic regimen, cessation of therapy or use of alternative therapy. 
     The term “biological sample” is intended to include a patient sample, e.g, tissue, cells, biological fluids and isolates thereof, isolated from a subject, as well as tissues, cells and fluids present within a subject and can be obtained from a patient or a normal subject. In hematological tumors of the bone marrow, e.g., myeloma tumors, primary analysis of the tumor can be performed on bone marrow samples. However, some tumor cells, (e.g., clonotypic tumor cells, circulating endothelial cells), are a percentage of the cell population in whole blood. These cells also can be mobilized into the blood during treatment of the patient with granulocyte-colony stimulating factor (G-CSF) in preparation for a bone marrow transplant, a standard treatment for hematological tumors, e.g., leukemias, lymphomas and myelomas. Examples of circulating tumor cells in multiple myeloma have been studied e.g., by Pilarski et al. (2000)  Blood  95:1056-65 and Rigolin et al. (2006)  Blood  107:2531-5. Thus, noninvasive samples, e.g., for in vitro measurement of markers to determine outcome of treatment, can include peripheral blood samples. Accordingly, cells within peripheral blood can be tested for marker amount. For patients with hematological tumors, a control, reference sample for normal characteristic, e.g., size, sequence, composition or amount can be obtained from skin or a buccal swab of the patient. For solid tumors, a typical tumor sample is a biopsy of the tumor. For solid tumors, a control reference sample for normal characteristic, e.g., size, sequence, composition or amount can be obtained from blood of the patient. 
     Blood collection containers can comprise an anti-coagulant, e.g., heparin or ethylene-diaminetetraacetic acid (EDTA), sodium citrate or citrate solutions with additives to preserve blood integrity, such as dextrose or albumin or buffers, e.g., phosphate. If the amount of marker is being measured by measuring the level of its DNA in the sample, a DNA stabilizer, e.g., an agent that inhibits DNAse, can be added to the sample. If the amount of marker is being measured by measuring the level of its RNA in the sample, an RNA stabilizer, e.g., an agent that inhibits RNAse, can be added to the sample. If the amount of marker is being measured by measuring the level of its protein in the sample, a protein stabilizer, e.g., an agent that inhibits proteases, can be added to the sample. An example of a blood collection container is PAXGENE® tubes (PREANALYTIX, Valencia, Calif.), useful for RNA stabilization upon blood collection. Peripheral blood samples can be modified, e.g., fractionated, sorted or concentrated (e.g., to result in samples enriched with tumor or depleted of tumor (e.g., for a reference sample)). Examples of modified samples include clonotypic myeloma cells, which can be collected by e.g., negative selection, e.g., separation of white blood cells from red blood cells (e.g., differential centrifugation through a dense sugar or polymer solution (e.g., FICOLL® solution (Amersham Biosciences division of GE healthcare, Piscataway, N.J.) or HISTOPAQUE®-1077 solution, Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co., St. Louis, Mo.)) and/or positive selection by binding B cells to a selection agent (e.g., a reagent which binds to a tumor cell or myeloid progenitor marker, such as CD34, CD38, CD138, or CD133, for direct isolation (e.g., the application of a magnetic field to solutions of cells comprising magnetic beads (e.g., from Miltenyi Biotec, Auburn, Calif.) which bind to the B cell markers) or fluorescent-activated cell sorting). 
     Alternatively, a tumor cell line, e.g., OCI-Ly3, OCI-Ly10 cell (Alizadeh et al. (2000)  Nature  403:503-511), a RPMI 6666 cell, a SUP-B15 cell, a KG-1 cell, a CCRF-SB cell, an 8ES cell, a Kasumi-1 cell, a Kasumi-3 cell, a BDCM cell, an HL-60 cell, a Mo-B cell, a JM1 cell, a GA-10 cell or a B-cell lymphoma (e.g., BC-3) or a cell line or a collection of tumor cell lines (see e.g., McDermott et al. (2007) PNAS 104:19936-19941 or ONCOPANEL™ anti-cancer tumor cell profiling screen (Ricerca Biosciences, Bothell, Wash.)) can be assayed. A skilled artisan readily can select and obtain the appropriate cells (e.g., from American Type Culture Collection (ATCC®), Manassas, Va.) that are used in the present method. If the compositions or methods are being used to predict outcome of treatment in a patient or monitor the effectiveness of a therapeutic protocol, then a tissue or blood sample having been obtained from the patient being treated is a useful source of cells or marker gene or gene products for an assay. 
     The sample, e.g., tumor, e.g., biopsy or bone marrow, blood or modified blood, (e.g., comprising tumor cells) and/or the reference, e.g., matched control (e.g., germline), sample can be subjected to a variety of well-known post-collection preparative and storage techniques (e.g., nucleic acid and/or protein extraction, fixation, storage, freezing, ultrafiltration, concentration, evaporation, centrifugation, etc.) prior to assessing the amount of the marker in the sample. 
     In an embodiment, a mutation in a marker can be identified by sequencing a nucleic acid, e.g., a DNA, RNA, cDNA or a protein correlated with the marker gene. There are several sequencing methods known in the art to sequence nucleic acids. A primer can be designed to bind to a region comprising a potential mutation site or can be designed to complement the mutated sequence rather than the wild type sequence. Primer pairs can be designed to bracket a region comprising a potential mutation in a marker gene. A primer or primer pair can be used for sequencing one or both strands of DNA corresponding to the marker gene. A primer can be used in conjunction with a probe to amplify a region of interest prior to sequencing to boost sequence amounts for detection of a mutation in a marker gene. Examples of regions which can be sequenced include an entire gene, transcripts of the gene and a fragment of the gene or the transcript, e.g., one or more of exons or untranslated regions. Examples of mutations to target for primer selection and sequence or composition analysis can be found in public databases which collect mutation information, such as COSMIC and dbGaP. Some mutations of marker genes such as LEF1, MAP2K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XPO1, ROR2, CCND1, CTNNB1, AMOT, DVL2, LATS1, LATS2, MOB1B, NPHP4, TJP1, TJP2, WWC1, WWC1, WWTR1 and YAP1, etc. are listed in Tables 9-10 in the Examples as examples of mutations that can be associated with sensitivity to Aurora A Kinase inhibition, e.g., inhibition by alisertib. 
     Sequencing methods are known to one skilled in the art. Examples of methods include the Sanger method, the SEQUENOM™ method and Next Generation Sequencing (NGS) methods. The Sanger method, comprising using electrophoresis, e.g., capillary electrophoresis to separate primer-elongated labeled DNA fragments, can be automated for high-throughput applications. The primer extension sequencing can be performed after PCR amplification of regions of interest. Software can assist with sequence base calling and with mutation identification. SEQUENOM™ MASSARRAY® sequencing analysis (San Diego, Calif.) is a mass-spectrometry method which compares actual mass to expected mass of particular fragments of interest to identify mutations. NGS technology (also called “massively parallel sequencing” and “second generation sequencing”) in general provides for much higher throughput than previous methods and uses a variety of approaches (reviewed in Zhang et al. (2011)  J. Genet. Genomics  38:95-109 and Shendure and Hanlee (2008)  Nature Biotech.  26:1135-1145). NGS methods can identify low frequency mutations in a marker in a sample. Some NGS methods (see, e.g., GS-FLX Genome Sequencer (Roche Applied Science, Branford, Conn.), Genome analyzer (Illumina, Inc. San Diego, Calif.) SOLID™ analyzer (Applied Biosystems, Carlsbad, Calif.), Polonator G.007 (Dover Systems, Salem, N.H.), HELISCOPE™ (Helicos Biosciences Corp., Cambridge, Mass.)) use cyclic array sequencing, with or without clonal amplification of PCR products spatially separated in a flow cell and various schemes to detect the labeled modified nucleotide that is incorporated by the sequencing enzyme (e.g., polymerase or ligase). In one NGS method, primer pairs can be used in PCR reactions to amplify regions of interest. Amplified regions can be ligated into a concatenated product. Clonal libraries are generated in the flow cell from the PCR or ligated products and further amplified (“bridge” or “cluster” PCR) for single-end sequencing as the polymerase adds a labeled, reversibly terminated base that is imaged in one of four channels, depending on the identity of the labeled base and then removed for the next cycle. Software can aid in the comparison to genomic sequences to identify mutations. 
     Composition of proteins and nucleic acids can be determined by many ways known in the art, such as by treating them in ways that cleave, degrade or digest them and then analyzing the components. Mass spectrometry, electrophoresis and chromatography can separate and define components for comparison. Mutations which cause deletions or insertions can be identified by size or charge differences in these methods. Protein digestion or restriction enzyme nucleic acid digestion can reveal different fragment patterns after some mutations. Antibodies that recognize particular mutant amino acids in their structural contexts can identify and detect these mutations in samples (see below). 
     In an embodiment, DNA, e.g., genomic DNA corresponding to the wild type or mutated marker can be analyzed both by in situ and by in vitro formats in a biological sample using methods known in the art. DNA can be directly isolated from the sample or isolated after isolating another cellular component, e.g., RNA or protein. Kits are available for DNA isolation, e.g., QIAAMP® DNA Micro Kit (Qiagen, Valencia, Calif.). DNA also can be amplified using such kits. 
     In another embodiment, mRNA corresponding to the marker can be analyzed both by in situ and by in vitro formats in a biological sample using methods known in the art. Many expression detection methods use isolated RNA. For in vitro methods, any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from tumor cells (see, e.g., Ausubel et al., ed.,  Current Protocols in Molecular Biology , John Wiley &amp; Sons, New York 1987-1999). Additionally, large numbers of tissue samples can readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski (1989, U.S. Pat. No. 4,843,155). RNA can be isolated using standard procedures (see e.g., Chomczynski and Sacchi (1987)  Anal. Biochem.  162:156-159), solutions (e.g., trizol, TRI REAGENT® (Molecular Research Center, Inc., Cincinnati, Ohio; see U.S. Pat. No. 5,346,994) or kits (e.g., a QIAGEN® Group RNEASY® isolation kit (Valencia, Calif.) or LEUKOLOCK™ Total RNA Isolation System, Ambion division of Applied Biosystems, Austin, Tex.). 
     Additional steps may be employed to remove DNA from RNA samples. Cell lysis can be accomplished with a nonionic detergent, followed by microcentrifugation to remove the nuclei and hence the bulk of the cellular DNA. DNA subsequently can be isolated from the nuclei for DNA analysis. In one embodiment, RNA is extracted from cells of the various types of interest using guanidinium thiocyanate lysis followed by CsCl centrifugation to separate the RNA from DNA (Chirgwin et al. (1979)  Biochemistry  18:5294-99). Poly(A)+RNA is selected by selection with oligo-dT cellulose (see Sambrook et al. (1989)  Molecular Cloning —A Laboratory Manual (2nd ed.), Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.). Alternatively, separation of RNA from DNA can be accomplished by organic extraction, for example, with hot phenol or phenol/chloroform/isoamyl alcohol. If desired, RNAse inhibitors may be added to the lysis buffer. Likewise, for certain cell types, it may be desirable to add a protein denaturation/digestion step to the protocol. For many applications, it is desirable to enrich mRNA with respect to other cellular RNAs, such as transfer RNA (tRNA) and ribosomal RNA (rRNA). Most mRNAs contain a poly(A) tail at their 3′ end. This allows them to be enriched by affinity chromatography, for example, using oligo(dT) or poly(U) coupled to a solid support, such as cellulose or SEPHADEX.R™. medium (see Ausubel et al. (1994)  Current Protocols In Molecular Biology , vol. 2, Current Protocols Publishing, New York). Once bound, poly(A)+mRNA is eluted from the affinity column using 2 mM EDTA/0.1% SDS. 
     The characteristic of a marker of the disclosure in a biological sample involves obtaining a biological sample (e.g., a bone marrow sample, a tumor biopsy or a reference sample) from a test subject may be assessed by any of a wide variety of well known methods for detecting or measuring the characteristic, e.g., of a nucleic acid (e.g., RNA, mRNA, genomic DNA, or cDNA) and/or translated protein. Non-limiting examples of such methods include immunological methods for detection of secreted, cell-surface, cytoplasmic, or nuclear proteins, protein purification methods, protein function or activity assays, nucleic acid hybridization methods, nucleic acid reverse transcription methods, and nucleic acid amplification methods. These methods include gene array/chip technology, RT-PCR, TAQMAN® gene expression assays (Applied Biosystems, Foster City, Calif.), e.g., under GLP approved laboratory conditions, in situ hybridization, immunohistochemistry, immunoblotting, FISH (flourescence in situ hybridization), FACS analyses, northern blot, southern blot, INFINIUM® DNA analysis Bead Chips (Illumina, Inc., San Diego, Calif.), quantitative PCR, bacterial artificial chromosome arrays, single nucleotide polymorphism (SNP) arrays (Affymetrix, Santa Clara, Calif.) or cytogenetic analyses. The detection methods of the disclosure can thus be used to detect RNA, mRNA, protein, cDNA, or genomic DNA, for example, in a biological sample in vitro as well as in vivo. Furthermore, in vivo techniques for detection of a polypeptide or nucleic acid corresponding to a marker of the disclosure include introducing into a subject a labeled probe to detect the biomarker, e.g., a nucleic acid complementary to the transcript of a biomarker or a labeled antibody, Fc receptor or antigen directed against the polypeptide, e.g., wild type or mutant marker. For example, the antibody can be labeled with a radioactive isotope whose presence and location in a subject can be detected by standard imaging techniques. These assays can be conducted in a variety of ways. A skilled artisan can select from these or other appropriate and available methods based on the nature of the marker(s), tissue sample and mutation in question. Some methods are described in more detail in later sections. Different methods or combinations of methods could be appropriate in different cases or, for instance in different types of tumors or patient populations. 
     In vitro techniques for detection of a polypeptide corresponding to a marker of the disclosure include enzyme linked immunosorbent assays (ELISAs), Western blots, protein array, immunoprecipitations and immunofluorescence. In such examples, expression of a marker is assessed using an antibody (e.g., a radio-labeled, chromophore-labeled, fluorophore-labeled, or enzyme-labeled antibody), an antibody derivative (e.g., an antibody conjugated with a substrate or with the protein or ligand of a protein-ligand pair (e.g., biotin-streptavidin)), or an antibody fragment (e.g., a single-chain antibody, an isolated antibody hypervariable domain, etc.) which binds specifically with a marker protein or fragment thereof, e.g., a protein or fragment comprising a region which can be mutated or a portion comprising a mutated sequence, or a mutated residue in its structural context, including a marker protein which has undergone all or a portion of its normal post-translational modification. An antibody can detect a protein with an amino acid sequence selected from the group of proteins disclosed by GenPept Accession numbers within Tables 9 and 10 herein. Alternatively, an antibody can detect a mutated protein with a variant amino acid sequence selected from the group of proteins disclosed by GenPept Accession numbers within Tables 9 and 10 herein. Residues listed as mutated in public databases such as COSMIC of dbGaP can be prepared in immunogenic compositions for generation of antibodies that will specifically recognize and bind to the mutant residues. Another method can employ pairs of antibodies, wherein one of the pair would bind a marker protein upstream, i.e. N-terminal to the region of expected mutation, e.g., nonsense or deletion and the other of the pair would bind the protein downstream. Wild type protein would bind both antibodies of the pair, but a protein with a nonsense or deletion mutation would bind only the N-terminal antibody of the pair. An assay such as a sandwich ELISA assay could detect a loss of quantity of the wild type protein in the tumor sample, e.g., in comparison to the reference sample, or a standard ELISA would comparison of the levels of binding of the antibodies to infer that a mutation is present in a tumor sample. 
     Indirect methods for determining the amount or functionality of a protein marker also include measurement of the activity of the protein. For example, a sample, or a protein isolated from the sample or expressed from nucleic acid isolated, cloned or amplified from the sample can be assessed for marker protein activity. Biomarker activity can be measured by its ability to associate with binding partners, e.g., in a cell-free assay or in a cell-based assay. Alternatively, biomarker activity can be measured by its activity in signal transduction, e.g., in a cell-free assay or in a cell-based assay. 
     In one embodiment, expression of a marker is assessed by preparing mRNA/cDNA (i.e., a transcribed polynucleotide) from cells in a patient sample, and by hybridizing the mRNA/cDNA with a reference polynucleotide which is a complement of a marker nucleic acid, or a fragment thereof. cDNA can, optionally, be amplified using any of a variety of polymerase chain reaction methods prior to hybridization with the reference polynucleotide. Expression of one or more markers likewise can be detected using quantitative PCR to assess the level of expression of the marker(s). An example of the use of measuring mRNA levels is that an inactivating mutation in a marker gene can result in an altered level of mRNA in a cell. The level can be upregulated due to feedback signaling protein production in view of nonfunctional or absent protein or downregulated due to instability of an altered mRNA sequence. Alternatively, any of the many known methods of detecting mutations or variants (e.g. single nucleotide polymorphisms, deletions, etc., discussed above) of a marker of the disclosure may be used to detect occurrence of a mutation in a marker gene in a patient. 
     An example of direct measurement is quantification of transcripts. As used herein, the level or amount of expression refers to the absolute amount of expression of an mRNA encoded by the marker or the absolute amount of expression of the protein encoded by the marker. As an alternative to making determinations based on the absolute expression amount of selected markers, determinations may be based on normalized expression amounts. Expression amount can be normalized by correcting the absolute expression level of a marker upon comparing its expression to the expression of a control marker that is not a marker, e.g., in a housekeeping role that is constitutively expressed. Suitable markers for normalization also include housekeeping genes, such as the actin gene or beta-2 microglobulin. Reference markers for data normalization purposes include markers which are ubiquitously expressed and/or whose expression is not regulated by oncogenes. Constitutively expressed genes are known in the art and can be identified and selected according to the relevant tissue and/or situation of the patient and the analysis methods. Such normalization allows one to compare the expression level in one sample, to another sample, e.g., between samples from different times or different subjects. Further, the expression level can be provided as a relative expression level. The baseline of a genomic DNA sample, e.g., diploid copy number, can be determined by measuring amounts in cells from subjects without a tumor or in non-tumor cells from the patient. To determine a relative amount of a marker or marker set, the amount of the marker or marker set is determined for at least 1, or 2, 3, 4, 5, or more samples, e.g., 7, 10, 15, 20 or 50 or more samples in order to establish a baseline, prior to the determination of the expression level for the sample in question. To establish a baseline measurement, the mean amount or level of each of the markers or marker sets assayed in the larger number of samples is determined and this is used as a baseline expression level for the biomarkers or biomarker sets in question. The amount of the marker or marker set determined for the test sample (e.g., absolute level of expression) is then divided by the baseline value obtained for that marker or marker set. This provides a relative amount and aids in identifying abnormal levels of marker protein activity. 
     Probes based on the sequence of a nucleic acid molecule of the disclosure can be used to detect transcripts or genomic sequences corresponding to one or more markers of the disclosure. The probe can comprise a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, e.g., detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted. 
     In addition to the nucleotide sequences described in the database records described herein, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (e.g., the human population). Such genetic polymorphisms can exist among individuals within a population due to naturally occurring allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus. In addition, it will be appreciated that DNA polymorphisms that affect RNA expression levels can also exist that may affect the overall expression level of that gene (e.g., by affecting regulation or degradation). 
     Primers or nucleic acid probes comprise a nucleotide sequence complementary to a specific marker or a mutated region thereof and are of sufficient length to selectively hybridize with a marker gene or nucleic acid associated with a marker gene. Primers and probes can be used to aid in the isolation and sequencing of marker nucleic acids. In one embodiment, the primer or nucleic acid probe, e.g., a substantially purified oligonucleotide, comprises a region having a nucleotide sequence which hybridizes under stringent conditions to about 6, 8, 10, 12, or 15, 20, 25, 30, 40, 50, 60, 75, 100 or more consecutive nucleotides of a marker gene. In another embodiment, the primer or nucleic acid probe is capable of hybridizing to a marker nucleic acid comprising a nucleotide sequence disclosed by GenBank Accession number within Tables 9 and 10 herein, or a complement of any of the foregoing. For example, a primer or nucleic acid probe comprising a nucleotide sequence of at least about 15 consecutive nucleotides, at least about 25 nucleotides or having from about 15 to about 20 nucleotides, 10 to 50 consecutive nucleotides, 12 to 35 consecutive nucleotides, 15 to 50 consecutive nucleotides, 20 to 100 consecutive nucleotides set forth in any of the nucleotide sequences disclosed by GenBank Accession number within Tables 9 and 10 herein, or a complement of any of the foregoing are provided by the disclosure. Primers or nucleic acid probes having a sequence of more than about 25 nucleotides are also within the scope of the disclosure. In another embodiment, a primer or nucleic acid probe can have a sequence at least 70%, at least 75%, 80% or 85%, or at least, 90%, 95% or 97% identical to the nucleotide sequence of any nucleotide sequence disclosed by GenBank Accession number within Tables 9 and 10 herein, or a complement of any of the foregoing. Nucleic acid analogs can be used as binding sites for hybridization. An example of a suitable nucleic acid analogue is peptide nucleic acid (see, e.g., Egholm et al.,  Nature  363:566 568 (1993); U.S. Pat. No. 5,539,083). 
     Primers or nucleic acid probes can be selected using an algorithm that takes into account binding energies, base composition, sequence complexity, cross-hybridization binding energies, and secondary structure (see Friend et al., International Patent Publication WO 01/05935, published Jan. 25, 2001; Hughes et al.,  Nat. Biotech.  19:342-7 (2001). Useful primers or nucleic acid probes of the disclosure bind sequences which are unique for each transcript, e.g., target mutated regions and can be used in PCR for amplifying, detecting and sequencing only that particular nucleic acid, e.g., transcript or mutated transcript. Examples of some mutations of marker genes, e.g., LEF1, MAP2K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XPO1, ROR2, CCND1, CTNNB1, AMOT, DVL2, LATS1, LATS2, MOB1B, NPHP4, TJP1, TJP2, WWC1, WWC1, WWTR1 and YAP1, etc. . . . are found in Tables in the Examples (Tables 9-10). Other mutations are described in reference articles cited herein and in public databases described herein. One of skill in the art can design primers and nucleic acid probes for the markers disclosed herein or related markers with similar characteristics, e.g., markers on the chromosome loci, or mutations in different regions of the same marker gene described herein, using the skill in the art, e.g., adjusting the potential for primer or nucleic acid probe binding to standard sequences, mutants or allelic variants by manipulating degeneracy or GC content in the primer or nucleic acid probe. Computer programs that are well known in the art are useful in the design of primers with the required specificity and optimal amplification properties, such as Oligo version 5.0 (National Biosciences, Plymouth, Minn.). While perfectly complementary nucleic acid probes and primers can be used for detecting the markers described herein and mutants, polymorphisms or alleles thereof, departures from complete complementarity are contemplated where such departures do not prevent the molecule from specifically hybridizing to the target region. For example, an oligonucleotide primer may have a non-complementary fragment at its 5′ end, with the remainder of the primer being complementary to the target region. Alternatively, non-complementary nucleotides may be interspersed into the nucleic acid probe or primer as long as the resulting probe or primer is still capable of specifically hybridizing to the target region. 
     An indication of treatment outcome can be assessed by studying the amount of 1 marker, 2 markers, 3 markers or 4 markers, or more, e.g., 5, 6, 7, 8, 9, 10, 15, 20, or 25 markers, or mutated portions thereof e.g., marker genes which participate in or interact with the Wnt/3-catenin signaling pathway, marker genes which participate in or interact with the Hippo pathway, or marker genes which participate in or interact with tumor suppressors. Markers can be studied in combination with another measure of treatment outcome, e.g., biochemical markers (e.g., M protein, proteinuria) or histology markers (e.g., blast count, number of mitotic figures per unit area). 
     Any marker, e.g., marker gene or combination of marker, e.g., marker genes of the disclosure, or mutations thereof as well as any known markers in combination with the markers, e.g., marker genes of the disclosure, may be used in the compositions, kits, and methods of the present disclosure. In general, markers are selected for as great as possible difference between the characteristic, e.g., size, sequence, composition or amount of the marker in samples comprising tumor cells and the characteristic, e.g., size, sequence, composition or amount of the same marker in control cells. Although this difference can be as small as the limit of detection of the method for assessing the amount of the marker, in another embodiment, the difference can be at least greater than the standard error of the assessment method. In the case of RNA or protein amount, a difference can be at least 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 100-, 500-, 1000-fold or greater. “Low” RNA or protein amount can be that expression relative to the overall mean across tumor samples (e.g., hematological tumor, e.g., myeloma) is low. In the case of amount of DNA, e.g., copy number, the amount is 0, 1, 2, 3, 4, 5, 6, or more copies. A deletion causes the copy number to be 0 or 1; an amplification causes the copy number to be greater than 2. The difference can be qualified by a confidence level, e.g., p&lt;0.05, p&lt;0.02, p&lt;0.01 or lower p-value. 
     Measurement of more than one marker, e.g., a set of 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, or 25 or more markers can provide an expression profile or a trend indicative of treatment outcome. In some embodiments, the marker set comprises no more than 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, or 25 markers. In some embodiments, the marker set comprises 1-5, 1-10, 1-15, 1-20, 1-25, 2-5, 2-10, 2-15, 2-20, 2-25, 3-5, 3-10, 3-15, 3-20, 3-25, 4-10, 4-15, 4-20, 4-25, 5-10, 5-15, 5-20, 5-25, 6-10, 6-15, 6-20, 6-25, 7-10, 7-15, 7-20, 7-25, 8-10, 8-15, 8-20, 8-25, 9-15, 9-20, 9-25, 10-15, 10-20, 10-25, 11-15, 11-20, 11-25, 12-15, 12-20, 12-25, 13-15, 13-20, 13-20, 14-20, 14-25, 15-20, 15-25, 16-20, 16-25, 17-20, 17-25, 18-20, 18-25, 19-25, 20-25, 21-25, 22-25, 23-25 or 24-25 markers. In some embodiments, the marker set includes a plurality of chromosome loci, a plurality of marker genes, or a plurality of markers of one or more marker genes (e.g., nucleic acid and protein, genomic DNA and mRNA, or various combinations of markers described herein). Analysis of treatment outcome through assessing the amount of markers in a set can be accompanied by a statistical method, e.g., a weighted voting analysis which accounts for variables which can affect the contribution of the amount of a marker in the set to the class or trend of treatment outcome, e.g., the signal-to-noise ratio of the measurement or hybridization efficiency for each marker. A marker set, e.g., a set of 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, or 25 or more markers, can comprise a primer, probe or primers to analyze at least one marker DNA or RNA described herein, e.g., LEF1, MAP3K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XPO1, ROR2, CCND1, CTNNB1, AMOT, DVL2, LATS1, LATS2, MOB1B, NPHP4, TJP1, TJP2, WWC1, WWTR1 and/or YAP1, or a complement of any of the foregoing. A marker set, e.g., a set of 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, or 25 or more markers, can comprise a primer, probe or primers to detect at least one or at least two or more markers, or at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, or 25 or more mutations on the markers e.g., LEF1, MAP3K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XPO1, ROR2, CCND1, CTNNB1, AMOT, DVL2, LATS1, LATS2, MOB1B, NPHP4, TJP1, TJP2, WWC1, WWTR1 and/or YAP1. In another embodiment, a marker set can comprise LEF1, MAP3K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XPO1, ROR2, CCND1, CTNNB1, AMOT, DVL2, LATS1, LATS2, MOB1B, NPHP4, TJP1, TJP2, WWC1, WWTR1 and/or YAP1. In an embodiment, a marker set for breast cancer comprises LEF1, MAP3K7, FZD2, LATS1 and/or WWC1. In an embodiment, a marker set for gastric cancer comprises FZD2 and/or LATS2. In an embodiment, a marker set for head and neck cancer comprises MAP3K7, JUN, ROR2, CCND1, LATS1, MOB1B and/or NPHP4. In an embodiment, a marker set for non-small cell lung cancer comprises XPO1 and/or TJP1. In an embodiment, a marker set for small cell lung cancer comprises LEF1, APC, PRKCA, RORA, CAMK2G, CTNNB1, AMOT, DVL2, TJP1, TJP2, WWTR1 and/or YAP1. Selected marker sets can be assembled from the markers provided herein or selected from among markers using methods provided herein and analogous methods known in the art. A way to qualify a new marker for use in an assay of the disclosure is to correlate DNA copy number in a sample comprising tumor cells with differences in expression (e.g., fold-change from baseline) of a marker, e.g., a marker gene. A useful way to judge the relationship is to calculate the coefficient of determination r2, after solving for r, the Pearson product moment correlation coefficient and/or preparing a least squares plot, using standard statistical methods. A correlation can analyze DNA copy number versus the level of expression of marker, e.g., a marker gene. A gene product can be selected as a marker if the result of the correlation (r2, e.g., the linear slope of the data in this analysis), is at least 0.1-0.2, at least 0.3-0.5, or at least 0.6-0.8 or more. Markers can vary with a positive correlation to response, TTP or survival (i.e., change expression levels in the same manner as copy number, e.g., decrease when copy number is decreased). Markers which vary with a negative correlation to copy number (i.e., change expression levels in the opposite manner as copy number levels, e.g., increase when copy number is decreased) provide inconsistent determination of outcome. 
     Another way to qualify a new marker for use in the assay would be to assay the expression of large numbers of markers in a number of subjects before and after treatment with a test agent. The expression results allow identification of the markers which show large changes in a given direction after treatment relative to the pre-treatment samples. One can build a repeated-measures linear regression model to identify the genes that show statistically significant changes or differences. To then rank these significant genes, one can calculate the area under the change from e.g., baseline vs time curve. This can result in a list of genes that would show the largest statistically significant changes. Then several markers can be combined together in a set by using such methods as principle component analysis, clustering methods (e.g., k-means, hierarchical), multivariate analysis of variance (MANOVA), or linear regression techniques. To use such a gene (or group of genes) as a marker, genes which show 2-, 2.5-, 3-, 3.5-, 4-, 4.5-, 5-, 7-, 10-fold, or more differences of expression from baseline would be included in the marker set. An expression profile, e.g., a composite of the expression level differences from baseline or reference of the aggregate marker set would indicate at trend, e.g., if a majority of markers show a particular result, e.g., a significant difference from baseline or reference, e.g., 60%, 70%, 80%, 90%, 95% or more markers; or more markers, e.g., 10% more, 20% more, 30% more, 40% more, show a significant result in one direction than the other direction. 
     In an embodiment, a probe set can comprise probes for assessing characteristics of markers selected from the group consisting of LEF1, MAP3K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XPO1, ROR2, CCND1, CTNNB1, AMOT, DVL2, LATS1, LATS2, MOB1B, NPHP4, TJP1, TJP2, WWC1, WWTR1 and YAP1. In an embodiment, a probe set for breast cancer comprises probes for assessing characteristics of LEF1, MAP3K7, FZD2, LATS1 and/or WWC1. In an embodiment, a probe set for gastric cancer comprises probes for assessing characteristics of FZD2 and/or LATS2. In an embodiment, a probe set for head and neck cancer comprises probes for assessing characteristics of MAP3K7, JUN, ROR2, CCND1, LATS1, MOB1B and/or NPHP4. In an embodiment, a probe set for non-small cell lung cancer comprises probes for assessing characteristics XPO1 and/or TJP1. In an embodiment, a probe set for small cell lung cancer comprises probes for assessing characteristics of LEF1, APC, PRKCA, RORA, CAMK2G, CTNNB1, AMOT, DVL2, TJP1, TJP2, WWTR1 and/or YAP1. 
     In embodiments when the compositions, kits, and methods of the disclosure are used for characterizing treatment outcome in a patient, the marker or set of markers of the disclosure is selected such that a significant result is obtained in at least about 20%, at least about 40%, 60%, or 80%, or in substantially all patients treated with the test agent. The marker or set of markers of the disclosure can be selected such that a positive predictive value (PPV) of greater than about 10% is obtained for the general population and additional confidence in a marker can be inferred when the PPV is coupled with an assay specificity greater than 80%. 
     Detection Methods 
     A general principle of prognostic assays involves preparing a sample or reaction mixture that may contain a marker, and a probe, under appropriate conditions and for a time sufficient to allow the marker and probe to interact and bind, thus forming a complex that can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways. 
     For example, one method to conduct such an assay would involve anchoring the marker or probe onto a solid phase support, also referred to as a substrate, and detecting target marker/probe complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, a sample from a subject, which is to be assayed for presence and/or concentration of marker, can be anchored onto a carrier or solid phase support. In another embodiment, the reverse situation is possible, in which the probe can be anchored to a solid phase and a sample from a subject can be allowed to react as an unanchored component of the assay. One example of such an embodiment includes use of an array or chip which contains a predictive marker or marker set anchored for expression analysis of the sample. 
     There are many established methods for anchoring assay components to a solid phase. These include, without limitation, marker or probe molecules which are immobilized through conjugation of biotin and streptavidin. Such biotinylated assay components can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In certain embodiments, the surfaces with immobilized assay components can be prepared in advance and stored. 
     Other suitable carriers or solid phase supports for such assays include any material capable of binding the class of molecule to which the marker or probe belongs. Well-known supports or carriers include, but are not limited to, glass, polystyrene, nylon, polypropylene, nylon, polyethylene, dextran, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. One skilled in the art will know many other suitable carriers for binding antibody or antigen, and will be able to adapt such support for use with the present disclosure. For example, protein isolated from cells can be run on a polyacrylamide gel electrophoresis and immobilized onto a solid phase support such as nitrocellulose. The support can then be washed with suitable buffers followed by treatment with the detectably labeled antibody. The solid phase support can then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on the solid support can then be detected by conventional means. 
     In order to conduct assays with the above mentioned approaches, the non-immobilized component is added to the solid phase upon which the second component is anchored. After the reaction is complete, uncomplexed components may be removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized upon the solid phase. The detection of marker/probe complexes anchored to the solid phase can be accomplished in a number of methods outlined herein. 
     In an embodiment, the probe, when it is the unanchored assay component, can be labeled for the purpose of detection and readout of the assay, either directly or indirectly, with detectable labels discussed herein and which are well-known to one skilled in the art. The term “labeled”, with regard to the probe (e.g., nucleic acid or antibody), is intended to encompass direct labeling of the probe by coupling (i.e., physically linking) a detectable substance to the probe, as well as indirect labeling of the probe by reactivity with another reagent that is directly labeled. An example of indirect labeling includes detection of a primary antibody using a fluorescently labeled secondary antibody. It is also possible to directly detect marker/probe complex formation without further manipulation or labeling of either component (marker or probe), for example by utilizing the technique of fluorescence energy transfer (FET, see, for example, Lakowicz et al., U.S. Pat. No. 5,631,169; Stavrianopoulos, et al., U.S. Pat. No. 4,868,103). A fluorophore label on the first, ‘donor’ molecule is selected such that, upon excitation with incident light of appropriate wavelength, its emitted fluorescent energy will be absorbed by a fluorescent label on a second ‘acceptor’ molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the ‘donor’ protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the ‘acceptor’ molecule label may be differentiated from that of the ‘donor’. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, spatial relationships between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the ‘acceptor’ molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter). 
     In another embodiment, determination of the ability of a probe to recognize a marker can be accomplished without labeling either assay component (probe or marker) by utilizing a technology such as real-time Biomolecular Interaction Analysis (BIA) (see, e.g., Sjolander, S. and Urbaniczky, C. (1991)  Anal. Chem.  63:2338-2345 and Szabo et al. (1995)  Curr. Opin. Struct. Biol.  5:699-705). As used herein, “BIA” or “surface plasmon resonance” is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIACORE™). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules. 
     Alternatively, in another embodiment, analogous diagnostic and prognostic assays can be conducted with marker and probe as solutes in a liquid phase. In such an assay, the complexed marker and probe are separated from uncomplexed components by any of a number of standard techniques, including but not limited to: differential centrifugation, chromatography, electrophoresis and immunoprecipitation. In differential centrifugation, marker/probe complexes may be separated from uncomplexed assay components through a series of centrifugal steps, due to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas, G., and Minton, A. P. (1993)  Trends Biochem Sci.  18:284-7). Standard chromatographic techniques also can be utilized to separate complexed molecules from uncomplexed ones. For example, gel filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for example, the relatively larger complex may be separated from the relatively smaller uncomplexed components. Similarly, the relatively different charge properties of the marker/probe complex as compared to the uncomplexed components may be exploited to differentiate the complex from uncomplexed components, for example through the utilization of ion-exchange chromatography resins. Such resins and chromatographic techniques are well known to one skilled in the art (see, e.g., Heegaard, N. H. (1998)  J. Mol. Recognit.  11:141-8; Hage, D. S., and Tweed, S. A. (1997)  J. Chromatogr. B. Biomed. Sci. Appl.  699:499-525). Gel electrophoresis may also be employed to separate complexed assay components from unbound components (see, e.g., Ausubel et al., ed.,  Current Protocols in Molecular Biology , John Wiley &amp; Sons, New York, 1987-1999). In this technique, protein or nucleic acid complexes are separated based on size or charge, for example. In some embodiments, non-denaturing gel matrix materials and conditions in the absence of reducing agent are used in order to maintain the binding interaction during the electrophoretic process. Appropriate conditions to the particular assay and components thereof will be well known to one skilled in the art. 
     The isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction and TAQMAN® gene expression assays (Applied Biosystems, Foster City, Calif.) and probe arrays. One diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected. Nucleic acids comprising mutations of marker genes can be used as probes or primers. The nucleic acid probes or primers of the disclosure can be single stranded DNA (e.g., an oligonucleotide), double stranded DNA (e.g., double stranded oligonucleotide) or RNA. Primers of the disclosure refer to nucleic acids which hybridize to a nucleic acid sequence which is adjacent to the region of interest and is extended or which covers the region of interest. A nucleic acid probe can be, for example, a full-length cDNA, or a portion thereof, such as an oligonucleotide of 10 to 50 consecutive nucleotides, 15 to 45 consecutive nucleotides, 15 to 75 consecutive nucleotides, 20 to 100 consecutive nucleotides, 25 to 250 consecutive nucleotides, or at least 7, 15, 20, 25, 30, 50, 75, 100, 125, 150, 175, 200, 250 or 500 or more consecutive nucleotides of the marker and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a marker of the present disclosure. The exact length of the nucleic acid probe will depend on many factors that are routinely considered and practiced by the skilled artisan. Nucleic acid probes of the disclosure may be prepared by chemical synthesis using any suitable methodology known in the art, may be produced by recombinant technology, or may be derived from a biological sample, for example, by restriction digestion. Other suitable probes for use in the diagnostic assays of the disclosure are described herein. The probe can comprise a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, an enzyme co-factor, a hapten, a sequence tag, a protein or an antibody. The nucleic acids can be modified at the base moiety, at the sugar moiety, or at the phosphate backbone. An example of a nucleic acid label is incorporated using SUPER™ Modified Base Technology (Nanogen, Bothell, Wash., see U.S. Pat. No. 7,045,610). The level of expression can be measured as general nucleic acid levels, e.g., after measuring the amplified DNA levels (e.g. using a DNA intercalating dye, e.g., the SYBR green dye (Qiagen Inc., Valencia, Calif.) or as specific nucleic acids, e.g., using a probe based design, with the probes labeled. TAQMAN® assay formats can use the probe-based design to increase specificity and signal-to-noise ratio. 
     Such primers or probes can be used as part of a diagnostic test kit for identifying cells or tissues which express the protein, such as by measuring amounts of a nucleic acid molecule transcribed in a sample of cells from a subject, e.g., detecting transcript, mRNA levels or determining whether a gene encoding the protein has been mutated or deleted. Hybridization of an RNA or a cDNA with the nucleic acid probe can indicate that the marker in question is being expressed. The disclosure further encompasses detecting nucleic acid molecules that differ, due to degeneracy of the genetic code, from the nucleotide sequence of nucleic acids encoding a marker protein (e.g., protein having the sequence disclosed by GenPept Accession number within Tables 9 and 10 herein), and thus encode the same protein. It will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (e.g., the human population). Such genetic polymorphisms can exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals, e.g., normal samples from individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Detecting any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity are intended to be within the scope of the disclosure. In addition, it will be appreciated that DNA polymorphisms that affect RNA expression levels can also exist that may affect the overall expression level of that gene (e.g., by affecting regulation or degradation). 
     As used herein, the term “hybridizes” is intended to describe conditions for hybridization and washing under which nucleotide sequences that are significantly identical or homologous to each other remain hybridized to each other. In some embodiments, the conditions are such that sequences at least about 70%, at least about 80%, at least about 85%, 90% or 95% identical to each other remain hybridized to each other for subsequent amplification and/or detection. Stringent conditions vary according to the length of the involved nucleotide sequence but are known to those skilled in the art and can be found or determined based on teachings in  Current Protocols in Molecular Biology , Ausubel et al., eds., John Wiley &amp; Sons, Inc. (1995), sections 2, 4 and 6. Additional stringent conditions and formulas for determining such conditions can be found in  Molecular Cloning: A Laboratory Manual , Sambrook et al., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989), chapters 7, 9 and 11. A non-limiting example of stringent hybridization conditions for hybrids that are at least 10 basepairs in length includes hybridization in 4× sodium chloride/sodium citrate (SSC), at about 65-70° C. (or hybridization in 4×SSC plus 50% formamide at about 42-50° C.) followed by one or more washes in 1×SSC, at about 65-70° C. A non-limiting example of highly stringent hybridization conditions for such hybrids includes hybridization in 1×SSC, at about 65-70° C. (or hybridization in 1×SSC plus 50% formamide at about 42-50° C.) followed by one or more washes in 0.3×SSC, at about 65-70° C. A non-limiting example of reduced stringency hybridization conditions for such hybrids includes hybridization in 4×SSC, at about 50-60° C. (or alternatively hybridization in 6×SSC plus 50% formamide at about 40-45° C.) followed by one or more washes in 2×SSC, at about 50-60° C. Ranges intermediate to the above-recited values, e.g., at 65-70° C. or at 42-50° C. are also intended to be encompassed by the present disclosure. Another example of stringent hybridization conditions are hybridization in 6× sodium chloride/sodium citrate (SSC) at about 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 50-65° C. A further example of stringent hybridization buffer is hybridization in 1 M NaCl, 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 6.5), 0.5% sodium sarcosine and 30% formamide. SSPE (1×SSPE is 0.15M NaCl, 10 mM NaH 2 PO 4 , and 1.25 mM EDTA, pH 7.4) can be substituted for SSC (1×SSC is 0.15M NaCl and 15 mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes each after hybridization is complete The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10° C. less than the melting temperature (T m ) of the hybrid, where T m  is determined according to the following equations. For hybrids less than 18 base pairs in length, T m (° C.)=2(# of A+T bases)+4(# of G+C bases). For hybrids between 18 and 49 base pairs in length, T m (° C.)=81.5+16.6(log 10 [Na + ])+0.41(% G+C)−(600/N), where N is the number of bases in the hybrid, and [Na + ] is the concentration of sodium ions in the hybridization buffer ([Na + ] for 1×SSC=0.165 M). It will also be recognized by the skilled practitioner that additional reagents may be added to hybridization and/or wash buffers to decrease non-specific hybridization of nucleic acid molecules to membranes, for example, nitrocellulose or nylon membranes, including but not limited to blocking agents (e.g., BSA or salmon or herring sperm carrier DNA), detergents (e.g., SDS), chelating agents (e.g., EDTA), Ficoll, polyvinylpyrrolidone (PVP) and the like. When using nylon membranes, in particular, an additional non-limiting example of stringent hybridization conditions is hybridization in 0.25-0.5M NaH 2 PO 4 , 7% SDS at about 65° C., followed by one or more washes at 0.02M NaH 2 PO 4 , 1% SDS at 65° C., see e.g., Church and Gilbert (1984)  Proc. Natl. Acad. Sci. USA  81:1991-1995, (or alternatively 0.2×SSC, 1% SDS). A primer or nucleic acid probe can be used alone in a detection method, or a primer can be used together with at least one other primer or nucleic acid probe in a detection method. Primers can also be used to amplify at least a portion of a nucleic acid. Nucleic acid probes of the disclosure refer to nucleic acids which hybridize to the region of interest and which are not further extended. For example, a nucleic acid probe is a nucleic acid which specifically hybridizes to a mutant region of a biomarker, and which by hybridization or absence of hybridization to the DNA of a patient or the type of hybrid formed can be indicative of the presence or identity of the mutation of the biomarker or the amount of marker activity. 
     In one format, the RNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated RNA on an agarose gel and transferring the RNA from the gel to a membrane, such as nitrocellulose. In an alternative format, the nucleic acid probe(s) are immobilized on a solid surface and the RNA is contacted with the probe(s), for example, in an AFFYMETRIX® gene chip array or a SNP chip (Santa Clara, Calif.) or customized array using a marker set comprising at least one marker indicative of treatment outcome. A skilled artisan can readily adapt known RNA and DNA detection methods for use in detecting the amount of the markers of the present disclosure. For example, the high density microarray or branched DNA assay can benefit from a higher concentration of tumor cell in the sample, such as a sample which had been modified to isolate tumor cells as described in earlier sections. In a related embodiment, a mixture of transcribed polynucleotides obtained from the sample is contacted with a substrate having fixed thereto a polynucleotide complementary to or homologous with at least a portion (e.g., at least 7, 10, 15, 20, 25, 30, 40, 50, 100, 500, or more nucleotide residues) of a marker nucleic acid. If polynucleotides complementary to or homologous with the marker are differentially detectable on the substrate (e.g., detectable using different chromophores or fluorophores, or fixed to different selected positions), then the levels of expression of a plurality of markers can be assessed simultaneously using a single substrate (e.g., a “gene chip” microarray of polynucleotides fixed at selected positions). In an embodiment when a method of assessing marker expression is used which involves hybridization of one nucleic acid with another, the hybridization can be performed under stringent hybridization conditions. 
     An alternative method for determining the amount of RNA corresponding to a marker of the present disclosure in a sample involves the process of nucleic acid amplification, e.g., by RT-PCR (the experimental embodiment set forth in Mullis, 1987, U.S. Pat. No. 4,683,202), ligase chain reaction (Barany, 1991 , Proc. Natl. Acad. Sci. USA,  88:189-193), self sustained sequence replication (Guatelli et al., 1990 , Proc. Natl. Acad. Sci. USA  87:1874-1878), transcriptional amplification system (Kwoh et al., 1989 , Proc. Natl. Acad. Sci. USA  86:1173-1177), Q-Beta Replicase (Lizardi et al., 1988 , Bio/Technology  6:1197), rolling circle replication (Lizardi et al., U.S. Pat. No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. As used herein, amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5′ or 3′ regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between. In general, amplification primers are from about 10 to about 30 nucleotides in length and flank a region from about 50 to about 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers. 
     For in situ methods, RNA does not need to be isolated from the cells prior to detection. In such methods, a cell or tissue sample is prepared/processed using known histological methods. The sample is then immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to RNA that encodes the marker. 
     In another embodiment of the present disclosure, a polypeptide corresponding to a marker is detected. In some embodiments, an agent for detecting a polypeptide of the disclosure is an antibody capable of binding to a polypeptide corresponding to a marker of the disclosure. In related embodiments, the antibody has a detectable label. Antibodies can be polyclonal, or monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′) 2 ) can be used. 
     A variety of formats can be employed to determine whether a sample contains a protein that binds to a given antibody. Examples of such formats include, but are not limited to, enzyme immunoassay (EIA), radioimmunoassay (RIA), Western blot analysis and enzyme linked immunoabsorbant assay (ELISA). A skilled artisan can readily adapt known protein/antibody detection methods for use in determining whether B cells express a marker of the present disclosure. 
     Another method for determining the level of a polypeptide corresponding to a marker is mass spectrometry. For example, intact proteins or peptides, e.g., tryptic peptides can be analyzed from a sample, e.g., a blood sample, a lymph sample or other sample, containing one or more polypeptide markers. The method can further include treating the sample to lower the amounts of abundant proteins, e.g., serum albumin, to increase the sensitivity of the method. For example, liquid chromatography can be used to fractionate the sample so portions of the sample can be analyzed separately by mass spectrometry. The steps can be performed in separate systems or in a combined liquid chromatography/mass spectrometry system (LC/MS, see for example, Liao, et al. (2004)  Arthritis Rheum.  50:3792-3803). The mass spectrometry system also can be in tandem (MS/MS) mode. The charge state distribution of the protein or peptide mixture can be acquired over one or multiple scans and analyzed by statistical methods, e.g. using the retention time and mass-to-charge ratio (m/z) in the LC/MS system, to identify proteins expressed at statistically significant levels differentially in samples from patients responsive or non-responsive to Aurora A Kinase inhibition therapy. Examples of mass spectrometers which can be used are an ion trap system (ThermoFinnigan, San Jose, Calif.) or a quadrupole time-of-flight mass spectrometer (Applied Biosystems, Foster City, Calif.). The method can further include the step of peptide mass fingerprinting, e.g. in a matrix-assisted laser desorption ionization with time-of-flight (MALDI-TOF) mass spectrometry method. The method can further include the step of sequencing one or more of the tryptic peptides. Results of this method can be used to identify proteins from primary sequence databases, e.g., maintained by the National Center for Biotechnology Information, Bethesda, Md., or the Swiss Institute for Bioinformatics, Geneva, Switzerland, and based on mass spectrometry tryptic peptide m/z base peaks. 
     Electronic Apparatus Readable Arrays 
     Electronic apparatus, including readable arrays comprising at least one predictive marker of the present disclosure is also contemplated for use in conjunction with the methods of the disclosure. As used herein, “electronic apparatus readable media” refers to any suitable medium for storing, holding or containing data or information that can be read and accessed directly by an electronic apparatus. As used herein, the term “electronic apparatus” is intended to include any suitable computing or processing apparatus or other device configured or adapted for storing data or information. Examples of electronic apparatus suitable for use with the present disclosure and monitoring of the recorded information include stand-alone computing apparatus; networks, including a local area network (LAN), a wide area network (WAN) Internet, Intranet, and Extranet; electronic appliances such as personal digital assistants (PDAs), cellular phone, pager and the like; and local and distributed processing systems. As used herein, “recorded” refers to a process for storing or encoding information on the electronic apparatus readable medium. Those skilled in the art can readily adopt any of the presently known methods for recording information on known media to generate manufactures comprising the markers of the present disclosure. 
     For example, microarray systems are well known and used in the art for assessment of samples, whether by assessment gene expression (e.g., DNA detection, RNA detection, protein detection), or metabolite production, for example. Microarrays for use according to the disclosure include one or more probes of predictive marker(s) of the disclosure characteristic of response and/or non-response to a therapeutic regimen as described herein. In one embodiment, the microarray comprises one or more probes corresponding to one or more of markers selected from the group consisting of markers which demonstrate increased expression in short term survivors, and genes which demonstrate increased expression in long term survivors in patients. A number of different microarray configurations and methods for their production are known to those of skill in the art and are disclosed, for example, in U.S. Pat. Nos. 5,242,974; 5,384,261; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,445,934; 5,556,752; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,472,672; 5,527,681; 5,529,756; 5,545,531; 5,554,501; 5,561,071; 5,571,639; 5,593,839; 5,624,711; 5,700,637; 5,744,305; 5,770,456; 5,770,722; 5,837,832; 5,856,101; 5,874,219; 5,885,837; 5,919,523; 5,981,185; 6,022,963; 6,077,674; 6,156,501; 6,261,776; 6,346,413; 6,440,677; 6,451,536; 6,576,424; 6,610,482; 5,143,854; 5,288,644; 5,324,633; 5,432,049; 5,470,710; 5,492,806; 5,503,980; 5,510,270; 5,525,464; 5,547,839; 5,580,732; 5,661,028; 5,848,659; and U.S. Pat. No. 5,874,219; Shena, et al. (1998),  Tibtech  16:301; Duggan et al. (1999)  Nat. Genet.  21:10; Bowtell et al. (1999)  Nat. Genet.  21:25; Lipshutz et al. (1999)  Nature Genet.  21:20-24, 1999; Blanchard, et al. (1996)  Biosensors and Bioelectronics,  11:687-90; Maskos, et al., (1993)  Nucleic Acids Res.  21:4663-69; Hughes, et al. (2001)  Nat. Biotechol.  19:342, 2001; each of which are herein incorporated by reference. A tissue microarray can be used for protein identification (see Hans et al. (2004)  Blood  103:275-282). A phage-epitope microarray can be used to identify one or more proteins in a sample based on whether the protein or proteins induce auto-antibodies in the patient (Bradford et al. (2006)  Urol. Oncol.  24:237-242). 
     A microarray thus comprises one or more probes corresponding to one or more markers identified herein, e.g., those indicative of treatment outcome, e.g., to identify wild type marker genes, normal allelic variants and mutations of marker genes. The microarray can comprise probes corresponding to, for example, at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 75, or at least 100, biomarkers and/or mutations thereof indicative of treatment outcome. The microarray can comprise probes corresponding to one or more biomarkers as set forth herein. Still further, the microarray may comprise complete marker sets as set forth herein and which may be selected and compiled according to the methods set forth herein. The microarray can be used to assay expression of one or more predictive markers or predictive marker sets in the array. In one example, the array can be used to assay more than one predictive marker or marker set expression in a sample to ascertain an expression profile of markers in the array. In this manner, up to about 44,000 markers can be simultaneously assayed for expression. This allows an expression profile to be developed showing a battery of markers specifically expressed in one or more samples. Still further, this allows an expression profile to be developed to assess treatment outcome. 
     The array is also useful for ascertaining differential expression patterns of one or more markers in normal and abnormal (e.g., sample, e.g., tumor) cells. This provides a battery of markers that could serve as a tool for ease of identification of treatment outcome of patients. Further, the array is useful for ascertaining expression of reference markers for reference expression levels. In another example, the array can be used to monitor the time course of expression of one or more markers in the array. 
     In addition to such qualitative determination, the disclosure allows the quantification of marker expression. Thus, predictive markers can be grouped on the basis of marker sets or outcome indications by the amount of the marker in the sample. This is useful, for example, in ascertaining the outcome of the sample by virtue of scoring the amounts according to the methods provided herein. 
     The array is also useful for ascertaining the effect of the expression of a marker on the expression of other predictive markers in the same cell or in different cells. This provides, for example, a selection of alternate molecular targets for therapeutic intervention if patient is predicted to have an unfavorable outcome. 
     Therapeutic Agents 
     The markers and marker sets of the present disclosure assess the likelihood of favorable outcome in cancer patients. Using this prediction, cancer therapies can be evaluated to design a therapy regimen best suitable for patients in either category. 
     Therapeutic agents for use in the methods of the disclosure include a class of therapeutic agents known as Aurora A Kinase inhibitors, as described herein. 
     The agents disclosed herein may be administered by any route, including intradermally, subcutaneously, orally, intraarterially or intravenously. In one embodiment, administration will be by the intravenous route. Parenteral administration can be provided in a bolus or by infusion. 
     The concentration of a disclosed compound in a pharmaceutically acceptable mixture will vary depending on several factors, including the dosage of the compound to be administered, the pharmacokinetic characteristics of the compound(s) employed, and the route of administration. The agent may be administered in a single dose or in repeat doses. Treatments may be administered daily or more frequently depending upon a number of factors, including the overall health of a patient, and the formulation and route of administration of the selected compound(s). 
     If a pharmaceutically acceptable salt of Aurora A kinase is utilized in these compositions, the salt preferably is derived from an inorganic or organic acid or base. For reviews of suitable salts, see, e.g., Berge et al,  J. Pharm. Sci.  66:1-19 (1977) and  Remington: The Science and Practice of Pharmacy,  20 th Ed ., ed. A. Gennaro, Lippincott Williams &amp; Wilkins, 2000. 
     Nonlimiting examples of suitable acid addition salts include the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, lucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. 
     Suitable base addition salts include, without limitation, ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine, N-methyl-D-glucamine, t-butylamine, ethylene diamine, ethanolamine, and choline, and salts with amino acids such as arginine, lysine, and so forth. 
     Also, basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. 
     The term “pharmaceutically acceptable carrier” is used herein to refer to a material that is compatible with a recipient subject, preferably a mammal, more preferably a human, and is suitable for delivering an active agent to the target site without terminating the activity of the agent. The toxicity or adverse effects, if any, associated with the carrier preferably are commensurate with a reasonable risk/benefit ratio for the intended use of the active agent. 
     The terms “carrier”, “adjuvant”, or “vehicle” are used interchangeably herein, and include any and all solvents, diluents, and other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.  Remington: The Science and Practice of Pharmacy,  20 th Ed ., ed. A. Gennaro, Lippincott Williams &amp; Wilkins, 2000 discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the disclosure, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this disclosure. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as disodium hydrogen phosphate, potassium hydrogen phosphate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium hydroxide and aluminum hydroxide, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, pyrogen-free water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose, sucrose, starches such as corn starch and potato starch, cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate, powdered tragacanth; malt, gelatin, talc, excipients such as cocoa butter and suppository waxes, oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil, glycols such as propylene glycol and polyethylene glycol, esters such as ethyl oleate and ethyl laurate, agar, alginic acid, isotonic saline, Ringer&#39;s solution, alcohols such as ethanol, isopropyl alcohol, hexadecyl alcohol, and glycerol, cyclodextrins, lubricants such as sodium lauryl sulfate and magnesium stearate, petroleum hydrocarbons such as mineral oil and petrolatum. Coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. 
     The pharmaceutical compositions of the disclosure can be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, or emulsifying processes, among others. Compositions may be produced in various forms, including granules, precipitates, or particulates, powders, including freeze dried, rotary dried or spray dried powders, amorphous powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions. Formulations may optionally contain solvents, diluents, and other liquid vehicles, dispersion or suspension aids, surface active agents, pH modifiers, isotonic agents, thickening or emulsifying agents, stabilizers and preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. 
     According to a preferred embodiment, the compositions of this disclosure are formulated for pharmaceutical administration to a mammal, preferably a human being. Such pharmaceutical compositions of the present disclosure may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intravenously, or subcutaneously. The formulations of the disclosure may be designed to be short-acting, fast-releasing, or long-acting. Still further, compounds can be administered in a local rather than systemic means, such as administration (e.g., by injection) at a tumor site. 
     Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, cyclodextrins, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. 
     Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer&#39;s solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use. Compositions formulated for parenteral administration may be injected by bolus injection or by timed push, or may be administered by continuous infusion. 
     In order to prolong the effect of a compound of the present disclosure, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues. 
     Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this disclosure with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound. 
     Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents such as phosphates or carbonates. 
     Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. 
     The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. 
     Dosage forms for topical or transdermal administration of a compound of this disclosure include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this disclosure. Additionally, the present disclosure contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel. 
     The selective inhibitor of Aurora A kinase can be administered by any method known to one skilled in the art. For example, the selective inhibitor of Aurora A kinase can be administered in the form of a composition, in one embodiment a pharmaceutical composition of the selective inhibitor of Aurora A kinase and a pharmaceutically acceptable carrier, such as those described herein. Preferably, the pharmaceutical composition is suitable for oral administration. In some embodiments, the pharmaceutical composition is a tablet for oral administration, such as an enteric coated tablet. Such tablets are described in US Publication No. 2010/0310651, which is hereby incorporated by reference in its entirety. In some other embodiments, the pharmaceutical composition is a liquid dosage form for oral administration. Such liquid dosage forms are described in US Publication No. 2011/0039826, hereby incorporated by reference. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents. 
     The expressions “therapeutically effective” and “therapeutic effect” refer to a benefit including, but not limited to, the treatment or prophylaxis or amelioration of symptoms of a proliferative disorder discussed herein. It will be appreciated that the therapeutically effective amount or the amount of agent required to provide a therapeutic effect will vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated (e.g., nature of the severity of the condition to be treated, the particular inhibitor, the route of administration and the age, weight, general health, and response of the individual patient), which can be readily determined by a person of skill in the art. For example, an amount of a selective inhibitor of Aurora A kinase is therapeutically effective if it is sufficient to effect the treatment or prophylaxis or amelioration of symptoms of a proliferative disorder discussed herein. 
     Compositions for use in the method of the disclosure may be formulated in unit dosage form for ease of administration and uniformity of dosage. The expression “unit dosage form” as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present disclosure will be decided by the attending physician within the scope of sound medical judgment. A unit dosage form for parenteral administration may be in ampoules or in multi-dose containers. 
     In some embodiments, the treatment period during which an agent is administered is then followed by a non-treatment period of particular time duration, during which the therapeutic agents are not administered to the patient. This non-treatment period can then be followed by a series of subsequent treatment and non-treatment periods of the same or different frequencies for the same or different lengths of time. In some embodiments, the treatment and non-treatment periods are alternated. It will be understood that the period of treatment in cycling therapy may continue until the patient has achieved a complete response or a partial response, at which point the treatment may be stopped. Alternatively, the period of treatment in cycling therapy may continue until the patient has achieved a complete response or a partial response, at which point the period of treatment may continue for a particular number of cycles. In some embodiments, the length of the period of treatment may be a particular number of cycles, regardless of patient response. In some other embodiments, the length of the period of treatment may continue until the patient relapses. 
     It will be appreciated that the frequency with which any of these therapeutic agents can be administered can be once or more than once over a period of about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 20 days, about 28 days, about a week, about 2 weeks, about 3 weeks, about 4 weeks, about a month, about every 2 months, about every 3 months, about every 4 months, about every 5 months, about every 6 months, about every 7 months, about every 8 months, about every 9 months, about every 10 months, about every 11 months, about every year, about every 2 years, about every 3 years, about every 4 years, or about every 5 years. 
     For example, an agent may be administered daily, weekly, biweekly, or monthly for a particular period of time. An agent may be dosed daily over a 14 day time period, or twice daily over a seven day time period. In some embodiments, a certain amount of the selective Aurora A kinase can be administered daily for 7 days. Alternatively, an agent may be administered daily, weekly, biweekly, or monthly for a particular period of time followed by a particular period of non-treatment. In some embodiments, a certain amount of the Aurora A kinase inhibitor can be administered daily for 14 days followed by seven days of non-treatment, and repeated for two more cycles of daily administration for 14 days followed by seven days of non-treatment. In some embodiments, a certain amount of the selective Aurora A kinase inhibitor can be administered twice daily for seven days followed by 14 days of non-treatment, which may be repeated for one or two more cycles of twice daily administration for seven days followed by 14 days of non-treatment. 
     In one embodiment, a certain amount of the selective Aurora A kinase inhibitor is administered daily over a period of seven days. In another embodiment, a certain amount of the Aurora A inhibitor is administered daily over a period of six days, or five days, or four days, or three days. In another embodiment, a certain amount of the selective Aurora A kinase inhibitor is administered twice daily over a period of seven days, followed by a treatment-free period of 7, 14 or 21 days. In another embodiment, alisertib is administered twice daily at a dose of 50 mg for 7 days, followed by a 14 day treatment-free interval, in 21-day cycles. 
     Suitable daily dosages of selective inhibitors of Aurora A kinase can generally range, in single or divided or multiple doses, from about 10% to about 120% of the maximum tolerated dose as a single agent. In certain embodiments, the suitable dosages are from about 20% to about 100% of the maximum tolerated dose as a single agent. In some other embodiments, the suitable dosages are from about 25% to about 90% of the maximum tolerated dose as a single agent. In some other embodiments, the suitable dosages are from about 30% to about 80% of the maximum tolerated dose as a single agent. In some other embodiments, the suitable dosages are from about 40% to about 75% of the maximum tolerated dose as a single agent. In some other embodiments, the suitable dosages are from about 45% to about 60% of the maximum tolerated dose as a single agent. In other embodiments, suitable dosages are about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 105%, about 110%, about 115%, or about 120% of the maximum tolerated dose as a single agent. 
     Suitable daily dosages of alisertib can generally range, in single or divided or multiple doses, from about 20 mg to about 120 mg per day. Other suitable daily dosages of alisertib can generally range, in single or divided or multiple doses, from about 30 mg to about 90 mg per day. Other suitable daily dosages of alisertib can generally range, in single or divided or multiple doses, from about 40 mg to about 80 mg per day. In some embodiments, the suitable dosages are from about 10 mg twice daily to about 50 mg twice daily. In some other embodiments, the suitable dosages are from about 15 mg twice daily to about 45 mg twice daily. In some other embodiments, the suitable dosages are from about 20 mg twice daily to about 40 mg twice daily. In some other embodiments, the suitable dosages are from about 25 mg twice daily to about 40 mg twice daily. In some embodiments, suitable dosages are about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, or about 120 mg per day. In certain other embodiments, suitable dosages are about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, or about 60 mg twice daily. In some embodiments, the suitable dosage of alisertib is about 30 mg twice daily. In some embodiments, the suitable dosage of alisertib is about 35 mg twice daily. In some embodiments, the suitable dosage of alisertib is about 40 mg twice daily. In some embodiments, the suitable dosage of alisertib is about 50 mg twice daily. 
     It will be understood that a suitable dosage of a selective inhibitor of Aurora A kinase may be taken at any time of the day or night. In some embodiments, a suitable dosage of a selective inhibitor of Aurora A kinase is taken in the morning. In some other embodiments, a suitable dosage of a selective inhibitor of Aurora A kinase is taken in the evening. In some other embodiments, a suitable dosage of a selective inhibitor of Aurora A kinase is taken both in the morning and the evening. It will be understood that a suitable dosage of a selective inhibitor of Aurora A kinase may be taken with or without food. In some embodiments a suitable dosage of a selective inhibitor of Aurora A kinase is taken with a meal. In some embodiments a suitable dosage of a selective inhibitor of Aurora A kinase is taken while fasting. 
     In some embodiments, a first treatment period in which a first amount of the selective inhibitor of Aurora A kinase is administered can be followed by another treatment period in which a same or different amount of the same or a different selective inhibitor of Aurora A kinase is administered. A wide variety of therapeutic agents may have a therapeutically relevant added benefit in combination with the Aurora A kinase of the present disclosure. Combination therapies that comprise the Aurora A kinase of the present disclosure with one or more other therapeutic agents can be used, for example, to: 1) enhance the therapeutic effect(s) of the methods of the present disclosure and/or the one or more other therapeutic agents; 2) reduce the side effects exhibited by the methods of the present disclosure and/or the one or more other therapeutic agents; and/or 3) reduce the effective dose of the Aurora A kinase of the present disclosure and/or the one or more other therapeutic agents. For example, such therapeutic agents may combine with the Aurora A kinase of the present disclosure to inhibit undesirable cell growth, such as inappropriate cell growth resulting in undesirable benign conditions or tumor growth. 
     Reagents and Kits 
     The disclosure also encompasses kits for detecting the presence of a polypeptide or nucleic acid corresponding to a marker of the disclosure in a biological sample (e.g. a bone marrow sample, tumor biopsy or a reference sample). Such kits can be used to assess treatment outcome, e.g., determine if a subject can have a favorable outcome, e.g., after Aurora A Kinase inhibitor treatment. For example, the kit can comprise a labeled compound or agent capable of detecting a genomic DNA segment, a polypeptide or a transcribed RNA corresponding to a marker of the disclosure or a mutation of a marker gene in a biological sample and means for determining the amount of the genomic DNA segment, the polypeptide or RNA in the sample. Suitable reagents for binding with a marker protein include antibodies, antibody derivatives, antibody fragments, and the like. Suitable reagents for binding with a marker nucleic acid (e.g., a genomic DNA, an mRNA, a spliced mRNA, a cDNA, or the like) include complementary nucleic acids. The kit can also contain a control or reference sample or a series of control or reference samples which can be assayed and compared to the test sample. For example, the kit may have a positive control sample, e.g., including one or more markers or mutations described herein, or reference markers, e.g. housekeeping markers to standardize the assay among samples or timepoints or reference genomes, e.g., form subjects without tumor e.g., to establish diploid copy number baseline or reference expression level of a marker. By way of example, the kit may comprise fluids (e.g., buffer) suitable for annealing complementary nucleic acids or for binding an antibody with a protein with which it specifically binds and one or more sample compartments. The kit of the disclosure may optionally comprise additional components useful for performing the methods of the disclosure, e.g., a sample collection vessel, e.g., a tube, and optionally, means for optimizing the amount of marker detected, for example if there may be time or adverse storage and handling conditions between the time of sampling and the time of analysis. For example, the kit can contain means for increasing the number of tumor cells in the sample, as described above, a buffering agent, a preservative, a stabilizing agent or additional reagents for preparation of cellular material or probes for use in the methods provided; and detectable label, alone or conjugated to or incorporated within the provided probe(s). In one exemplary embodiment, a kit comprising a sample collection vessel can comprise e.g., a tube comprising anti-coagulant and/or stabilizer, as described above, or known to those skilled in the art. The kit can further comprise components necessary for detecting the detectable label (e.g., an enzyme or a substrate). For marker sets, the kit can comprise a marker set array or chip for use in detecting the biomarkers. Kits also can include instructions for interpreting the results obtained using the kit. The kit can contain reagents for detecting one or more biomarkers, e.g., 2, 3, 4, 5, or more biomarkers described herein. 
     In one embodiment, the kit comprises a probe to detect at least one biomarker, e.g., a marker indicative of treatment outcome (e.g., upon Aurora A Kinase inhibitor treatment). In an exemplary embodiment, the kit comprises a nucleic acid probe to detect a marker gene selected from the group consisting of the marker genes disclosed in Tables 9 and 10 herein. In some embodiments, the kit comprises a probe to detect a marker selected from the group consisting of LEF1, MAP2K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XPO1, ROR2, CCND1, CTNNB1, AMOT, DVL2, LATS1, LATS2, MOB1B, NPHP4, TJP1, TJP2, WWC1, WWC1, WWTR1 and YAP1. In an embodiment, a kit comprises probes to detect a marker set comprising two or more markers from the group consisting of LEF1, MAP2K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XPO1, ROR2, CCND1, CTNNB1, AMOT, DVL2, LATS1, LATS2, MOB1B, NPHP4, TJP1, TJP2, WWC1, WWC1, WWTR1 and YAP1. In related embodiments, the kit comprises a nucleic acid probe comprising or derived from (e.g., a fragment, mutant or variant (e.g., homologous or complementary) thereof) a nucleic acid sequence selected from the group consisting of the nucleotide sequences disclosed by GenBank Accession numbers within Tables 9 and 10 herein. For kits comprising nucleic acid probes, e.g., oligonucleotide-based kits, the kit can comprise, for example: one or more nucleic acid reagents such as an oligonucleotide (labeled or non-labeled) which hybridizes to a nucleic acid sequence corresponding to a marker of the disclosure, optionally fixed to a substrate; labeled oligonucleotides not bound with a substrate, a pair of PCR primers, useful for amplifying a nucleic acid molecule corresponding to a marker of the disclosure, molecular beacon probes, a marker set comprising oligonucleotides which hybridize to at least two nucleic acid sequences corresponding to markers of the disclosure, and the like. The kit can contain an RNA-stabilizing agent. 
     For kits comprising protein probes, e.g., antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide corresponding to a marker of the disclosure; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable label. The kit can contain a protein stabilizing agent. The kit can contain reagents to reduce the amount of non-specific binding of non-biomarker material from the sample to the probe. Examples of reagents include nonioinic detergents, non-specific protein containing solutions, such as those containing albumin or casein, or other substances known to those skilled in the art. 
     An isolated polypeptide corresponding to a predictive marker of the disclosure, or a fragment or mutant thereof, can be used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation. For example, an immunogen typically is used to prepare antibodies by immunizing a suitable (i.e., immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate. In still a further aspect, the disclosure provides monoclonal antibodies or antigen binding fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences of the present disclosure, an amino acid sequence encoded by the cDNA of the present disclosure, a fragment of at least 8, 10, 12, 15, 20 or 25 amino acid residues of an amino acid sequence of the present disclosure, an amino acid sequence which is at least 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence of the present disclosure (wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM 120 weight residue table, a gap length penalty of 12, and a gap penalty of 4) and an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleic acid molecules of the present disclosure, or a complement thereof, under conditions of hybridization of 6×SSC at 45° C. and washing in 0.2×SSC, 0.1% SDS at 65° C. The monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies. An appropriate immunogenic preparation can contain, for example, recombinantly-expressed or chemically-synthesized polypeptide. The preparation can further include an adjuvant, such as Freund&#39;s complete or incomplete adjuvant, or a similar immunostimulatory agent. 
     Methods for making human antibodies are known in the art. One method for making human antibodies employs the use of transgenic animals, such as a transgenic mouse. These transgenic animals contain a substantial portion of the human antibody producing genome inserted into their own genome and the animal&#39;s own endogenous antibody production is rendered deficient in the production of antibodies. Methods for making such transgenic animals are known in the art. Such transgenic animals can be made using XENOMOUSE™ technology or by using a “minilocus” approach. Methods for making XENOMICE™ are described in U.S. Pat. Nos. 6,162,963, 6,150,584, 6,114,598 and 6,075,181, which are incorporated herein by reference. Methods for making transgenic animals using the “minilocus” approach are described in U.S. Pat. Nos. 5,545,807, 5,545,806 and 5,625,825; also see International Publication No. WO93/12227, which are each incorporated herein by reference. 
     Antibodies include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds an antigen, such as a polypeptide of the disclosure, e.g., an epitope of a polypeptide of the disclosure. A molecule which specifically binds to a given polypeptide of the disclosure is a molecule which binds the polypeptide, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide. For example, antigen-binding fragments, as well as full-length monomeric, dimeric or trimeric polypeptides derived from the above-described antibodies are themselves useful. Useful antibody homologs of this type include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′) 2  fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al.,  Nature  341:544-546 (1989)), which consists of a VH domain; (vii) a single domain functional heavy chain antibody, which consists of a VHH domain (known as a nanobody) see e.g., Cortez-Retamozo, et al.,  Cancer Res.  64: 2853-2857(2004), and references cited therein; and (vii) an isolated complementarity determining region (CDR), e.g., one or more isolated CDRs together with sufficient framework to provide an antigen binding fragment. Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al.  Science  242:423-426 (1988); and Huston et al.  Proc. Natl. Acad Sci. USA  85:5879-5883 (1988). Such single chain antibodies are also intended to be encompassed within the term “antigen-binding fragment” of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies. Antibody fragments, such as Fv, F(ab′) 2  and Fab may be prepared by cleavage of the intact protein, e.g. by protease or chemical cleavage. The disclosure provides polyclonal and monoclonal antibodies. Synthetic and genetically engineered variants (See U.S. Pat. No. 6,331,415) of any of the foregoing are also contemplated by the present disclosure. Polyclonal and monoclonal antibodies can be produced by a variety of techniques, including conventional murine monoclonal antibody methodology e.g., the standard somatic cell hybridization technique of Kohler and Milstein,  Nature  256: 495 (1975) the human B cell hybridoma technique (see Kozbor et al., 1983 , Immunol. Today  4:72), the EBV-hybridoma technique (see Cole et al., pp. 77-96 In  Monoclonal Antibodies and Cancer Therapy , Alan R. Liss, Inc., 1985) or trioma techniques. See generally, Harlow, E. and Lane, D. (1988)  Antibodies: A Laboratory Manual , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; and  Current Protocols in Immunology , Coligan et al. ed., John Wiley &amp; Sons, New York, 1994. For diagnostic applications, the antibodies can be monoclonal antibodies, e.g., generated in mouse, rat, or rabbit. Additionally, for use in in vivo applications the antibodies of the present disclosure can be human or humanized antibodies. Hybridoma cells producing a monoclonal antibody of the disclosure are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide of interest, e.g., using a standard ELISA assay. 
     If desired, the antibody molecules can be harvested or isolated from the subject (e.g., from the blood or serum of the subject) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. Alternatively, antibodies specific for a protein or polypeptide of the disclosure can be selected or (e.g., partially purified) or purified by, e.g., affinity chromatography to obtain substantially purified and purified antibody. By a substantially purified antibody composition is meant, in this context, that the antibody sample contains at most only 30% (by dry weight) of contaminating antibodies directed against epitopes other than those of the desired protein or polypeptide of the disclosure, and at most 20%, at most 10%, or at most 5% (by dry weight) of the sample is contaminating antibodies. A purified antibody composition means that at least 99% of the antibodies in the composition are directed against the desired protein or polypeptide of the disclosure. 
     An antibody directed against a polypeptide corresponding to a marker of the disclosure (e.g., a monoclonal antibody) can be used to detect the marker (e.g., in a cellular sample) in order to evaluate the level and pattern of expression of the marker. The antibodies can also be used diagnostically to monitor protein levels in tissues or body fluids (e.g. in a blood sample) as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  125 I,  131 I,  35 S or  3 H. 
     Accordingly, in one aspect, the disclosure provides substantially purified antibodies or fragments thereof, and non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence encoded by a marker identified herein. The substantially purified antibodies of the disclosure, or fragments thereof, can be human, non-human, chimeric and/or humanized antibodies. 
     In another aspect, the disclosure provides non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence which is encoded by a nucleic acid molecule of a predictive marker of the disclosure. Such non-human antibodies can be goat, mouse, sheep, horse, chicken, rabbit, or rat antibodies. Alternatively, the non-human antibodies of the disclosure can be chimeric and/or humanized antibodies. In addition, the non-human antibodies of the disclosure can be polyclonal antibodies or monoclonal antibodies. 
     The substantially purified antibodies or fragments thereof may specifically bind to a signal peptide, a secreted sequence, an extracellular domain, a transmembrane or a cytoplasmic domain or cytoplasmic loop of a polypeptide of the disclosure. The substantially purified antibodies or fragments thereof, the non-human antibodies or fragments thereof, and/or the monoclonal antibodies or fragments thereof, of the disclosure specifically bind to a secreted sequence or an extracellular domain of the amino acid sequences of the present disclosure. 
     The disclosure also provides a kit containing an antibody of the disclosure conjugated to a detectable substance, and instructions for use. Still another aspect of the disclosure is a diagnostic composition comprising a probe of the disclosure and a pharmaceutically acceptable carrier. In one embodiment, the diagnostic composition contains an antibody of the disclosure, a detectable moiety, and a pharmaceutically acceptable carrier. 
     Sensitivity Assays 
     A sample of cancerous cells is obtained from a patient. An expression level is measured in the sample for a marker corresponding to at least one of the markers described herein. A marker set comprising markers as described herein can be put together using the methods described herein. Such analysis is used to obtain an expression profile of the tumor in the patient. Evaluation of the expression profile is then used to determine whether the patient is expected to have a favorable outcome and would benefit from treatment with, e.g., Aurora A Kinase inhibittion therapy (e.g., treatment with an Aurora A Kinase inhibitor (e.g., alisertib) alone, or in combination with additional agents)), or with an alternative agent expected to have a similar effect on survival. Evaluation of the expression profile can also be used to determine whether a patient is expected to have an unfavorable outcome and would benefit from a cancer therapy other than Aurora A Kinase inhibition therapy or would benefit from an altered Aurora A Kinase inhibition therapy regimen. Evaluation can include use of one marker set prepared using any of the methods provided or other similar scoring methods known in the art (e.g., weighted voting, combination of threshold features (CTF), Cox proportional hazards analysis, principal components scoring, linear predictive score, K-nearest neighbor, etc), e.g., using expression values deposited with the Gene Expression Omnibus (GEO) program at the National Center for Biotechnology Information (NCBI, Bethesda, Md.). Still further, evaluation can comprise use of more than one prepared marker set. An Aurora A Kinase inhibition therapy will be identified as appropriate to treat the cancer when the outcome of the evaluation demonstrates a favorable outcome or a more aggressive therapy regimen will be identified for a patient with an expected unfavorable outcome. 
     In one aspect, the disclosure features a method of evaluating a patient, e.g., a patient with cancer, e.g. a hematological cancer or solid tumor cancer for treatment outcome. The method includes i) evaluating the expression of the markers in a marker set in the patient sample, wherein the marker set has the following properties: a) it includes a plurality of genes, each of which is differentially expressed between patients with identified outcome and non-afflicted subjects; b) it contains a sufficient number of differentially expressed markers, such that differential amount (e.g., as compared to a level in a non-afflicted reference sample) of each of the markers in the marker set in a subject is predictive of treatment outcome with no more than about 15%, about 10%, about 5%, about 2.5%, or about 1% false positives (wherein false positive means incorrectly predicting whether a patient is responsive or non-responsive); and ii) comparing the amount of each of the markers in the set from the patient to a reference value, thereby evaluating the patient. 
     By examining the amount of one or more of the identified markers or marker sets in a tumor sample taken from a patient during the course of Aurora A Kinase inhibition therapy, it is also possible to determine whether the therapeutic agent is continuing to work or whether the cancer has become non-responsive (refractory) to the treatment protocol. For example, a patient receiving a treatment regiment comprising alisertib would have tumor cells removed and monitored for the expression of a marker or marker set. If the profile of one or more markers as disclosed herein typifies favorable outcome in the presence of the agent, e.g., the Aurora A Kinase inhibitor (alisertib), the treatment would continue. However, if the profile of the one or more markers identified herein typifies unfavorable outcome in the presence of the agent, then the cancer may have become resistant to therapy, e.g., Aurora A Kinase inhibition (alisertib) therapy, and another treatment protocol should be initiated to treat the patient. 
     Importantly, these determinations can be made on a patient-by-patient basis or on an agent-by-agent (or combinations of agents). Thus, one can determine whether or not a particular Aurora A Kinase inhibition therapy is likely to benefit a particular patient or group/class of patients, or whether a particular treatment should be continued. 
     Use of Information 
     In one method, information, e.g., about the patient&#39;s marker(s) characteristic, e.g., size, sequence, composition or amount (e.g., the result of evaluating a marker or marker set described herein), or about whether a patient is expected to have a favorable outcome, is provided (e.g., communicated, e.g., electronically communicated) to a third party, e.g., a hospital, clinic, a government entity, reimbursing party or insurance company (e.g., a life insurance company). For example, choice of medical procedure, payment for a medical procedure, payment by a reimbursing party, or cost for a service or insurance can be function of the information. E.g., the third party receives the information, makes a determination based at least in part on the information, and optionally communicates the information or makes a choice of procedure, payment, level of payment, coverage, etc. based on the information. In the method, informative expression level of a marker or a marker set selected from or derived from Table 8 and/or described herein is determined. 
     In one embodiment, a premium for insurance (e.g., life or medical) is evaluated as a function of information about one or more marker expression levels, e.g., a marker or marker set, e.g., a level of expression associated with treatment outcome (e.g., the informative amount). For example, premiums can be increased (e.g., by a certain percentage) if the marker genes of a patient or a patient&#39;s marker set described herein have different characteristic, e.g., size, sequence, composition or amount between an insured candidate (or a candidate seeking insurance coverage) and a reference value (e.g., a non-afflicted person) or a reference sample, e.g., matched control. Premiums can also be scaled depending on the result of evaluating a marker or marker set described herein. For example, premiums can be assessed to distribute risk, e.g., as a function of marker, e.g., the result of evaluating a marker or marker set described herein. In another example, premiums are assessed as a function of actuarial data that is obtained from patients that have known treatment outcomes. 
     Information about marker characteristic, e.g., size, sequence, composition or amount, e.g., the result of evaluating a marker or marker set described herein (e.g., the informative amount), can be used, e.g., in an underwriting process for life insurance. The information can be incorporated into a profile about a subject. Other information in the profile can include, for example, date of birth, gender, marital status, banking information, credit information, children, and so forth. An insurance policy can be recommended as a function of the information on marker characteristic, e.g., size, sequence, composition or amount, e.g., the result of evaluating a marker or marker set described herein, along with one or more other items of information in the profile. An insurance premium or risk assessment can also be evaluated as function of the marker or marker set information. In one implementation, points are assigned on the basis of expected treatment outcome. 
     In one embodiment, information about marker characteristic, e.g., size, sequence, composition or amount, e.g., the result of evaluating a marker or marker set described herein, is analyzed by a function that determines whether to authorize the transfer of funds to pay for a service or treatment provided to a subject (or make another decision referred to herein). For example, the results of analyzing a characteristic, e.g., size, sequence, composition or amount of a marker or marker set described herein may indicate that a subject is expected to have a favorable outcome, suggesting that a treatment course is needed, thereby triggering an result that indicates or causes authorization to pay for a service or treatment provided to a subject. In one example, informative characteristic, e.g., size, sequence, composition or amount of a marker or a marker set selected from or derived from Tables 9-10 and/or described herein is determined and payment is authorized if the informative amount identifies a favorable outcome. For example, an entity, e.g., a hospital, care giver, government entity, or an insurance company or other entity which pays for, or reimburses medical expenses, can use the result of a method described herein to determine whether a party, e.g., a party other than the subject patient, will pay for services (e.g., a particular therapy) or treatment provided to the patient. For example, a first entity, e.g., an insurance company, can use the outcome of a method described herein to determine whether to provide financial payment to, or on behalf of, a patient, e.g., whether to reimburse a third party, e.g., a vendor of goods or services, a hospital, physician, or other care-giver, for a service or treatment provided to a patient. For example, a first entity, e.g., an insurance company, can use the outcome of a method described herein to determine whether to continue, discontinue, enroll an individual in an insurance plan or program, e.g., a health insurance or life insurance plan or program. 
     In one aspect, the disclosure features a method of providing data. The method includes providing data described herein, e.g., generated by a method described herein, to provide a record, e.g., a record described herein, for determining if a payment will be provided. In some embodiments, the data is provided by computer, compact disc, telephone, facsimile, email, or letter. In some embodiments, the data is provided by a first party to a second party. In some embodiments, the first party is selected from the subject, a healthcare provider, a treating physician, a health maintenance organization (HMO), a hospital, a governmental entity, or an entity which sells or supplies the drug. In some embodiments, the second party is a third party payor, an insurance company, employer, employer sponsored health plan, HMO, or governmental entity. In some embodiments, the first party is selected from the subject, a healthcare provider, a treating physician, an HMO, a hospital, an insurance company, or an entity which sells or supplies the drug and the second party is a governmental entity. In some embodiments, the first party is selected from the subject, a healthcare provider, a treating physician, an HMO, a hospital, an insurance company, or an entity which sells or supplies the drug and the second party is an insurance company. 
     In another aspect, the disclosure features a record (e.g., computer readable record) which includes a list and value of characteristic, e.g., size, sequence, composition or amount for the marker or marker set for a patient. In some embodiments, the record includes more than one value for each marker. 
     Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, the preferred methods, devices and materials are herein described. All publications mentioned herein are hereby incorporated by reference in their entirety for the purpose of describing and disclosing the materials and methodologies that are reported in the publication which might be used in connection with the disclosure. 
     The present disclosure will now be illustrated by the following Examples, which are not intended to be limiting in any way. 
     EXAMPLES 
     Clinical Trial 
     In a mutlicenter phase ½ clinical trial of single agent alisertib in patients with five predefined advanced solid tumor types [relapsed/refractory breast cancer (BC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and gastroesophageal (GE) adenocarcinoma], alisertib demonstrated single agent clinically meaningful antitumor activity in four of the five solid tumor types testes (all except NSCLC) (Melichar B. et al., Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm pase 2 study. Lancet Oncology Vol 16, pages 395-405, April 2015). Archived tumor biopsies and normal blood samples were obtained from 47 patients enrolled in this study. Table 3 below provides the distribution of the tumor types of these 47 patients. 
     
       
         
           
               
               
               
             
               
                   
                 TABLE 3 
               
               
                   
                   
               
               
                   
                 Cancer indication 
                 Number of patients 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                   
                 Breast (BC) 
                 14 
               
               
                   
                 Head and neck squamous cell (HNSCC) 
                 19 
               
               
                   
                 Small cell lung (SCLC) 
                 4 
               
               
                   
                 Non-small cell lung (NSCLC) 
                 4 
               
               
                   
                 Gastroesophageal (GE) 
                 6 
               
               
                   
                   
               
            
           
         
       
     
     Efficacy Endpoint and Clinical Covariates: 
     The best tumor size change and progression-free survival (PFS) of the patients were used as the efficacy response endpoints. Since the tumor type showed moderate association with the efficacy endpoints among several clinical variables; the tumor type was included as a covariate in the statistical model for association analysis to correct its effect. 
     Whole Exome Sequencing: 
     The genomic DNA was isolated from 47 patients with 2-4 slides of 5 micron thickness from archived tumor biopsies with Qiagen FFPE kit (Qiagen, Germany). Genomic DNA from blood samples were extracted utilizing blood DNA kit (Qiagen, Germany). Tumor-normal (blood) paired DNAs were sequenced by whole exome DNA sequencing employing Agilent SureSelect exome capture and Illumina Hi-Seq™ technologies. The average sequencing depth of the whole exome sequencing was achieved at ˜100× per bp. 
     Bioinformatics Analysis Pipeline 
     The analysis pipeline for whole exome sequencing was designed to identify mutations from raw sequence reads and evaluate their potential correlation with clinical response. For this purpose, three major analytical units, the upstream, middle-stream, and downstream modules, were devised to process DNA-Seq data. The upstream analysis module runs preprocessing for DNA-Seq, including raw sequence read quality control (QC), read alignment/mapping, and raw somatic mutation calling from the tumor and germline genomes of the patients. Raw mutation calls are evaluated in the middle-stream analysis based on quality statistics and mutation annotations in order to deliver high-confidence mutation calls for the downstream analysis. In the downstream analysis, efforts were made for identifying individual mutated genes or groups of mutated genes that are significantly associated with the response to alisertib. 
     Upstream Analysis 
     The upstream analysis focuses on processing raw DNA-Seq files and calling raw mutations. Short sequence reads of 75 bp produced by next-generation sequencing (NGS) are electronically present in the FASTQ or BAM file format. The quality of sequence reads was assessed using fastQC (ver. 0.10.1) to determine if each sample has enough quality for mutation calling. Next, raw sequence reads were mapped to the human reference genome (hg19) using BWA (ver. 0.6.2-r126). After reads were mapped to the reference genome, raw somatic mutations and germline variants, including SNVs and small indels, were called using a VarScan2(ver. 2.3.4) and GATK (ver. 2.3.9), respectively. 
     Middle-Stream Analysis: 
     The raw mutations were processed in the middle-stream analysis in order to identify high-confidence somatic mutations. Germline variants were also processed similarly. The middle-stream analysis is composed of variant annotation and filtering based on the annotation and variant quality. The annotation sources are summarized in Table 4. RefSeq (hg19), dbSNP, COSMIC, 1000 genome, and The Cancer Genome Atlas (TCGA), and Thomson Reuters Genetic Variant Database (GVDB) were selected as public and proprietary annotation sources. 
     
       
         
           
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                 Annotation sources for raw mutation calls from the upstream analysis: 
               
            
           
           
               
               
            
               
                 Database 
                 Note 
               
               
                   
               
            
           
           
               
               
               
            
               
                 1 
                 RefSeq 
                 Genomic regions (e.g. coding vs. non-coding), 
               
               
                   
                   
                 chromosomal coordinate, and gene symbol. Hg19 was 
               
               
                   
                   
                 used. 
               
               
                 2 
                 dbSNP 
                 Reported human SNPs. dbSNP137 was used. 
               
               
                 3 
                 COSMIC 
                 Reported somatic mutations in cancers. v68 was used. 
               
               
                 4 
                 1000 
                 Low coverage and exome studies. 
               
               
                   
                 genome 
               
               
                 5 
                 TCGA 
                 Reported somatic mutations in TCGA samples. 
               
               
                 6 
                 GVDB 
                 Thomson Reuters Genetic Variant Database (GVDB). 
               
               
                 7 
                 Prediction of 
                 Bioinformatics tools for functional impact on protein 
               
               
                   
                 functional 
                 (FATHMM, MutationTaster). 
               
               
                   
                 impact on 
               
               
                   
                 protein 
               
               
                   
               
            
           
         
       
     
     The filtering criteria are summarized in Table 5. Through the filtering steps, only coding-changing somatic mutations were kept (Table 5 row number 1) and mutations found in the matched germline genome were eliminated (Table 5 row number 2). Sequence depth denotes the number of sequence reads piled up at a variant site (Table 5 row number 3). A higher sequence depth better supports an identified variant because NGS is known to have a relatively high error rate. For example, if many reads support the same sequence variation, the variant would be more likely to be a real one, not a sequencing artifact. Similarly, minor allele fraction (MAF) was considered to reduce the chance of including sequencing artifacts and subclonal mutations (Table 5 row number 4). Next, filters about sequencing quality and mapping quality were applied to raw mutations (Table 5 row number 5-7). In order to eliminate potential germline variants, variants overlapped by dbSNP and 1000 genome were discarded, but if they were reported by TCGA, they were kept (Table 5 row number 8). Finally, an optional filtering step was added so that only variants with functional impact on protein coding will remain (Table 5 row number 9). The functional consequences of variants were predicted by publicly available bioinformatics tools, FATHMM (ver. 2.3) and MutationTaster and the results were used as supplementary information to assess the functional impact of each coding-mutation. This filter was used in pathway-level association tests because the use of the filter may reduce the influence of potential passenger genes in each pathway. 
     
       
         
           
               
             
               
                 TABLE 5 
               
             
            
               
                   
               
               
                 Variant filtering criteria for high-confidence somatic mutations: 
               
            
           
           
               
               
            
               
                 QC criterion 
                 Note 
               
               
                   
               
            
           
           
               
               
               
            
               
                 1 
                 Non-synonymous SNVs and small 
                 Only coding change mutations are kept. 
               
               
                   
                 Insertions/deletions in coding regions. 
               
               
                 2 
                 VarScan2 somatic p value &lt;= 0.01 
                 This p value cut-off roughly corresponds to 
               
               
                   
                   
                 10% FDR. 
               
               
                 3 
                 Total read depth &gt;= 20, variant read 
                 Variants must be supported by an enough 
               
               
                   
                 depth &gt;= 2 in the tumor BAM. 
                 number of reads. 
               
               
                 4 
                 MAF &gt;= 0.1 
                 This cut-off was adjusted by tumor purity. 
               
               
                   
                   
                 For example, if tumor purity = 80%, then the 
               
               
                   
                   
                 MAF cut-off becomes 0.1 * 0.8 = 0.08. 
               
               
                 5 
                 Variant MAPQ &gt;= 45, BaseQ &gt;= 25 
                 The median MAPQ and BaseQ of variant 
               
               
                   
                   
                 reads must be high enough. 
               
               
                 6 
                 Strand bias (ratio of + strand reads and − 
                 Ratio &lt;= 0.9 (less than 90% of reads 
               
               
                   
                 strand reads) 
                 supporting a variant are mapped on one 
               
               
                   
                   
                 strand. 
               
               
                 7 
                 Variants overlapped by dbSNP and 1000 
                 Any potential germline variants were 
               
               
                   
                 genome were removed; however, if they had 
                 removed. 
               
               
                   
                 been reported by COSMIC as somatic 
               
               
                   
                 mutations, they were kept. 
               
               
                 8 
                 Fpfilter.pl provided by the VarScan2 authors 
                 Sequence read quality was considered. 
               
               
                   
                 were applied 
               
               
                 9 
                 Functional consequences of coding sequence 
                 FATHMM and MutationTaster were used to 
               
               
                   
                 change 
                 predict the functional consequences of 
               
               
                   
                   
                 variants. 
               
               
                   
               
            
           
         
       
     
     Downstream Analysis for Single Genes: 
     The downstream analysis was designed to identify potential biomarkers predictive of drug response using the high-confidence mutations obtained from the middle-stream analysis. A linear regression model and Cox proportional hazard model were used for best tumor size change and PFS as endpoints, respectively. Tumor type was considered as a covariate in both models to adjust its confounding effect. In case of linear regression for best tumor size change as an endpoint, baseline tumor size was added as an additional covariate since baseline tumor size is weakly correlated with the endpoint. In the following linear regression equation, y=β 0 +β 1 x+β c     1   c 1 +β c     2   c 2 +ε, y, x, c 1 , c 2 , and ε represent the best tumor size change, a single gene mutation status, tumor type, baseline tumor size, and random error, respectively. When the gene harbors high-confidence mutation(s), x becomes 1; otherwise, it is 0. The 1 st  covariate c 1  was converted into five binary variables to represent the five different tumor types and the 2 nd  covariate c 2  is a continuous variable. As a result, the coefficient β 1  indicates the contribution of the mutated gene to sensitivity or resistance to alisertib treatment after adjusting the potential confounding effects of the covariates. A p-value was computed for testing the null hypothesis β 1 =0. Since multiple genes were tested using these models and the p-values were corrected for multiple hypothesis testing using false discovery rate (FDR). 
     Downstream Analysis for Pathways: 
     A similar approach was used for the pathway association analysis. A pathway can be defined as a group of genes that are known to be interacting together for a common biological function. As can be seen in Table 6 below, six public and proprietary pathway databases were combined in the pathway association analysis to maximize our search ability. Two types of statistical tests were selected in order to test the degree of association of mutations on the pathway level and alisertib treatment outcome, particularly best tumor size change. First, a binary variable was set to 1 (mutated) if any of the genes belonging to a pathway were found to be somatically mutated. A linear regression model was built using this binary variable as an independent variable and tumor type and baseline tumor size were used as covariates, similar to the equation used for gene-level association. Secondly, sequence kernel association tests (SKAT) were run to account for cases where individual mutated genes in a pathway contribute differently to drug sensitivity or resistance. The two tests resulted in a pair of p-values for each of the pathways in Table 6. As the two methods, linear regression and SKAT, provide different angles in terms of association between pathways and alisertib response, the smaller p-value (the best of the two tests, BOT from here on) was selected as a representative p-value for each pathway. The p-values of the pathways were subjected to multiplicity adjustments in order to control the type I error of the statistical tests. 
     
       
         
           
               
             
               
                 TABLE 6 
               
             
            
               
                   
               
               
                 Pathways tested in terms of association with alisertib response. A total 
               
               
                 of 3,505 pathways were tested. 
               
            
           
           
               
               
               
            
               
                   
                 Pathway DB 
                 Number of pathways 
               
               
                   
                   
               
            
           
           
               
               
               
            
               
                   
                 MetaCore ™ 
                 912 
               
               
                   
                 BIOCYC 
                 33 
               
               
                   
                 KEGG 
                 794 
               
               
                   
                 REACTOME 
                 1358 
               
               
                   
                 Wiki Pathways 
                 225 
               
               
                   
                 Pathway interaction DB 
                 183 
               
               
                   
                   
               
            
           
         
       
     
     Association Between Mutated Genes/Pathways and Progression-Free Survival: 
     The Cox proportional hazard models were used to see potential association between mutated genes/pathways and progression-free survival (PFS). This analysis was done as a supplementary study in order to confirm that the genes and pathways identified by the aforementioned analyses also showed significant differences in PFS between mutant and WT groups. 
     Multiplicity Adjustment: 
     For single gene-level association, the Benjamini &amp; Hochberg (BH) method was used to compute FDR (also known as q-value). For pathway-level association, as multiple statistical association analyses (linear regression, SKAT and BOT) were conducted for each pathway, and pathways are often correlated through commonly present genes, multiplicity adjustment becomes more complicated. To address these challenges, a re-sampling-based multiplicity adjustment was implemented. The null distributions of p-values from pathway association tests were simulated using parametric bootstrapping. The adjusted p-values were obtained by comparing the observed p-values to the simulated null distributions as reference distributions. 
     High-Confidence Somatic Mutations: 
     After the middle-stream analysis, a total of 6,410 genes had high-confidence somatic mutations in their coding exons from the 47 patient whole exome sequencing data. When the last filter in Table 5 was also applied, 4,400 mutated genes remained as high-confidence and also functional variants.  FIG. 2  provides a visual representation of the mutation landscape of the 47 patients in the study (6,410 genes). 
     The Results of Single Gene Association: 
     The linear regression model of single gene mutation status (x) and tumor type (c 1 ) and baseline tumor size (c 2 ) as covariates was run to identify mutated genes that are correlated with sensitivity or resistance to alisertib treatment. The 6,410 genes were tested and their associated p-values were corrected using BH adjustment. Four genes were selected among the top genes in p-values based on Aurora A Kinase biology (Table 7). One gene (FAT1) was identified to be significantly associated with tumor reduction when a raw p-value cut-off of 0.05 was applied. Three other genes (MLL3, EP300, FBXW7) were determined to be associated with tumor reduction when a more relaxed cut-off, 0.1 was used. MLL3 was identified by both best tumor size change and PFS and EP300 showed a correlation with only longer PFS. These two genes are known to play an important role in chromatin modification and cell division, which is closely related to the key functions of Aurora A Kinase. Interestingly, FBXW7 was correlated with tumor progression while other genes are associated with tumor reduction or longer PFS. 
     
       
         
           
               
             
               
                 TABLE 7 
               
               
                   
               
               
                 The single genes, when mutated, showing association with drug 
               
               
                 response and backed by Aurora A Kinase biology. 
               
               
                   
               
             
            
               
                 Genes associated with best tumor size changes across all five 
               
               
                 tumors tested, namely breast cancer, small cell lung cancer, non- 
               
               
                 small cell lung cancer, head and neck squamous cell carcinoma 
               
               
                 and gastroesophageal adenocarcinoma. Changes when adjusted 
               
               
                 by tumor indication and tumor baseline size. 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 g 
                 p 
                 q 
                 est* 
                 cilow 
                 ciup 
               
               
                   
                   
               
               
                   
                 FAT1 
                 0.0403 
                 0.302 
                 −39.70 
                 −77.6 
                 −1.84 
               
               
                   
                 MLL3 
                 0.0651 
                 0.302 
                 −28.84 
                 −59.6 
                 1.89 
               
               
                   
                 FBXW7 
                 0.0697 
                 0.302 
                 41.96 
                 −3.55 
                 87.5 
               
               
                   
                   
               
            
           
           
               
            
               
                 Genes associated with progression free survival (PFS) when 
               
               
                 adjusted by baseline and patients were stratified by indication. 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 g 
                 p 
                 q 
                 est** 
                 cilow 
                 ciup 
               
               
                   
                   
               
               
                   
                 MLL3 
                 0.055 
                 0.592 
                 0.129 
                 0.016 
                 1.049 
               
               
                   
                 EP300 
                 0.091 
                 0.592 
                 0.271 
                 0.0599 
                 1.232 
               
               
                   
                   
               
               
                   
                 Notations: 
               
               
                   
                 P &amp; q: raw p-value and BH adjusted p-values or FDR. 
               
               
                   
                 *est: estimated coefficient in the model (est is the mean % best tumor size change between mutant and WT groups). 
               
               
                   
                 **est: estimated coefficient in the model (est in the bottom table indicates HR (hazard ratio)). 
               
               
                   
                 Cilow/ciup: 95% confidence interval for the estimation. 
               
            
           
         
       
     
     The Results of Pathway-Level Association: 
     Two pathways were identified as pathways associated with responsiveness to treatment with alisertib (Table 8). The 1 st  pathway is the WNT/β-catenin signaling pathway in Thomson Reuters MetaCore™. The WNT/β-catenin signaling pathway is known to interact with Aurora A Kinase in many diseases including multiple myeloma and glioma. Also, silencing Aurora A Kinase leads to the down-regulation of WNT/β-catenin signaling. This WNT/β-catenin pathway is composed of 23 genes (Table 8) and 12 of them, namely; LEF1, MAP3K7, APC, FZD2, PRKCA, RORA, CAMK2G, JUN, XPO1, ROR2, CCND1, CTNNB1, were identified to be somatically mutated in the whole exome sequencing data. The mutation patterns of these 12 genes are illustrated in the heatmap in  FIG. 3  (top). The other pathway is the Hippo signaling pathway in REACTOME. The Hippo signaling pathway is composed of 22 genes (Table 8) and 11 out of the 22 genes were mutated in the patient samples of the clinical trial. The 11 mutated genes are LOC646561, YWHAEP5, AMOTL1, SAV1, MOB1A, AMOTL2, YWHAE, YWHAB, STK4, STK3 and CASP3. This pathway is known to be related to cell proliferation and apoptosis, particularly tetraploidy-induced cell cycle arrest. This implies a functional link to alisertib since inhibition of Aurora A Kinase leads cells to death by causing mitotic defects leading to aneuploidy and finally cell cycle arrest. The mutation patterns of the Hippo signaling pathway are shown in  FIG. 3  (bottom). As can be seen in  FIGS. 3 and 4 , patients with the mutated WNT or Hippo signaling pathways tend to respond more favorably to alisertib treatment. 
     
       
         
           
               
             
               
                 TABLE 8 
               
             
            
               
                   
               
               
                 The pathways identified to be significantly associated with 
               
               
                 sensitivity to alisertib treatment. These pathways were 
               
               
                 selected based on the adjusted p-values from the association 
               
               
                 tests and Aurora A Kinase/alisertib biology. 
               
            
           
           
               
               
               
               
            
               
                   
                   
                 Adjusted p- 
                   
               
               
                   
                 Pathway 
                 value (raw 
               
               
                 Pathway name 
                 source 
                 pvalue) 
                 Genes 
               
               
                   
               
               
                 Inhibition of WNT5A 
                 MetaCore ™ 
                 0.0454  
                 LEF1, MAP3K7, 
               
               
                 dependent 
                   
                 (3.43E−05) 
                 APC, FZD2, 
               
               
                 non-canonical 
                   
                   
                 PRKCA, RORA, 
               
               
                 pathway in 
                   
                   
                 CAMK2G, JUN, 
               
               
                 colorectal cancer 
                   
                   
                 XPO1, ROR2, 
               
               
                   
                   
                   
                 CCND1, 
               
               
                   
                   
                   
                 CTNNB1, 
               
               
                   
                   
                   
                 CAMK2A, 
               
               
                   
                   
                   
                 CAMK2B, 
               
               
                   
                   
                   
                 CAMK2D, 
               
               
                   
                   
                   
                 CALM1, 
               
               
                   
                   
                   
                 CALM2, 
               
               
                   
                   
                   
                 CALM3, NLK, 
               
               
                   
                   
                   
                 SIAH2, TCF7, 
               
               
                   
                   
                   
                 WNT5A, MYC 
               
               
                 Signaling by Hippo 
                 REACTOME 
                 0.0163 
                 AMOT, DVL2, 
               
               
                   
                   
                 (1.10E−05) 
                 LATS1, LATS2, 
               
               
                   
                   
                   
                 MOB1B, NPHP4, 
               
               
                   
                   
                   
                 TJP1, TJP2, 
               
               
                   
                   
                   
                 WWC1, 
               
               
                   
                   
                   
                 WWTR1, YAP1, 
               
               
                   
                   
                   
                 LOC646561, 
               
               
                   
                   
                   
                 YWHAEP5, 
               
               
                   
                   
                   
                 AMOTL1, 
               
               
                   
                   
                   
                 SAV1, MOB1A, 
               
               
                   
                   
                   
                 AMOTL2, 
               
               
                   
                   
                   
                 YWHAE, 
               
               
                   
                   
                   
                 YWHAB, STK4, 
               
               
                   
                   
                   
                 STK3, CASP3 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 9 
               
             
            
               
                   
               
               
                 Marker Genes of the WNT/β -catenin signaling pathway for Aurora A Kinase Inhibitor Treatment 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                   
                   
                 GenBank 
                 GenPept 
               
               
                 Gene 
                 Marker 
                   
                   
                   
                   
                 Accession No./ 
                 Accession No./ 
               
               
                 symbol 
                 Gene Name 
                 Entrez 
                 chromosome 
                 start 
                 end 
                 SEQ ID NO: 
                 SEQ ID NO: 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 LEF1 
                 lymphoid 
                 51176 
                 chr4 
                 108968700 
                 109090112 
                 NM_016269.4/ 
                 NP_057353.1/ 
               
               
                   
                 enhancer- 
                   
                   
                   
                   
                 SEQ ID NO: 1 
                 SEQ ID NO: 2 
               
               
                   
                 binding 
               
               
                   
                 factor 1 
               
               
                 MAP3K7 
                 mitogen- 
                 6885 
                 chr6 
                 91223291 
                 91297020 
                 NM_145331.2/ 
                 NP_663304.1/ 
               
               
                   
                 activated 
                   
                   
                   
                   
                 SEQ ID NO: 3 
                 SEQ ID NO: 4 
               
               
                   
                 protein 
               
               
                   
                 kinase 
               
               
                   
                 kinase 
               
               
                   
                 kinase 7 
               
               
                 APC 
                 adenomatous 
                 324 
                 chr5 
                 112073555 
                 112181936 
                 NM_000038.5/ 
                 NP_000029.2/ 
               
               
                   
                 polyposis 
                   
                   
                   
                   
                 SEQ ID NO: 5 
                 SEQ ID NO: 6 
               
               
                   
                 coli 
               
               
                 FZD2 
                 frizzled 
                 2535 
                 chr17 
                 42634811 
                 42638630 
                 NM_001466.3/ 
                 NP_001457.1/ 
               
               
                   
                 class 
                   
                   
                   
                   
                 SEQ ID NO: 7 
                 SEQ ID NO: 8 
               
               
                   
                 receptor 2 
               
               
                 PRKCA 
                 protein 
                 5578 
                 chr17 
                 64298925 
                 64806862 
                 XM_011524990.1/ 
                 XP_011523292.1/ 
               
               
                   
                 kinase C, 
                   
                   
                   
                   
                 SEQ ID NO: 9 
                 SEQ ID NO: 10 
               
               
                   
                 alpha 
               
               
                 RORA 
                 RAR- 
                 6095 
                 chr15 
                 60780482 
                 60919729 
                 NM_002943.3/ 
                 NP_002934.1/ 
               
               
                   
                 related 
                   
                   
                   
                   
                 SEQ ID NO: 11 
                 SEQ ID NO: 12 
               
               
                   
                 orphan 
               
               
                   
                 receptor A 
               
               
                 CAMK2G 
                 calcium/ 
                 818 
                 chr10 
                 75572258 
                 75634349 
                 NM_172171.2/ 
                 NP_751911.1/ 
               
               
                   
                 calmodulin - 
                   
                   
                   
                   
                 SEQ ID NO: 13 
                 SEQ ID NO: 14 
               
               
                   
                 dependent 
               
               
                   
                 protein 
               
               
                   
                 kinase II 
               
               
                   
                 gamma 
               
               
                 JUN 
                 jun proto- 
                 3725 
                 chr1 
                 59246462 
                 59249785 
                 NM_002228.3/ 
                 NP_002219.1/ 
               
               
                   
                 oncogene 
                   
                   
                   
                   
                 SEQ ID NO: 15 
                 SEQ ID NO: 16 
               
               
                 XPO1 
                 exportin 1 
                 7514 
                 chr2 
                 61705068 
                 61765418 
                 NM_003400.3/ 
                 NP_003391.1/ 
               
               
                   
                   
                   
                   
                   
                   
                 SEQ ID NO: 17 
                 SEQ ID NO: 18 
               
               
                 ROR2 
                 receptor 
                 4920 
                 chr9 
                 94484877 
                 94712444 
                 NM_004560.3/ 
                 NP_004551.2/ 
               
               
                   
                 tyrosine 
                   
                   
                   
                   
                 SEQ ID NO: 19 
                 SEQ ID NO: 20 
               
               
                   
                 kinase-like 
               
               
                   
                 orphan 
               
               
                   
                 receptor 2 
               
               
                 CCND1 
                 cyclin D 
                 595 
                 chr11 
                 69455872 
                 69469242 
                 NM_053056.2/ 
                 NP_444284.1/ 
               
               
                   
                   
                   
                   
                   
                   
                 SEQ ID NO: 21 
                 SEQ ID NO: 22 
               
               
                 CTNNB1 
                 catenin 
                 1499 
                 chr3 
                 41240941 
                 41281939 
                 NM_001098209.1/ 
                 NP_001091679.1/ 
               
               
                   
                 (cadherin- 
                   
                   
                   
                   
                 SEQ ID NO: 23 
                 SEQ ID NO: 24 
               
               
                   
                 associated 
               
               
                   
                 protein), 
               
               
                   
                 beta 1 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 10 
               
             
            
               
                   
               
               
                 Marker Genes of the Hippo signaling pathway for Aurora A Kinase Inhibitor Treatment 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                   
                   
                   
                 GenBank 
                 GenPept 
               
               
                 Gene 
                 Marker 
                   
                   
                   
                   
                 Accession No./ 
                 Accession No./ 
               
               
                 symbol 
                 Gene Name 
                 Entrez 
                 chromosome 
                 start 
                 end 
                 SEQ ID NO: 
                 SEQ ID NO: 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 AMOT 
                 angiomotin 
                 154796 
                 chrX 
                 112018104 
                 112066372 
                 NM_001113490.1/ 
                 NP_001106962.1/ 
               
               
                   
                   
                   
                   
                   
                   
                 SEQ ID NO: 25 
                 SEQ ID NO: 26 
               
               
                 DVL2 
                 dishevelled 
                 1856 
                 chr17 
                 7128660 
                 7137863 
                 NM_004422.2/ 
                 NP_004413.1/ 
               
               
                   
                 segment 
                   
                   
                   
                   
                 SEQ ID NO: 27 
                 SEQ ID NO: 28 
               
               
                   
                 polarity 
               
               
                   
                 protein 2 
               
               
                 LATS1 
                 large tumor 
                 9113 
                 chr6 
                 149979288 
                 150039392 
                 NM_004690.3/ 
                 NP_004681.1/ 
               
               
                   
                 suppressor 
                   
                   
                   
                   
                 SEQ ID NO: 29 
                 SEQ ID NO: 30 
               
               
                   
                 kinase 1 
               
               
                 LATS2 
                 large tumor 
                 26524 
                 chr13 
                 21547175 
                 21635722 
                 XM_005266342.1/ 
                 XP_005266399.1/ 
               
               
                   
                 suppressor 
                   
                   
                   
                   
                 SEQ ID NO: 31 
                 SEQ ID NO: 32 
               
               
                   
                 kinase 2 
               
               
                 MOB1B 
                 MOB kinase 
                 92597 
                 chr4 
                 71768056 
                 71853891 
                 NM_001244766.1/ 
                 NP_001231695.1/ 
               
               
                   
                 activator 1B 
                   
                   
                   
                   
                 SEQ ID NO: 33 
                 SEQ ID NO: 34 
               
               
                 NPHP4 
                 nephronophthisis 4 
                 261734 
                 chr1 
                 5922869 
                 6052533 
                 NM_015102.4/ 
                 NP_055917.1/ 
               
               
                   
                   
                   
                   
                   
                   
                 SEQ ID NO: 35 
                 SEQ ID NO: 36 
               
               
                 TJP1 
                 tight junction 
                 7082 
                 chr15 
                 29992356 
                 30114706 
                 NM_003257.4/ 
                 NP_003248.3/ 
               
               
                   
                 protein 1 
                   
                   
                   
                   
                 SEQ ID NO: 37 
                 SEQ ID NO: 38 
               
               
                 TJP2 
                 tight junction 
                 9414 
                 chr9 
                 71820077 
                 71870124 
                 NM_004817.3/ 
                 NP_004808.2/ 
               
               
                   
                 protein 2 
                   
                   
                   
                   
                 SEQ ID NO: 39 
                 SEQ ID NO: 40 
               
               
                 WWC1 
                 WW and C2 
                 23286 
                 chr5 
                 167719064 
                 167899308 
                 NM_001161661.1/ 
                 NP_001155133.1/ 
               
               
                   
                 domain 
                   
                   
                   
                   
                 SEQ ID NO: 41 
                 SEQ ID NO: 42 
               
               
                   
                 containing 1 
               
               
                 WWTR1 
                 WW domain 
                 25937 
                 chr3 
                 149235021 
                 149375812 
                 NM_001168278.1/ 
                 NP_001161750.1/ 
               
               
                   
                 containing 
                   
                   
                   
                   
                 SEQ ID NO: 43 
                 SEQ ID NO: 44 
               
               
                   
                 transcription 
               
               
                   
                 regulator 1 
               
               
                 YAP1 
                 Yes- 
                 10413 
                 chr11 
                 101981191 
                 102104154 
                 NM_001282101.1/ 
                 NP_001269030.1/ 
               
               
                   
                 associated 
                   
                   
                   
                   
                 SEQ ID NO: 45 
                 SEQ ID NO: 46 
               
               
                   
                 protein 1